CA3021417A1 - Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents - Google Patents
Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents Download PDFInfo
- Publication number
- CA3021417A1 CA3021417A1 CA3021417A CA3021417A CA3021417A1 CA 3021417 A1 CA3021417 A1 CA 3021417A1 CA 3021417 A CA3021417 A CA 3021417A CA 3021417 A CA3021417 A CA 3021417A CA 3021417 A1 CA3021417 A1 CA 3021417A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- chosen
- cells
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 8
- 239000002260 anti-inflammatory agent Substances 0.000 title claims abstract description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 title claims abstract description 7
- 239000002257 antimetastatic agent Substances 0.000 title claims abstract description 7
- 150000005417 aminobenzoic acid derivatives Chemical class 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 278
- 230000001028 anti-proliverative effect Effects 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 186
- 201000011510 cancer Diseases 0.000 claims description 115
- 238000000034 method Methods 0.000 claims description 80
- -1 propiolyl Chemical group 0.000 claims description 75
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 50
- 206010005003 Bladder cancer Diseases 0.000 claims description 46
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 44
- 206010006187 Breast cancer Diseases 0.000 claims description 40
- 208000026310 Breast neoplasm Diseases 0.000 claims description 40
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 40
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 39
- 206010046766 uterine cancer Diseases 0.000 claims description 39
- 206010033128 Ovarian cancer Diseases 0.000 claims description 38
- 206010060862 Prostate cancer Diseases 0.000 claims description 38
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 38
- 201000001441 melanoma Diseases 0.000 claims description 38
- 238000004519 manufacturing process Methods 0.000 claims description 37
- 230000003247 decreasing effect Effects 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 29
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 17
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 17
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 206010027476 Metastases Diseases 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000010261 cell growth Effects 0.000 claims description 12
- 230000004614 tumor growth Effects 0.000 claims description 12
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 11
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 230000019491 signal transduction Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 8
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000005493 quinolyl group Chemical group 0.000 claims description 5
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000008899 Habitual abortion Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000002787 Pregnancy Complications Diseases 0.000 claims description 2
- 208000005107 Premature Birth Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 208000012113 pregnancy disease Diseases 0.000 claims description 2
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 201000007954 uterine fibroid Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 139
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 70
- 125000003118 aryl group Chemical group 0.000 description 55
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 37
- 238000000132 electrospray ionisation Methods 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- 210000002540 macrophage Anatomy 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 29
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 26
- 150000007857 hydrazones Chemical class 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 22
- 230000003110 anti-inflammatory effect Effects 0.000 description 22
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 108700012920 TNF Proteins 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 102000004889 Interleukin-6 Human genes 0.000 description 17
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 241001529936 Murinae Species 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000001093 anti-cancer Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 230000003595 spectral effect Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 8
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 8
- 230000002001 anti-metastasis Effects 0.000 description 8
- 229940125904 compound 1 Drugs 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 6
- 150000001993 dienes Chemical class 0.000 description 6
- 230000001667 episodic effect Effects 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 5
- UXNWIRHZMHGOCE-UHFFFAOYSA-N 3-[4-chloro-1-(diaminomethylideneamino)isoquinolin-7-yl]benzoic acid Chemical compound C1=C2C(NC(=N)N)=NC=C(Cl)C2=CC=C1C1=CC=CC(C(O)=O)=C1 UXNWIRHZMHGOCE-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 238000010217 densitometric analysis Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 210000000947 motile cell Anatomy 0.000 description 5
- 230000004899 motility Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 101100315768 Homo sapiens UBC gene Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000011167 hydrochloric acid Nutrition 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IUNJCFABHJZSKB-UHFFFAOYSA-N 2,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(O)=C1 IUNJCFABHJZSKB-UHFFFAOYSA-N 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- GBKPNGVKZQBPCZ-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)acetic acid Chemical compound OC(=O)CN1C(=O)C=CC1=O GBKPNGVKZQBPCZ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- KVMFXHRQSIDONN-ARJAWSKDSA-N 3-[[(z)-3-carboxyprop-2-enoyl]amino]-4-chlorobenzoic acid Chemical compound OC(=O)\C=C/C(=O)NC1=CC(C(O)=O)=CC=C1Cl KVMFXHRQSIDONN-ARJAWSKDSA-N 0.000 description 2
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- MBWJZARDAIRROP-ARJAWSKDSA-N 4-[[(Z)-3-carboxyprop-2-enoyl]amino]-2-chlorobenzoic acid Chemical compound C(=O)(O)\C=C/C(=O)NC1=CC(=C(C(=O)O)C=C1)Cl MBWJZARDAIRROP-ARJAWSKDSA-N 0.000 description 2
- KDCFOKATFSLHQS-WAYWQWQTSA-N 4-[[(z)-3-carboxyprop-2-enoyl]amino]benzoic acid Chemical compound OC(=O)\C=C/C(=O)NC1=CC=C(C(O)=O)C=C1 KDCFOKATFSLHQS-WAYWQWQTSA-N 0.000 description 2
- 150000005418 4-aminobenzoic acid derivatives Chemical class 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 102100021723 Arginase-1 Human genes 0.000 description 2
- 101710129000 Arginase-1 Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NULAJYZBOLVQPQ-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1 NULAJYZBOLVQPQ-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 238000012338 Therapeutic targeting Methods 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000001740 anti-invasion Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000003935 benzaldehydes Chemical class 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- WLNSBJLNUVUNHN-UHFFFAOYSA-N cyclohepta-1,3-diene cyclohexa-1,3-diene Chemical compound C1=CC=CCCC1.C1=CC=CCC1 WLNSBJLNUVUNHN-UHFFFAOYSA-N 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- JJVNINGBHGBWJH-UHFFFAOYSA-N ortho-vanillin Chemical compound COC1=CC=CC(C=O)=C1O JJVNINGBHGBWJH-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229950000244 sulfanilic acid Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- DOZRDZLFLOODMB-UHFFFAOYSA-N 3,5-di-tert-Butyl-4-hydroxybenzaldehyde Chemical compound CC(C)(C)C1=CC(C=O)=CC(C(C)(C)C)=C1O DOZRDZLFLOODMB-UHFFFAOYSA-N 0.000 description 1
- DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- MBDUKNCPOPMRJQ-UHFFFAOYSA-N 4-amino-2-chlorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C(Cl)=C1 MBDUKNCPOPMRJQ-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- TYNJQOJWNMZQFZ-UHFFFAOYSA-N 4-prop-2-enoxybenzaldehyde Chemical compound C=CCOC1=CC=C(C=O)C=C1 TYNJQOJWNMZQFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108010004718 Lipoglycopeptides Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 101710141393 MAP kinase-activated protein kinase 3 Proteins 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical group NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 231100000755 favorable toxicity profile Toxicity 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- OBMJQRLIQQTJLR-USGQOSEYSA-N n-[(e)-[1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\CO)=N\NC(=O)CCCCCN1C(C=CC1=O)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OBMJQRLIQQTJLR-USGQOSEYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 description 1
- 108010006945 oritavancin Proteins 0.000 description 1
- 229960001607 oritavancin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012533 structure-function relationship study Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- GSJJCZSHYJNRPN-UHFFFAOYSA-N tert-butyl n-(2-sulfanylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCS GSJJCZSHYJNRPN-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There are provided compounds of formula (I) (see formula I) in which R2, R2, R3, R4 and Q can represent various different possibilities. These compounds can be useful as anticancer agents as well as anti-inflammatory agents, anti-proliferative agents and/or anti-metastatic agents.
Description
AMINOBENZOIC ACID DERIVATIVES FOR USE AS ANTI-INFLAMMATORY
AGENTS, ANTI-METASTATIC AGENTS AND/OR ANTICANCER AGENTS
FIELD OF THE DISCLOSURE
[0001] This disclosure relates to the field of active agents. More particularly, this disclosure relates to anti-inflammatory agents, anti-metastatic agents, anti-proliferative agents and anticancer agents. The present disclosure also relates to methods for treating cancers using these agents.
BACKGROUND OF THE DISCLOSURE
AGENTS, ANTI-METASTATIC AGENTS AND/OR ANTICANCER AGENTS
FIELD OF THE DISCLOSURE
[0001] This disclosure relates to the field of active agents. More particularly, this disclosure relates to anti-inflammatory agents, anti-metastatic agents, anti-proliferative agents and anticancer agents. The present disclosure also relates to methods for treating cancers using these agents.
BACKGROUND OF THE DISCLOSURE
[0002] There are several methods used to treat cancer) The most common are:
surgery, chemotherapy, radiation therapy, targeted therapy and immunotherapy.1-Other procedures are based on stem cell transplant, photodynamic therapy, and cryogenic therapy) Lasers are nowadays a useful tool during surgery of localized cancers. Many of these methods are quite effective. However, most present important side effects.7,8 Hence, the need to discover alternative therapeutics and treatment modalities. Particularly, compounds and treatment protocols that could simultaneously attack cancer on diverse fronts (initiation, propagation, metastasis etc.) are of great interest.
surgery, chemotherapy, radiation therapy, targeted therapy and immunotherapy.1-Other procedures are based on stem cell transplant, photodynamic therapy, and cryogenic therapy) Lasers are nowadays a useful tool during surgery of localized cancers. Many of these methods are quite effective. However, most present important side effects.7,8 Hence, the need to discover alternative therapeutics and treatment modalities. Particularly, compounds and treatment protocols that could simultaneously attack cancer on diverse fronts (initiation, propagation, metastasis etc.) are of great interest.
[0003] Urothelial bladder cancer (UBC) is the fifth most common malignancy of all cancers in North America. Although most of detectable tumors are initially non-muscle-invasive and are generally curable by means of chirurgical resection, 27-30%
of them exhibit a lethal phenotype characterized by high histological grade and muscle invasion. Recent studies have also provided ample evidence that UBC
intravesical therapy response is influenced by infiltration of major inflammatory cells (mainly macrophages) and activation of key inflammatory mediators (including the cytokines TNFa and IL6 and the transcription factors NFKB and STAT3).
Considering the critical functions of inflammatory mediators in UBC growth, dissemination and resistance to cell death, they may represent potential drug targets to improve the efficacy of immunotherapy and chemotherapy agents.
SUMMARY OF THE DISCLOSURE
of them exhibit a lethal phenotype characterized by high histological grade and muscle invasion. Recent studies have also provided ample evidence that UBC
intravesical therapy response is influenced by infiltration of major inflammatory cells (mainly macrophages) and activation of key inflammatory mediators (including the cytokines TNFa and IL6 and the transcription factors NFKB and STAT3).
Considering the critical functions of inflammatory mediators in UBC growth, dissemination and resistance to cell death, they may represent potential drug targets to improve the efficacy of immunotherapy and chemotherapy agents.
SUMMARY OF THE DISCLOSURE
[0004] According to one aspect, there are included compounds of formula (I) :
R3 ................õ( \ Q
R4V.-:----'.......<N _____________ C 1 N
RI
(I) wherein RI is H, alkyl or halogen;
R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
Q is QA or QB;
QA=
H
N
( /
QB = R7;
= a single bond or a double bond;
R5 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R6 is H, Boc, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R7 is a substituted or unsubstituted member chosen from C1-C8 alkyl, C3-C8 cycloalkyl, phenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
R3 and R4 are independently chosen from H, -SR8 and ¨NR9R10, or R3 and R4 are joined together to form a 5-7 membered ring that optionally comprises an heteroatom chosen from N, S and 0;
R8 is H, Ci -C8 alkyl, -(CH2)nNHBoc, or -(CH2)nNH2 wherein n = I to 6;
R9 is H or Ci-C8 alkyl;
Rio is H, Ci -C8 alkyl, acetyl, propiolyl, butyryl, isobutyryl, or benzoyl;
wherein R2, R5, R6 and R7, when substituted, are substituted with at least one substituent chosen from -0R9, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, C1-C8 alkyl, methoxycarbonyl-, or alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
R3 ................õ( \ Q
R4V.-:----'.......<N _____________ C 1 N
RI
(I) wherein RI is H, alkyl or halogen;
R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
Q is QA or QB;
QA=
H
N
( /
QB = R7;
= a single bond or a double bond;
R5 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R6 is H, Boc, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R7 is a substituted or unsubstituted member chosen from C1-C8 alkyl, C3-C8 cycloalkyl, phenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
R3 and R4 are independently chosen from H, -SR8 and ¨NR9R10, or R3 and R4 are joined together to form a 5-7 membered ring that optionally comprises an heteroatom chosen from N, S and 0;
R8 is H, Ci -C8 alkyl, -(CH2)nNHBoc, or -(CH2)nNH2 wherein n = I to 6;
R9 is H or Ci-C8 alkyl;
Rio is H, Ci -C8 alkyl, acetyl, propiolyl, butyryl, isobutyryl, or benzoyl;
wherein R2, R5, R6 and R7, when substituted, are substituted with at least one substituent chosen from -0R9, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, C1-C8 alkyl, methoxycarbonyl-, or alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
[0005] According to another aspect, there is provided compounds of formulae (IIA), (JIB) or (IIC):
II1)n N
(IA) (IIB) (IIC) wherein Q is QA or QB;
QA
( Qs = R7;
R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R5 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R6 is H, Boc, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R7 is a substituted or unsubstituted member chosen from Ci -C8 alkyl, C3-C8 cycloalkyl, phenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
R9 is H or Ci-C8 alkyl;
Xis 0, S or NR2, n is 1,2 or 3;
wherein R2, R5, R6 and R7, when substituted, are substituted with at least one substituent chosen from -0R9, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, Ci-C8 alkyl, methoxycarbonyl-, or alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
10006] According to another aspect, there is provided a compound of formula (IF) H
H N ¨ N
(IF) R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
RH is a substituted or unsubstituted member chosen from phenyl, phenylethenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
wherein R11, when substituted, are substituted with at least one substituent chosen from ¨01212, -F, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, -CH20H, nitrophenyl, phenylethenyl, -CF3, CI-Cs alkyl, C2-Cs alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
R12 is H, acetyl, propiolyl, Cu-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
II1)n N
(IA) (IIB) (IIC) wherein Q is QA or QB;
QA
( Qs = R7;
R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R5 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R6 is H, Boc, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R7 is a substituted or unsubstituted member chosen from Ci -C8 alkyl, C3-C8 cycloalkyl, phenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
R9 is H or Ci-C8 alkyl;
Xis 0, S or NR2, n is 1,2 or 3;
wherein R2, R5, R6 and R7, when substituted, are substituted with at least one substituent chosen from -0R9, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, Ci-C8 alkyl, methoxycarbonyl-, or alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
10006] According to another aspect, there is provided a compound of formula (IF) H
H N ¨ N
(IF) R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
RH is a substituted or unsubstituted member chosen from phenyl, phenylethenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
wherein R11, when substituted, are substituted with at least one substituent chosen from ¨01212, -F, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, -CH20H, nitrophenyl, phenylethenyl, -CF3, CI-Cs alkyl, C2-Cs alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
R12 is H, acetyl, propiolyl, Cu-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
6 or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
[0007] According to another aspect, there is provided a compound of formula (IG) ¨ N
______________________________________________________ kRi3 (IG) ---1¨=>R14 R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R12 is H, acetyl, propiolyl, CI-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
RI3, RI4 and RI5 are each independently chosen from H, ¨0R12, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
______________________________________________________ kRi3 (IG) ---1¨=>R14 R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R12 is H, acetyl, propiolyl, CI-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
RI3, RI4 and RI5 are each independently chosen from H, ¨0R12, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
[0008] According to another aspect, there is provided a compound of formula (IH) I N . 0 ----\ NHN=--\
(IH) wherein R16 is chosen from 2,4-dihydroxyphenyl 3,5-ditertbuty1-4- 4-methoxyphenyl hydroxybenzaldehyde 2-hydroxy-3-methoxyphenyl 3,4-dimethoxyphenyl 4-allyloxyphenyl 2-furanyl 2-pyridyl 3-pyridyl 4-pyridyl phenylethenyl 4-chlorophenyl 4-fluorophenyl 4-trifluoromethylphenyl and 4-nitropheny I.
(IH) wherein R16 is chosen from 2,4-dihydroxyphenyl 3,5-ditertbuty1-4- 4-methoxyphenyl hydroxybenzaldehyde 2-hydroxy-3-methoxyphenyl 3,4-dimethoxyphenyl 4-allyloxyphenyl 2-furanyl 2-pyridyl 3-pyridyl 4-pyridyl phenylethenyl 4-chlorophenyl 4-fluorophenyl 4-trifluoromethylphenyl and 4-nitropheny I.
[0009] According to another aspect, there is included a composition comprising a pharmaceutically acceptable carrier and at least one compound of the present disclosure.
[0010] According to another aspect, there is included a method for treating cancer or at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma, the method comprising administering to a subject in need thereof an effective amount of at least one compound of the present disclosure.
[0011] According to another aspect, there is included a method for reducing the risks of developing cancer or for reducing the risk of developing at least one cancer in a subject, the cancer being, for example, chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma, the method comprising administering to the subject an effective amount of at least one compound of the present disclosure.
[0012] According to another aspect, there is included a method for inhibiting cancer cell growth, the method comprising administering to a subject in need thereof an effective amount of at least one compound of the present disclosure. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0013] According to another aspect, there is included a method for inhibiting cancer cell growth, the method comprising contacting cancer cells with an effective amount of at least one compound of the present disclosure. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0014] According to another aspect, there is included a method for inhibiting cancer tumor growth and/or cancer tumor size, the method comprising administering to a subject in need thereof an effective amount of at least one compound of the present disclosure. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0015] According to another aspect, there is included a method for decreasing and/or preventing cancer tumor metastases, the method comprising administering to a subject in need thereof an effective amount of at least one compound of the present disclosure. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0016] According to another aspect, there is included the use of at least one compound of the present disclosure for treating cancer or for treating at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0017] According to another aspect, there is included the use of at least one compound of the present disclosure for reducing the risks of developing cancer or for reducing the risks of developing at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0018] According to another aspect, there is included the use of at least one compound of the present disclosure for inhibiting cancer cell growth. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0019] According to another aspect, there is included the use of at least one compound of the present disclosure for inhibiting cancer tumor growth and/or cancer tumor size of at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0020] According to another aspect, there is included the use of at least one compound of the present disclosure for decreasing and/or preventing cancer tumor metastases of at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0021] According to another aspect, there is included the use of at least one compound of the present disclosure in the manufacture of a medicament for treating cancer or for treating at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0022] According to another aspect, there is included the use of at least one compound of the present disclosure in the manufacture of a medicament for reducing the risks of developing cancer or for reducing the risks of developing at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0023] According to another aspect, there is included the use of at least one compound of the present disclosure in the manufacture of a medicament for inhibiting cancer cell growth. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0024] According to another aspect, there is included the use of at least one compound of the present disclosure in the manufacture of a medicament for inhibiting cancer tumor growth and/or cancer tumor size. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
[0025] According to another aspect, there is included the use of at least one compound of the present disclosure in the manufacture of a medicament for decreasing and/or preventing cancer tumor metastases. For example, the cancer can be chosen from breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, and melanoma.
BRIEF DESCRIPTION OF FIGURES
BRIEF DESCRIPTION OF FIGURES
[0026] The following drawings represent in a non-limitative manner examples of specific embodiments in which:
Figs. 1(a) and 1(b) represents images (1(a)) and graphical analysis (1(b)) showing Western blot analysis to determine the expression level of phosphorylated STAT1 and STAT3 in human macrophages (MO) pretreated for 30 min with vehicle (DMSO) or compounds 4 and 5 (both at 0, 10 and 50 ?AM), and then washed and recovered immediately (t= 0) or after 30 min of activation with either 50 U/mL IFNy or ng/mL IL6. The ratio of phosphorylated/no phosphorylated proteins was calculated from densitometric analysis of each sample to evaluate the relative activation of pSTAT1 or pSTAT3. Compounds 4 and 5 efficiently inhibited IFNy-induced STAT1 activation and IL6-induced STAT3 activation. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 2(a) and 2(b) represents images (2(a)) and graphical analysis (2(b)) showing flow cytometry analysis to determine the expression level of MHC-II and CD40 surface antigens in resting and IFNy-activated human macrophages untreated and pretreated with compounds 4 (10 M) and 5 (25 'LIM). Compounds 4 and 5 efficiently inhibited IFNy-induced CD40 and MHC-II expression. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 3(a) and 3(b) represents images (3(a)) and graphical analysis (3(b)) showing scratch wound healing assays to determine the motility of human macrophages monolayers cultured for 3 h with vehicle (DMSO) or compounds 4 (10 M) and 5 (25 M), and then activated for 48 h with vehicle (PBS) or 25 ng/mL IL6. The images of the scratch were acquired at t= 0 h and t= 48 h by fluorescence microscopy.
Five fields were taken randomly for each different treatment. All observations were performed at 5x magnification. Cell motility was expressed as percent (%) of control of motile cells at t= 48 h relative to motile cells at t= 0 h. Compounds 4 and efficiently inhibited IFNy-induced STAT1 activation and IL6-induced STAT3 activation. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 4 is a graphical representation of NO production in the macrophage-like J774A.1 cells following a pro-inflammatory stimulation by IFNy and TNFa after pretreatment with vehicle (DMSO) and the derivatives 4 and 5. Compounds 4 and 5 efficiently inhibited combined IFNy/TNFa-induced NO synthesis. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 5 is a graphical representation of NO production by the murine UBC cell line MB49-I following a pro-inflammatory stimulation by IFNy and TNFa after pretreatment with vehicle (DMSO) and derivatives 4 and 5. Compounds 4 and 5 at and 50 p,M efficiently inhibited combined IFNy/TNFa-induced NO synthesis. * p <
0.05 and **p < 0.01 denote significant differences between treatments;
Fig. 6 is a graphical representation of relative cell viability on the murine UBC cell line MB49-I following a pro-inflammatory stimulation by IFNy and TNFa after pretreatment with vehicle (DMSO) and anti-inflammatory derivatives 4 and 5 at different concentrations. Compounds 4 and 5 at low doses (10, 25 and 37.5 1AM) had little or no effect on the anti-proliferative activity of combined IFNy and TNFa in MB49-I cells. * p < 0.05 denote significant differences between treatments with combined IFNy and TNFa plus compounds 4 or 5 versus combined IFNy and TNFa alone;
Fig. 7 refers to relative cell viability on MB49 and MB49-I cell lines 24-hour post treatment (3h) with either vehicle (DMSO) or compound 4 at different concentrations (0, 10, 15, 20, 30, and 50 M). The negative effects of compound 4 on cell survival would not be caused by an increase in cell mortality of UBC MB49 or MB49-I
cells but rather by stopping cell proliferation. * p < 0.05 denote significant difference compared to control (without compound 4);
Figs. 8(a) and 8(b) refers to (8(a)) Western blot analysis: compound 4 efficiently inhibited TNFa/NFKB and IL6/STAT3 signaling pathways in murine UBC MB49-I
cells at doses as lower as 10 1.1M; and (8(b)) Luciferase assay: compound 4 at 50 !AM
efficiently inhibited NFKB activation. MB49-I cells were transfected with an NFKB-responsive luciferase construct encoding the firefly luciferase reporter gene under the control of CMV promoter and tandem repeats of the NFKB transcriptional response element. *p <0.01 denote significant difference compared to control;
Figs. 9(a) and 9(b) refers to (9(a)) microinvasion assays: compound 4 efficiently inhibited Ml-induced human UBC T24 cell invasion (matrigel in Boyden chamber);
and (9(b)) motility assays: compound 4 at 30 p.M efficiently inhibited 1L6-induced motility (scratch assay) in human UBC T24 cells. * p < 0.05 denote significant difference compared to control (M1 DMS0);
Fig. 10 refers to cellular analysis of 3D spheroid-based tumor invasion assays:
compound 4 at 30 }AM efficiently inhibited the invasiveness activity of MDA-MB-cells, a highly invasive human breast cancer cell line, thus demonstrating that the anti-invasion effects of compound 4 is not cell-specific. * p < 0.01 denote significant difference compared to day 0;
Figs. 11(a), 11(b) and 11(c) refers to acute toxicity studies with episodic intraperitoneal (i.p.) injections of compound 4 at different concentrations (0, 90, 150, and 300 1.1M) in C57B1/6J mice (n=4) during 3 weeks. Treatments have no obvious effect on normal development and viability (11(a)), as well as in organs weight (11(b)) and hematocrit (11(c));
Fig. 12 represents images showing liver histological analysis in C57B1/6J mice at the end of treatment by periodic i.p. injections of compound 4 at different concentrations (0, 90, 150, and 300 04) during 3 weeks. Treatment, even at higher dose, does not induce features of liver dysfunction such as hepatocellular injury, inflammation, fibrosis and steatosis (haematoxylin and eosin, 100 x and 400 x magnification). These results showed no evidence of toxicity from the anti-inflammatory treatment, indicating that compound 4 concentrations up to 300 IAM were well tolerated in these mice;
Fig. 13 refers to in vivo targeting study showing the effects of episodic i.p.
injections of compound 4 at different concentrations (0, 90, and 150 p,M) in C57B1/6J
male mice bearing MB49-I tumors ectopically implanted in the right flank of animals (n=6).
Treatment at 150 1AM significantly affects tumor development of MB49-1 cells subcutaneously implanted in mice. *p < 0.01 compared to control;
Figs. 14(a) and 14(b) refers to the anti-metastatic effects of episodic i.p.
injections of compound 4 at different concentrations (0, 90, and 150 I.A.M) in C57B1/6J male mice bearing MB49-I tumors ectopically implanted in animals (n=6). Treatment at 150 M
significantly reduce the size of subcutaneously implanted MB49-1 tumors (14(a)) and the number of lung metastases (14(b)). Histological examination of lung specimens demonstrated that MB49-1 tumor cell infiltration induced multifocal fibrotic lesions in the lungs of control mice (as indicated by the arrows), whereas no metastatic foci and a well-alveolized normal histology was seen in the lungs of mice treated with compound 4. *p < 0.01 compared to control;
Figs. 15(a) and 15(b) refers to in vivo targeting study showing the effects of episodic i.p. injections of compound 4 in C57B1/6J female mice bearing MB49-1 tumors orthotopically implanted in the bladder of animals (n=6). (15(a)) Represents images of bladders from normal age-matched mice and bladders that were chirurgically recovered at the end of the study (day 16 after tumor implantation) from control (Ctl) and treated tumor-bearing mice. (15(b)) Graphical representation showing i.p.
injections of compound 4 biweekly at 150 1.1M during two weeks completely abolished the development of muscle-invasive MB49-I tumors (n=6). *p < 0.5 compared to Ctl.
Figs. 16(a) and 16(b) refers to the regulatory effects of pro-inflammatory IL6 and TNFcc in the production of iNOS proteins (16(a)) and NO molecules (16(b)) by MB49 and MB49-1 cells. These results shown that non-muscle invasive UBC MB49 cells produced low levels of iNOS and NO relative to highly invasive MB49-1 cells in response to TNFoc but not IL6. These results strongly support the idea that NO
production via inflammatory pathway TNFa/NFKB may provide a permissive environment for MB49-1 tumor progression in vivo. *p <0.01 compared to control;
Figs. 17(a), 17(b) and 17(c) refers to in vivo study showing loss of basal and TNFa-induced iNOS expression (17(a)) and NO production (17(b)) by shRNA affects luciferase-expressing MB49-1 tumor development (17(c)) ectopically implanted in the bladder of C57B1/6J female mice. These results strongly suggest that MB49-I
tumors is probably highly dependent on the presence of functional iNOS/NO system to develop in C57B1/6J mice *p < 0.01 compared to control;
Fig. 18 refers to in vivo targeting study showing the effects of episodic i.p.
injections of compound 4 at different concentrations (0, 90, and 150 pi,M) in C57B1/6J
male mice bearing non-muscle invasive MB49 tumors ectopically implanted in the right flank of animals (n=6). Treatment at 90 and 150 [IM significantly reduce the size of subcutaneously implanted MB49 tumors. These results shown that compound 4 is highly efficient to stop the development of UBC tumors producing very low levels of iNOS protein and NO molecules. *p < 0.001 compared to Ctl;
Figs. 19(a) and 19(b) refers to the anti-inflammatory effects of compound 4 in peritoneal macrophages after in vivo therapeutic targeting of ectopically implanted MB49 tumors in C57B1/6J male mice. Treatment at 90 and 150 1.1.M significantly decrease NO production (19(a)) and urea synthesis and release (19(b)) in peritoneal macrophages. Peritoneal macrophages were recovered at the end of the study (day 26 after tumor implantation). Polarization to pro-inflammatory M1 macrophages is characterized by NO production through iNOS activity while urea synthesis through arginase-1 activity is related to polarization to anti-inflammatory M2 macrophages.
These results strongly suggest that in vivo therapeutic targeting of bladder tumors with compound 4 directly affects macrophage polarization in mice, probably via induction of an inflammatory anergy status, a process typically observed in normal intestinal macrophages. *p < 0.05 and ** p < 0.01 denote significant differences between treatments.
Figs. 20(a) and 20(b) refers to structure-function relationship study on the anti-inflammatory activity of compound 4. (20(a)) Chemical structures of compounds and 12. (20(b)) Graphical representation of LPS/IFN7-induced NO production in MB49-I cells after pretreatment with vehicle (DMSO) and the compounds 4 (30 M) and 12 at different concentrations (10, 20, 37.5 and 50 ?AM). Compound 12 even at higher concentration does not affect LPS/IFNThinduced NO synthesis. These results shown that the double bond in the heterocycle of the left part of the molecule is important for the inhibitory effect of compound 4 on NO production by macrophages and tumor cells * p < 0.01 denote significant difference compared to positive control (DMSO + LPS /IFN7);
Figs. 21(a) and 21(b) refers to the comparative effects of compounds 4, 8, 10, and 11 in NO production in MB49-1 cells. (21(a)) Chemical structures of compounds 4, 8, 10, and 11; (21(b)) Graphical representation of IFN7/LPS-induced NO production in MB49-1 cells after pretreatment with vehicle (DMSO) and the compounds 4, 8, 10, and 11 at 20 and 37.5 j.tM. These results shown that compound 8 at the same concentrations (20 and 37.5 i_tM) is more efficient than compound 4 to inhibit NO
production. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Figs. 22(a) and 22(b) represents images (22(a)) and graphical analysis (22(b)) showing Western blot analysis to determine the expression level of phosphorylated STAT1 in murine macrophages (RAW 264.7 cells) pretreated for 90 min with vehicle (DMSO) or compounds 4, 8, 10, and 11 (at 20 and 37.5 M), and then washed and recovered after 15 min of activation with 5 ng/mL IF1\17. The ratio of p-STAT1/STAT1 was calculated from densitometric analysis of each sample to evaluate the relative activation of the transcription factor STAT1. These results shown that compound 8 is more efficient than other compounds to inhibit 1FNy-activated signaling pathway in RAW 264.7 cells. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Figs. 23(a) and 23(b) represents images (23(a)) and graphical analysis (23(b)) showing Western blot analysis to determine the expression level of phosphorylated 1KB in murine macrophages (RAW 264.7 cells) pretreated for 90 min with vehicle (DMSO) or compounds 4, 8, 10, and 11 (at 20 and 37.5 M), and then washed and recovered after 15 min of activation with 100 ng/mL LPS. The ratio of p-IkB/IkB was calculated from densitometric analysis of each sample to evaluate the relative deactivation of IKB proteins, the negative regulator of the transcription factor NFKB.
These results shown that all compounds are efficient to inhibit LPS-activated NFKB
signaling pathway in RAW 264.7 cells. * p < 0.05 and ** p <0.01 denote significant differences between treatments;
Figs. 24(a), 24(b) and 24(c) represents images and graphical analysis showing the comparative effects of compounds 4 and 8 in cell viability of murine UBC MB49-I
cells (24(a)), murine macrophages RAW 264.7 cells (24(b)) and human macrophages THP-1 cells (24(c)). Cells were pretreated for 90 min, with vehicle (DMSO) and compounds 4 and 8 at different concentrations, and then washed and counted after a 24-hour period of incubation to estimate the number of viable cells. These results demonstrated that the cytotoxic effect of compound 8 is lower than that of compound 4. * p < 0.05 denote significant differences between treatments.
Fig. 25 refers to the comparative anticancer activities of compounds 4 and 8 in the development of MB49-I tumors ectopically implanted in C57B1/6J male mice. In vivo targeting study showing episodic i.p. injections of compound 8 during 18 days is more efficient than compound 4 to reduce the tumor volume of muscle-invasive MB49-I
tumors (n=6) at the same concentration (150 PM). Tumors were chirurgically recovered at the end of the study (day 20 after tumor implantation). These results shown that compound 8 is more efficient than compound 4 to inhibit the development of highly invasive MB49-I tumors. * p < 0.05 and ** p < 0.01 denote significant differences between treatments.
Figs. 26(a) and 26(b) is a graphical representation of (26(a)) NO production and (26(b)) cell viability in the macrophage-like RAW 264.7 cells. (26(a)) Griess reagent and (26(b)) MTT assays were performed following a 24-h period of pro-inflammatory stimulation by IFNy (10 ng/mL) and LPS (100 ng/mL) after pretreatment with control (DMSO) and the molecules 1, 13a, 13b, and 13j. (26(a)) Compound 13j, but not 13a nor 13b, efficiently inhibited combined IFN7/LPS-induced NO synthesis;
compared to compound 1, compound 13j was 1.8 fold and 12 fold more efficient at 5 piM and [iM, respectively. (26(b)) While compounds 13a, 13b, and 13j had little or not positive effects on RAW 264.7 cell proliferation, compound 13j was 1.6 less toxic at 20 [i.1VI compared to compound 1. * p < 0.05 and ** p < 0.01 denote significant difference between each treatment dose with similar dose of compound 1.
Figs. 27(a) and 27(b) is a graphical representation of (27(a)) NO production and
Figs. 1(a) and 1(b) represents images (1(a)) and graphical analysis (1(b)) showing Western blot analysis to determine the expression level of phosphorylated STAT1 and STAT3 in human macrophages (MO) pretreated for 30 min with vehicle (DMSO) or compounds 4 and 5 (both at 0, 10 and 50 ?AM), and then washed and recovered immediately (t= 0) or after 30 min of activation with either 50 U/mL IFNy or ng/mL IL6. The ratio of phosphorylated/no phosphorylated proteins was calculated from densitometric analysis of each sample to evaluate the relative activation of pSTAT1 or pSTAT3. Compounds 4 and 5 efficiently inhibited IFNy-induced STAT1 activation and IL6-induced STAT3 activation. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 2(a) and 2(b) represents images (2(a)) and graphical analysis (2(b)) showing flow cytometry analysis to determine the expression level of MHC-II and CD40 surface antigens in resting and IFNy-activated human macrophages untreated and pretreated with compounds 4 (10 M) and 5 (25 'LIM). Compounds 4 and 5 efficiently inhibited IFNy-induced CD40 and MHC-II expression. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 3(a) and 3(b) represents images (3(a)) and graphical analysis (3(b)) showing scratch wound healing assays to determine the motility of human macrophages monolayers cultured for 3 h with vehicle (DMSO) or compounds 4 (10 M) and 5 (25 M), and then activated for 48 h with vehicle (PBS) or 25 ng/mL IL6. The images of the scratch were acquired at t= 0 h and t= 48 h by fluorescence microscopy.
Five fields were taken randomly for each different treatment. All observations were performed at 5x magnification. Cell motility was expressed as percent (%) of control of motile cells at t= 48 h relative to motile cells at t= 0 h. Compounds 4 and efficiently inhibited IFNy-induced STAT1 activation and IL6-induced STAT3 activation. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 4 is a graphical representation of NO production in the macrophage-like J774A.1 cells following a pro-inflammatory stimulation by IFNy and TNFa after pretreatment with vehicle (DMSO) and the derivatives 4 and 5. Compounds 4 and 5 efficiently inhibited combined IFNy/TNFa-induced NO synthesis. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Fig. 5 is a graphical representation of NO production by the murine UBC cell line MB49-I following a pro-inflammatory stimulation by IFNy and TNFa after pretreatment with vehicle (DMSO) and derivatives 4 and 5. Compounds 4 and 5 at and 50 p,M efficiently inhibited combined IFNy/TNFa-induced NO synthesis. * p <
0.05 and **p < 0.01 denote significant differences between treatments;
Fig. 6 is a graphical representation of relative cell viability on the murine UBC cell line MB49-I following a pro-inflammatory stimulation by IFNy and TNFa after pretreatment with vehicle (DMSO) and anti-inflammatory derivatives 4 and 5 at different concentrations. Compounds 4 and 5 at low doses (10, 25 and 37.5 1AM) had little or no effect on the anti-proliferative activity of combined IFNy and TNFa in MB49-I cells. * p < 0.05 denote significant differences between treatments with combined IFNy and TNFa plus compounds 4 or 5 versus combined IFNy and TNFa alone;
Fig. 7 refers to relative cell viability on MB49 and MB49-I cell lines 24-hour post treatment (3h) with either vehicle (DMSO) or compound 4 at different concentrations (0, 10, 15, 20, 30, and 50 M). The negative effects of compound 4 on cell survival would not be caused by an increase in cell mortality of UBC MB49 or MB49-I
cells but rather by stopping cell proliferation. * p < 0.05 denote significant difference compared to control (without compound 4);
Figs. 8(a) and 8(b) refers to (8(a)) Western blot analysis: compound 4 efficiently inhibited TNFa/NFKB and IL6/STAT3 signaling pathways in murine UBC MB49-I
cells at doses as lower as 10 1.1M; and (8(b)) Luciferase assay: compound 4 at 50 !AM
efficiently inhibited NFKB activation. MB49-I cells were transfected with an NFKB-responsive luciferase construct encoding the firefly luciferase reporter gene under the control of CMV promoter and tandem repeats of the NFKB transcriptional response element. *p <0.01 denote significant difference compared to control;
Figs. 9(a) and 9(b) refers to (9(a)) microinvasion assays: compound 4 efficiently inhibited Ml-induced human UBC T24 cell invasion (matrigel in Boyden chamber);
and (9(b)) motility assays: compound 4 at 30 p.M efficiently inhibited 1L6-induced motility (scratch assay) in human UBC T24 cells. * p < 0.05 denote significant difference compared to control (M1 DMS0);
Fig. 10 refers to cellular analysis of 3D spheroid-based tumor invasion assays:
compound 4 at 30 }AM efficiently inhibited the invasiveness activity of MDA-MB-cells, a highly invasive human breast cancer cell line, thus demonstrating that the anti-invasion effects of compound 4 is not cell-specific. * p < 0.01 denote significant difference compared to day 0;
Figs. 11(a), 11(b) and 11(c) refers to acute toxicity studies with episodic intraperitoneal (i.p.) injections of compound 4 at different concentrations (0, 90, 150, and 300 1.1M) in C57B1/6J mice (n=4) during 3 weeks. Treatments have no obvious effect on normal development and viability (11(a)), as well as in organs weight (11(b)) and hematocrit (11(c));
Fig. 12 represents images showing liver histological analysis in C57B1/6J mice at the end of treatment by periodic i.p. injections of compound 4 at different concentrations (0, 90, 150, and 300 04) during 3 weeks. Treatment, even at higher dose, does not induce features of liver dysfunction such as hepatocellular injury, inflammation, fibrosis and steatosis (haematoxylin and eosin, 100 x and 400 x magnification). These results showed no evidence of toxicity from the anti-inflammatory treatment, indicating that compound 4 concentrations up to 300 IAM were well tolerated in these mice;
Fig. 13 refers to in vivo targeting study showing the effects of episodic i.p.
injections of compound 4 at different concentrations (0, 90, and 150 p,M) in C57B1/6J
male mice bearing MB49-I tumors ectopically implanted in the right flank of animals (n=6).
Treatment at 150 1AM significantly affects tumor development of MB49-1 cells subcutaneously implanted in mice. *p < 0.01 compared to control;
Figs. 14(a) and 14(b) refers to the anti-metastatic effects of episodic i.p.
injections of compound 4 at different concentrations (0, 90, and 150 I.A.M) in C57B1/6J male mice bearing MB49-I tumors ectopically implanted in animals (n=6). Treatment at 150 M
significantly reduce the size of subcutaneously implanted MB49-1 tumors (14(a)) and the number of lung metastases (14(b)). Histological examination of lung specimens demonstrated that MB49-1 tumor cell infiltration induced multifocal fibrotic lesions in the lungs of control mice (as indicated by the arrows), whereas no metastatic foci and a well-alveolized normal histology was seen in the lungs of mice treated with compound 4. *p < 0.01 compared to control;
Figs. 15(a) and 15(b) refers to in vivo targeting study showing the effects of episodic i.p. injections of compound 4 in C57B1/6J female mice bearing MB49-1 tumors orthotopically implanted in the bladder of animals (n=6). (15(a)) Represents images of bladders from normal age-matched mice and bladders that were chirurgically recovered at the end of the study (day 16 after tumor implantation) from control (Ctl) and treated tumor-bearing mice. (15(b)) Graphical representation showing i.p.
injections of compound 4 biweekly at 150 1.1M during two weeks completely abolished the development of muscle-invasive MB49-I tumors (n=6). *p < 0.5 compared to Ctl.
Figs. 16(a) and 16(b) refers to the regulatory effects of pro-inflammatory IL6 and TNFcc in the production of iNOS proteins (16(a)) and NO molecules (16(b)) by MB49 and MB49-1 cells. These results shown that non-muscle invasive UBC MB49 cells produced low levels of iNOS and NO relative to highly invasive MB49-1 cells in response to TNFoc but not IL6. These results strongly support the idea that NO
production via inflammatory pathway TNFa/NFKB may provide a permissive environment for MB49-1 tumor progression in vivo. *p <0.01 compared to control;
Figs. 17(a), 17(b) and 17(c) refers to in vivo study showing loss of basal and TNFa-induced iNOS expression (17(a)) and NO production (17(b)) by shRNA affects luciferase-expressing MB49-1 tumor development (17(c)) ectopically implanted in the bladder of C57B1/6J female mice. These results strongly suggest that MB49-I
tumors is probably highly dependent on the presence of functional iNOS/NO system to develop in C57B1/6J mice *p < 0.01 compared to control;
Fig. 18 refers to in vivo targeting study showing the effects of episodic i.p.
injections of compound 4 at different concentrations (0, 90, and 150 pi,M) in C57B1/6J
male mice bearing non-muscle invasive MB49 tumors ectopically implanted in the right flank of animals (n=6). Treatment at 90 and 150 [IM significantly reduce the size of subcutaneously implanted MB49 tumors. These results shown that compound 4 is highly efficient to stop the development of UBC tumors producing very low levels of iNOS protein and NO molecules. *p < 0.001 compared to Ctl;
Figs. 19(a) and 19(b) refers to the anti-inflammatory effects of compound 4 in peritoneal macrophages after in vivo therapeutic targeting of ectopically implanted MB49 tumors in C57B1/6J male mice. Treatment at 90 and 150 1.1.M significantly decrease NO production (19(a)) and urea synthesis and release (19(b)) in peritoneal macrophages. Peritoneal macrophages were recovered at the end of the study (day 26 after tumor implantation). Polarization to pro-inflammatory M1 macrophages is characterized by NO production through iNOS activity while urea synthesis through arginase-1 activity is related to polarization to anti-inflammatory M2 macrophages.
These results strongly suggest that in vivo therapeutic targeting of bladder tumors with compound 4 directly affects macrophage polarization in mice, probably via induction of an inflammatory anergy status, a process typically observed in normal intestinal macrophages. *p < 0.05 and ** p < 0.01 denote significant differences between treatments.
Figs. 20(a) and 20(b) refers to structure-function relationship study on the anti-inflammatory activity of compound 4. (20(a)) Chemical structures of compounds and 12. (20(b)) Graphical representation of LPS/IFN7-induced NO production in MB49-I cells after pretreatment with vehicle (DMSO) and the compounds 4 (30 M) and 12 at different concentrations (10, 20, 37.5 and 50 ?AM). Compound 12 even at higher concentration does not affect LPS/IFNThinduced NO synthesis. These results shown that the double bond in the heterocycle of the left part of the molecule is important for the inhibitory effect of compound 4 on NO production by macrophages and tumor cells * p < 0.01 denote significant difference compared to positive control (DMSO + LPS /IFN7);
Figs. 21(a) and 21(b) refers to the comparative effects of compounds 4, 8, 10, and 11 in NO production in MB49-1 cells. (21(a)) Chemical structures of compounds 4, 8, 10, and 11; (21(b)) Graphical representation of IFN7/LPS-induced NO production in MB49-1 cells after pretreatment with vehicle (DMSO) and the compounds 4, 8, 10, and 11 at 20 and 37.5 j.tM. These results shown that compound 8 at the same concentrations (20 and 37.5 i_tM) is more efficient than compound 4 to inhibit NO
production. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Figs. 22(a) and 22(b) represents images (22(a)) and graphical analysis (22(b)) showing Western blot analysis to determine the expression level of phosphorylated STAT1 in murine macrophages (RAW 264.7 cells) pretreated for 90 min with vehicle (DMSO) or compounds 4, 8, 10, and 11 (at 20 and 37.5 M), and then washed and recovered after 15 min of activation with 5 ng/mL IF1\17. The ratio of p-STAT1/STAT1 was calculated from densitometric analysis of each sample to evaluate the relative activation of the transcription factor STAT1. These results shown that compound 8 is more efficient than other compounds to inhibit 1FNy-activated signaling pathway in RAW 264.7 cells. * p < 0.05 and ** p < 0.01 denote significant differences between treatments;
Figs. 23(a) and 23(b) represents images (23(a)) and graphical analysis (23(b)) showing Western blot analysis to determine the expression level of phosphorylated 1KB in murine macrophages (RAW 264.7 cells) pretreated for 90 min with vehicle (DMSO) or compounds 4, 8, 10, and 11 (at 20 and 37.5 M), and then washed and recovered after 15 min of activation with 100 ng/mL LPS. The ratio of p-IkB/IkB was calculated from densitometric analysis of each sample to evaluate the relative deactivation of IKB proteins, the negative regulator of the transcription factor NFKB.
These results shown that all compounds are efficient to inhibit LPS-activated NFKB
signaling pathway in RAW 264.7 cells. * p < 0.05 and ** p <0.01 denote significant differences between treatments;
Figs. 24(a), 24(b) and 24(c) represents images and graphical analysis showing the comparative effects of compounds 4 and 8 in cell viability of murine UBC MB49-I
cells (24(a)), murine macrophages RAW 264.7 cells (24(b)) and human macrophages THP-1 cells (24(c)). Cells were pretreated for 90 min, with vehicle (DMSO) and compounds 4 and 8 at different concentrations, and then washed and counted after a 24-hour period of incubation to estimate the number of viable cells. These results demonstrated that the cytotoxic effect of compound 8 is lower than that of compound 4. * p < 0.05 denote significant differences between treatments.
Fig. 25 refers to the comparative anticancer activities of compounds 4 and 8 in the development of MB49-I tumors ectopically implanted in C57B1/6J male mice. In vivo targeting study showing episodic i.p. injections of compound 8 during 18 days is more efficient than compound 4 to reduce the tumor volume of muscle-invasive MB49-I
tumors (n=6) at the same concentration (150 PM). Tumors were chirurgically recovered at the end of the study (day 20 after tumor implantation). These results shown that compound 8 is more efficient than compound 4 to inhibit the development of highly invasive MB49-I tumors. * p < 0.05 and ** p < 0.01 denote significant differences between treatments.
Figs. 26(a) and 26(b) is a graphical representation of (26(a)) NO production and (26(b)) cell viability in the macrophage-like RAW 264.7 cells. (26(a)) Griess reagent and (26(b)) MTT assays were performed following a 24-h period of pro-inflammatory stimulation by IFNy (10 ng/mL) and LPS (100 ng/mL) after pretreatment with control (DMSO) and the molecules 1, 13a, 13b, and 13j. (26(a)) Compound 13j, but not 13a nor 13b, efficiently inhibited combined IFN7/LPS-induced NO synthesis;
compared to compound 1, compound 13j was 1.8 fold and 12 fold more efficient at 5 piM and [iM, respectively. (26(b)) While compounds 13a, 13b, and 13j had little or not positive effects on RAW 264.7 cell proliferation, compound 13j was 1.6 less toxic at 20 [i.1VI compared to compound 1. * p < 0.05 and ** p < 0.01 denote significant difference between each treatment dose with similar dose of compound 1.
Figs. 27(a) and 27(b) is a graphical representation of (27(a)) NO production and
27(b) cell viability in the macrophage-like RAW 264.7 cells. (27(a)) Griess reagent and (27(b)) MIT assays were performed following a 24-h period of pro-inflammatory stimulation by IFNy (10 ng/mL) and LPS (100 ng/mL) after pretreatment with control (DMSO) and the molecules 1, 13q, 13h, and 131. (27(a)) While compound 13q had similar anti-inflammatory activity than compound 1, compounds 13h and 131 were more efficient to inhibit combined IFNy/LPS-induced NO synthesis in RAW 264.7 cells; for instance, compared to compound 1, compound 131 was 2.7 fold and 7.5 fold more efficient at 5 !AM and 10 ttM, respectively. (27(b)) While compounds 13q and 131 had similar cytotoxic activity than compound 1, compound 13h was 1.5 more toxic at 10 ItM compared to compound 1. * p < 0.05 and ** p < 0.01 denote significant difference between each treatment dose with similar dose of compound 1.
Figs. 28(a) and 28(b) represents images (28(a)) and graphical analysis (28(b)) showing Western blot analysis to determine the expression level of phosphorylated STAT3 in human triple negative breast cancer cell line MDA-MB-231. (a) Cells were pretreated for 30 min with vehicle (DMSO) or compounds 1, 13a and 13j (all at 0, 10, 20 and 30 ccM), and then washed and recovered after 15 min of activation with ng/mL IL6. (b) The ratio of phosphorylated/no phosphorylated proteins was calculated from densitometric analysis of each sample to evaluate the relative activation of pSTAT1 or pSTAT3. These ratios were used to express the relative inhibition rate of pSTAT3. Compounds 1 and 13j, but not compound 13a, efficiently inhibited IL6-induced STAT3 activation. However, compared to compound 1, compound 13j was 1.6 fold and 3 fold more efficient at 20 ttM and 30 ttM, respectively. * p < 0.01 denote significant differences between each treatment dose with control (DMSO).
Figs. 29(a) and 29(b) represents images (29(a)) and graphical analysis (29(b)) showing Western blot analysis to determine the expression level of phosphorylated 1KB in human triple negative breast cancer cell line MDA-MB-231. (29(a)) Cells were pretreated for 30 min with vehicle (DMSO) or compounds 1, 13a and 13j (all at 0, 10, 20 and 30 ccM), and then washed and recovered after 5 min of activation with ng/mL TNFa. (29(b)) The ratio of phosphorylated IKB/r3-actine proteins was calculated from densitometric analysis of each sample to evaluate the relative activation of 11(13. These ratios were used to express the relative inhibition rate of 'KB.
Compounds 1 and 13j, but not compound 13a, efficiently inhibited IL6-induced STAT3 activation at lower doses. However, compared to compound 1, compound 13j was 3 fold and 2 fold more efficient at 20 [IM and 30 pIVI, respectively. * p <0.05 and ** p < 0.01 denote significant differences between each treatment dose with control (DMSO).
Fig. 30 is a graphical representation of relative cell viability on human triple negative breast cancer cell line MDA-MB-231 after pretreatment with vehicle (DMSO) and anti-inflammatory derivatives 1, 13a and 13j at different concentrations.
While all compounds had cytotoxic activity against MDA-MB-231 cells, compounds 13a and 13j were less toxic at 20, 30, and 40 M compared to compound 1; for instance, compared to compound 1, compound 13a was 1.4 fold, 2.5 fold, and 6.1 fold less toxic at 20, 30, and 40 p.M, respectively. * p < 0.01 denote significant difference between each treatment dose with similar dose of compound 1.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0027] The present disclosure concerns the discovery of small aminobenzoic acid derivatives showing anti-inflammatory, anti-metastatic, anti-proliferative and anticancer properties in vitro and in vivo. It describes the synthetic methodology to make these derivatives from readily available ortho-, meta- and para-benzoic acid and their biological applications for the treatment of a several types of cancers.
In addition, this disclosure relates to different pharmaceutical compositions comprising these compounds. The compounds and the pharmaceutical composition of this disclosure have been shown to possess anticancerous activity on various types of cancers. Furthermore, this disclosure provides novel treatment modalities against cancer. The unique biological properties of these compounds may be advantageously used to provide compounds with anticancer activity against cancers including but not limited to breast, prostate, ovarian and bladder cancers.
Figs. 28(a) and 28(b) represents images (28(a)) and graphical analysis (28(b)) showing Western blot analysis to determine the expression level of phosphorylated STAT3 in human triple negative breast cancer cell line MDA-MB-231. (a) Cells were pretreated for 30 min with vehicle (DMSO) or compounds 1, 13a and 13j (all at 0, 10, 20 and 30 ccM), and then washed and recovered after 15 min of activation with ng/mL IL6. (b) The ratio of phosphorylated/no phosphorylated proteins was calculated from densitometric analysis of each sample to evaluate the relative activation of pSTAT1 or pSTAT3. These ratios were used to express the relative inhibition rate of pSTAT3. Compounds 1 and 13j, but not compound 13a, efficiently inhibited IL6-induced STAT3 activation. However, compared to compound 1, compound 13j was 1.6 fold and 3 fold more efficient at 20 ttM and 30 ttM, respectively. * p < 0.01 denote significant differences between each treatment dose with control (DMSO).
Figs. 29(a) and 29(b) represents images (29(a)) and graphical analysis (29(b)) showing Western blot analysis to determine the expression level of phosphorylated 1KB in human triple negative breast cancer cell line MDA-MB-231. (29(a)) Cells were pretreated for 30 min with vehicle (DMSO) or compounds 1, 13a and 13j (all at 0, 10, 20 and 30 ccM), and then washed and recovered after 5 min of activation with ng/mL TNFa. (29(b)) The ratio of phosphorylated IKB/r3-actine proteins was calculated from densitometric analysis of each sample to evaluate the relative activation of 11(13. These ratios were used to express the relative inhibition rate of 'KB.
Compounds 1 and 13j, but not compound 13a, efficiently inhibited IL6-induced STAT3 activation at lower doses. However, compared to compound 1, compound 13j was 3 fold and 2 fold more efficient at 20 [IM and 30 pIVI, respectively. * p <0.05 and ** p < 0.01 denote significant differences between each treatment dose with control (DMSO).
Fig. 30 is a graphical representation of relative cell viability on human triple negative breast cancer cell line MDA-MB-231 after pretreatment with vehicle (DMSO) and anti-inflammatory derivatives 1, 13a and 13j at different concentrations.
While all compounds had cytotoxic activity against MDA-MB-231 cells, compounds 13a and 13j were less toxic at 20, 30, and 40 M compared to compound 1; for instance, compared to compound 1, compound 13a was 1.4 fold, 2.5 fold, and 6.1 fold less toxic at 20, 30, and 40 p.M, respectively. * p < 0.01 denote significant difference between each treatment dose with similar dose of compound 1.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0027] The present disclosure concerns the discovery of small aminobenzoic acid derivatives showing anti-inflammatory, anti-metastatic, anti-proliferative and anticancer properties in vitro and in vivo. It describes the synthetic methodology to make these derivatives from readily available ortho-, meta- and para-benzoic acid and their biological applications for the treatment of a several types of cancers.
In addition, this disclosure relates to different pharmaceutical compositions comprising these compounds. The compounds and the pharmaceutical composition of this disclosure have been shown to possess anticancerous activity on various types of cancers. Furthermore, this disclosure provides novel treatment modalities against cancer. The unique biological properties of these compounds may be advantageously used to provide compounds with anticancer activity against cancers including but not limited to breast, prostate, ovarian and bladder cancers.
[0028] The term a "therapeutically effective amount", "effective amount" or a "sufficient amount" of a compound of the present disclosure is a quantity sufficient to, when administered to the subject, including a mammal, for example a human, effect beneficial or desired results, including clinical results, and, as such, an "effective amount" or synonym thereto depends upon the context in which it is being applied.
For example, in the context of treating cancer, for example, it is an amount of the compound sufficient to achieve such treatment of the cancer as compared to the response obtained without administration of the compound. The amount of a given compound of the present disclosure that will correspond to an effective amount will vary depending upon various factors, such as the given drug or compound, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the art. Also, as used herein, a "therapeutically effective amount", "effective amount" or a "sufficient amount" of a compound of the present disclosure is an amount which inhibits, suppresses or reduces a cancer (e.g., as determined by clinical symptoms or the amount of cancerous cells) in a subject as compared to a control.
For example, in the context of treating cancer, for example, it is an amount of the compound sufficient to achieve such treatment of the cancer as compared to the response obtained without administration of the compound. The amount of a given compound of the present disclosure that will correspond to an effective amount will vary depending upon various factors, such as the given drug or compound, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the art. Also, as used herein, a "therapeutically effective amount", "effective amount" or a "sufficient amount" of a compound of the present disclosure is an amount which inhibits, suppresses or reduces a cancer (e.g., as determined by clinical symptoms or the amount of cancerous cells) in a subject as compared to a control.
[0029] The term "subject" as used herein includes all members of the animal kingdom including human. According to one embodiment, the subject is a human.
[0030] The term "alkyl" as used herein means straight and/or branched chain, saturated alkyl groups containing from one to n carbon atoms and includes (depending on the identity of n) methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, 2,2-dimethylbutyl, n-pentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, n-hexyl and the like, wherein n is the maximum number of carbon atoms in the group.
[0031] The expression "an alkyl component of a naturally occurring amino acid" as used herein refers to the portion of a naturally occurring amino acid that is comprised between the carbon of the carbonyl group of the amino acid and the nitrogen atom of the amino acid.
[0032] The expression "compound(s) of the present disclosure" as used in the present document refers to compounds of formulae I, IA, IB, IC, ID, IE, IIA, IIB and IIC presented in the present disclosure, isomers thereof, such as stereoisomers (for example, enantiomers, diastereoisomers, including racemic mixtures) or tautomers, or to pharmaceutically acceptable salts, solvates, hydrates and/or prodrugs of these compounds, isomers of these latter compounds, or racemic mixtures of these latter compounds. The expression "compound(s) of the present disclosure" also refers to mixtures of the various compounds or variants mentioned in the present paragraph.
[0033] The term "halogen" as used herein comprises fluoro, chloro, bromo and iodo.
[0034] It is to be clear that the present disclosure includes isomers, racemic mixtures, pharmaceutically acceptable salts, solvates, hydrates and prodrugs of compounds described therein and mixtures comprising two or more of such compounds.
[0035] The compounds of the disclosure may have at least one asymmetric centre. Where the compounds according to the present document possess more than one asymmetric centre, they may exist as diastereomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present disclosure. It is to be understood that while the stereochemistry of the compounds of the present disclosure may be as provided for in any given compound listed herein, such compounds of the disclosure may also contain certain amounts (for example less than 30%, less than 20%, less than 10%, or less than 5%) of compounds of the present disclosure having alternate stereochemistry.
[0036] The term "suitable", as in for example, "suitable counter anion" or "suitable reaction conditions" means that the selection of the particular group or conditions would depend on the specific synthetic manipulation to be performed and the identity of the molecule but the selection would be well within the skill of a person trained in the art. All process steps described herein are to be conducted under conditions suitable to provide the product shown. A person skilled in the art would understand that all reaction conditions, including, for example, reaction solvent, reaction time, reaction temperature, reaction pressure, reactant ratio and whether or not the reaction should be performed under an anhydrous or inert atmosphere, can be varied to optimize the yield of the desired product and it is within their skill to do so.
[0037] The expression "pharmaceutically acceptable" means compatible with the treatment of subjects such as animals or humans.
[0038] The expression "pharmaceutically acceptable salt" means an acid addition salt or basic addition salt which is suitable for or compatible with the treatment of subjects such as animals or humans.
[0039] The expression "pharmaceutically acceptable acid addition salt" as used herein means any non-toxic organic or inorganic salt of any compound of the present disclosure, or any of its intermediates. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as para-toluene sulfonic and methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of the compounds of the present disclosure are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts, e.g. oxalates, may be used, for example, in the isolation of the compounds of the present disclosure, for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt. In embodiments of the present disclosure, the pharmaceutically acceptable acid addition salt is the hydrochloride salt.
[0040] The term "pharmaceutically acceptable basic addition salt- as used herein means any non-toxic organic or inorganic base addition salt of any acid compound of the disclosure, or any of its intermediates. Acidic compounds of the disclosure that may form a basic addition salt include, for example, where R
is CO2H.
Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art. Other non-pharmaceutically acceptable basic addition salts, may be used, for example, in the isolation of the compounds of the disclosure, for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
is CO2H.
Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art. Other non-pharmaceutically acceptable basic addition salts, may be used, for example, in the isolation of the compounds of the disclosure, for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
[0041] The formation of a desired compound salt is achieved using standard techniques. For example, the neutral compound is treated with an acid or base in a suitable solvent and the formed salt is isolated by filtration, extraction or any other suitable method.
[0042] The term "solvate" as used herein means a compound of the present disclosure, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent is physiologically tolerable at the dosage administered.
Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a "hydrate". The formation of solvates of the compounds of the present disclosure will vary depending on the compound and the solvate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.
Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a "hydrate". The formation of solvates of the compounds of the present disclosure will vary depending on the compound and the solvate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.
[0043] Compounds of the present disclosure include prodrugs. In general, such prodrugs will be functional derivatives of these compounds which are readily convertible in vivo into the compound from which it is notionally derived.
Prodrugs of the compounds of the present disclosure may be conventional esters formed with available hydroxy, or amino group. For example, an available OH or nitrogen in a compound of the present disclosure may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g. an acid chloride in pyridine).
Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C8-C24) esters, acyloxymethyl esters, carbamates and amino acid esters. In certain instances, the prodrugs of the compounds of the present disclosure are those in which one or more of the hydroxy groups in the compounds is masked as groups which can be converted to hydroxy groups in vivo. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985.
Prodrugs of the compounds of the present disclosure may be conventional esters formed with available hydroxy, or amino group. For example, an available OH or nitrogen in a compound of the present disclosure may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g. an acid chloride in pyridine).
Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C8-C24) esters, acyloxymethyl esters, carbamates and amino acid esters. In certain instances, the prodrugs of the compounds of the present disclosure are those in which one or more of the hydroxy groups in the compounds is masked as groups which can be converted to hydroxy groups in vivo. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985.
[0044] Compounds of the present disclosure include radiolabeled forms, for example, compounds labeled by incorporation within the structure 2H, 3H, 14C, 15N, or a radioactive halogen such as 1251. A radiolabeled compound of the compounds of the present disclosure may be prepared using standard methods known in the art.
[0045] As used herein, and as well understood in the art, "treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" or "treating" can also mean prolonging survival as compared to expected survival if not receiving treatment.
[0046] "Palliating" a disease or disorder, means that the extent and/or undesirable clinical manifestations of a disorder or a disease state are lessened and/or time course of the progression is slowed or lengthened, as compared to not treating the disorder.
[0047] In understanding the scope of the present disclosure, the term "comprising" and its derivatives, as used herein, are intended to be open ended terms that specify the presence of the stated features, elements, components, groups, integers, and/or steps, but do not exclude the presence of other unstated features, elements, components, groups, integers and/or steps. The foregoing also applies to words having similar meanings such as the terms, "including", "having" and their derivatives. Finally, terms of degree such as "substantially", "about" and "approximately" as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least 5% of the modified term if this deviation would not negate the meaning of the word it modifies.
[0048] In an embodiment of the present disclosure, there are included compounds of formula (IA) :
(IA) wherein R2, R3, R4 and Q are as previously defined.
(IA) wherein R2, R3, R4 and Q are as previously defined.
[0049] In another embodiment of the present disclosure, there are included compounds of formula (TB) :
R3 N.......................<
zi....,......< N ___ Q
/
(IB) wherein R2, R3, R4 and Q are as previously defined.
R3 N.......................<
zi....,......< N ___ Q
/
(IB) wherein R2, R3, R4 and Q are as previously defined.
[0050] In a further embodiment of the present disclosure, there are included compounds of formula (IC) :
H........
/
HV---------< \
(IC) wherein R2, R5 and R6 are as previously defined.
H........
/
HV---------< \
(IC) wherein R2, R5 and R6 are as previously defined.
[0051] In still a further embodiment of the present disclosure, there are included compounds of formula (ID) :
N-N
( (ID) wherein R2, R3, R4 and R7 are as previously defined.
N-N
( (ID) wherein R2, R3, R4 and R7 are as previously defined.
[0052] In still a further embodiment of the present disclosure, there are included compounds of formula (IE) :
H
/N-N
H
( (1E) wherein R2 and R7 are as previously defined.
H
/N-N
H
( (1E) wherein R2 and R7 are as previously defined.
[0053] In still a further embodiment of the present disclosure, R2 is H, unsubstituted member chosen from acetyl and propiolyl;
Q is QA;
R5 is H, unsubstituted member chosen from acetyl and propiolyl; and R6 is Boc, H, or an unsubstituted member chosen from acetyl and propiolyl.
Q is QA;
R5 is H, unsubstituted member chosen from acetyl and propiolyl; and R6 is Boc, H, or an unsubstituted member chosen from acetyl and propiolyl.
[0054] In still a further embodiment of the present disclosure, R2 is H or unsubstituted member chosen from acetyl and propiolyl; and R7 is an unsubstituted member chosen from Cl-Cs alkyl, C3-C6 cycloalkyl, phenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl.
[0055] For example, in a further embodiment of the present disclosure, the compound of formula I is as previously defined with the proviso that the compound is different from 41\1 c _____ 0 NHNH2*HC1 and NHNH2*CF3CO211 0 0
[0056] However, according to an embodiment the above three excluded compounds are not to be excluded from the scope of the various uses and methods as previously described.
[0057] According to another embodiment, the above three excluded compounds are to be excluded from the scope of the various uses and methods as previously described.
[0058] In still a further embodiment of the present disclosure, there are included compounds of the following formulas:
0 0 o ci ---1( NHNH-- ( . . 0 I N 0 _____________________________ 0 ---1 --AC NHNH¨ /
0 CI 0 0 __ 4a 4b ,--A . 0 0 I N )1"-R
N li ----- NHN
O Ir-R NEINBoc 0 R 1:) 8 (R = CH3) 10 (R = CH3) * 0 ---A
N = 0 I N Boc ----\ N¨N ---.1 NHNHBoc O R-i =o 0 11 (R = CH3) H
,N..._"--s4N * HN-NH
Boc 0 'Floc
0 0 o ci ---1( NHNH-- ( . . 0 I N 0 _____________________________ 0 ---1 --AC NHNH¨ /
0 CI 0 0 __ 4a 4b ,--A . 0 0 I N )1"-R
N li ----- NHN
O Ir-R NEINBoc 0 R 1:) 8 (R = CH3) 10 (R = CH3) * 0 ---A
N = 0 I N Boc ----\ N¨N ---.1 NHNHBoc O R-i =o 0 11 (R = CH3) H
,N..._"--s4N * HN-NH
Boc 0 'Floc
[0059] For example, the compound can be chosen from 0 yt... .7-14 I N Iii N 4. 0 I N . 0 ,Boc NHN
0 IrCH3 NHNBoc ----\ N¨N
0 H3C .(1) 0 H3C
I N li 0 I N . 0 ----\ HN-NH N¨N11 O ,31 and 1) H3C--i 0
0 IrCH3 NHNBoc ----\ N¨N
0 H3C .(1) 0 H3C
I N li 0 I N . 0 ----\ HN-NH N¨N11 O ,31 and 1) H3C--i 0
[0060] For example, the compounds can be chosen from ()tcH3 * 1 N * ,Boc NHNIrCH3 NHNBoc ----\ N¨N
HN-NH I N *
0 0 ---1 N¨NH
H3C 0 H3C- =O
---I ----k I N 1, 0 I N * 0 ---- FIN-N
HN- \ N ii and ---1 *
\
HN-NH I N *
0 0 ---1 N¨NH
H3C 0 H3C- =O
---I ----k I N 1, 0 I N * 0 ---- FIN-N
HN- \ N ii and ---1 *
\
[0061] For example, the compounds can be chosen from O o o o 0 . Boc . 0 yi...c NHN H . 3 NHNBoc N¨N
O )r-CH3 0 H3C '-0 0 H3C
.
( II
NHNH-i< ( NHNH2*HC1 O _____________________________________ 0 0 HN-NH N¨NH
O o 0 H3C- 0 H3C 0 H3c o 0 N. 0 0 1---k I N .
HN-N and HN-N
O \ li OH 0 0C113 \ . '
O )r-CH3 0 H3C '-0 0 H3C
.
( II
NHNH-i< ( NHNH2*HC1 O _____________________________________ 0 0 HN-NH N¨NH
O o 0 H3C- 0 H3C 0 H3c o 0 N. 0 0 1---k I N .
HN-N and HN-N
O \ li OH 0 0C113 \ . '
[0062] For example, the compounds can be chosen from ip 0 NHNH2*I ICI
O ______________________________________ 0 0 1-14N = 0 0 =
NHN
CFHI33 NHNBoc and N _N Boc 0 H3C 0113c
O ______________________________________ 0 0 1-14N = 0 0 =
NHN
CFHI33 NHNBoc and N _N Boc 0 H3C 0113c
[0063] For example, RH can be substituted or unsubstituted member chosen from phenyl, furanyl and thiophenyl.
[0064] For example, at least one of R13, R14 and R15 can be different from H.
[0065] For example, at least one of R13, R14 and R15 is -OH.
[0066] For example, at least one of R13, R14 and R15 is -OCH3.
[0067] For example, at least one of R13, R14 and Ris is C2-C8 alkyl.
[0068] For example, at least one of R13, Ri4 and R15 is -0R12 in which R12 is C2-Cs alkenyl.
[0069] For example, the compound is chosen from OH
0 and HN __ N
OCH,
0 and HN __ N
OCH,
[0070] For example, said compound is chosen from N
HN __ N
HN¨N
HO OCH, HN __ N
N
FIN N
o/
j(1 0 FIN¨N
100711 For example, RI I can be chosen from 2,4-dihydroxyphenyl 3,5-ditertbuty1-4- 4-methoxyphenyl hydroxybenzaldehyde 2-hydroxy-3-methoxyphenyl 3,4-dimethoxyphenyl 4-allyloxyphenyl 2-furanyl 2-pyridyl 3-pyridyl 4-pyridyl phenylethenyl 4-chlorophenyl 4-fluorophenyl 4-trifluoromethylphenyl and .. 4-nitrophenyl.
[0072] Schemes 1 to 4 represent examples of synthetic routes used for the preparation of the compounds of the present disclosure. The reaction conditions of each step are presented directly in the schemes.
[0073] Using para-amino benzoic acid (1) as the starting material derivative 4 was made in a three-step reaction sequence (Scheme 1).9-11 Para-amino benzoic acid (1 or PABA) was first reacted with maleic anhydride (MA) in dry acetone to give the diacid (2) with 90% yield. Cyclisation to form the maleimide was accomplished with acetic anhydride and sodium acetate to give compound 3 with 89% yield after hydrolysis of the mixed anhydride intermediate with water. Finally, activation of acid 3 with iso-butyl chloroformate in the presence of pyridine was done followed by treatment with tert-butyl carbazate gave the desired anti-inflammatory derivative 4 with 54% yield. Deprotection of 4 with hydrochloric acid in ether gave the hydrochloride salt 5 with 46% yield after recrystallization. Example 1 shows the preparation of compounds 4 and 5. This reaction sequence can be used to produce other derivatives starting from unsubstituted or substituted ortho-, meta- and para-benzoic acid starting materials. Hence, this approach lead to the synthesis of N'13-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoy11-hydrazine carboxylic acid tent-butyl ester (4a) and N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-2-chloro-benzoyl]-hydrazine carboxylic acid tert-butyl ester (4b) shown in examples 2 and 3, respectively.
1-1,1\1 =
a HN
1 2 (90%) 3 (88%) <14 () N 0 IN
NHNH¨ ( NHNII)*IICI
0 0 ___________________ 0 4 (54%) 5 (46%) Reagents and conditions: a) Maleic anhydride (MA), dry acetone, methanol, 22 C, 1 h; b) I) Ac,O.
AcONa, 50 C, 2 h; 2) H20, 70 C, 2 h; c) 1) iso-butyl chloroformate, Et3N, CH2Cl2, 0 C, I h and 22 C, 1 h; 2) tert-butyl carbazate, CH2Cl2, 22 C, 12 h; d) HCI, dioxane, 22 C, 5 h.
Scheme 1 100741 Further transformations of derivative 4 can lead to novel compounds with anti-inflammatory, anti-metastatic, anti-proliferative and anticancer activities (Scheme 2). However, catalytic hydrogenation of 4 led to compound 12 which lost its anti-inflammatory activity (see example 4). Otherwise, compound 4 is transformed into its trifluoroacetate salt 6 upon treatment with trifluoroacetic acid in dichloromethane. The crude material 6 can be reacted either with acetyl chloride or acetic anhydride (or any relevant anhydride or acid chloride) to give derivative 8. Of note, derivatives 7 and 9 were likely produced but not isolated in example 5.
Alternatively, compound 4 can be acylated with a relevant anhydride or acid chloride to yield compound 10 and 11. Interestingly, using acetyl chloride, compound 4 was transformed efficienly into the diacetylated derivative 11 (R = CH3) and, with acetic anhydride the main product of the reaction was the monoacetylated derivative 10 (R =
CH3). Derivative 10 can be deprotected to give 7 and derivative 11 can lead to derivative 9. It is possible to produce efficienly compound 7 and 9 via a two-step sequence from 4.
- o o 11 NHNHBoc NHNHBoc a [ N '11 b HN¨N
NHNH2*CF3CO2H 0 +
b N *
N XR
NHNHBoc li = e*
NHNIT¨R
0 0 =c' 8 (R = CH3) 0 e + N * Boc 0 NHNBoc N¨N. a 0 0 N li .1c, (from 11 to yield 9) NNH 1\ 0 10 (R = CH3) 11 (R = CH3) 9 OR
Reagents and conditions: a) TFA, CH2C12, 22 C, 0.5 h; b) Relevant anhydride or acid chloride, Et0Ac, 22 C, 30 mm to 2 h; c) H2, Pd/C, CH3OH, 22 C, 3 h.
Scheme 2 [0075] Scheme 3 presents the methodology leading to 13 the alkylhydrazones or arylhydrazones derivatives following the procedure described by Taha et al.12 Accordingly, compound 5 can be treated with a relevant aldehyde (alkyl aldehydes (linear or branched), benzaldehyde or substituted benzaldehydes or other arylaldehydes) under acidic conditions at reflux in butanol (or other solvent) to give the desired derivatives of general structure 13.
N li a .---1( NHNH2 --,..------ HN¨N=\
R = alkyl or aromatic (unsubstituted or substituted) Reagents and conditions: a) RCHO, H+, Butanol, reflux, 1 to 5 h.
Scheme 3 [0076] On Scheme 4, derivative 4 (or any other maleimides described herein) can be reacted with an appropriate diene (butadiene (unsubstituted or substituted), cyclopentadiene, cyclohexadiene cycloheptadiene, furane, thiophene, pyrrole, N-alkylpyrrole) to give the desired cycloadducts (Diets-Alder products) such as 14, 15 and 16. This reaction can be performed by heating the pure reagents (diene and dienophile) either neat or in solution, with or without pressure as it is described in example 10.
H
N
HN¨Q
a or or 41) N
NI-I-Q
4 H X=O,S,NHorNR
N
n = I, 2 or 3 Relevant diene = butadiene (unsubstituted or substituted), cyclopentadiene, cyclohexadiene, furane, thiophene, pyrrole, N-alkyl pyrrole.
Reagents and conditions: a) Relevant diene, toluene, A, 3 h.
Scheme 4 [0077] As it can be appreciated by the skilled artisan, the above synthetic schemes are not intended to be a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized.
Further methods can also potentially be used to prepare the compounds of the present disclosure.
[0078] The compounds of the present disclosure may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
[0079] The compounds of the present disclosure may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomer, diastereomeric mixtures and individual diastereoisomers.
All such isomeric forms of these compounds are expressly included in the present disclosure.
Each stereogenic carbon may be of the R or S configuration.
[0080] It has been found that the small aminobenzoic acid derivatives herein disclosed display anti-inflammatory, anti-metastatic, anti-proliferative and/or anti-cancer properties as well as favorable toxicity profiles, and may be used for example in treating malignancies, for example muscle-invasive and superficial UBC
tumors, for example in humans.
[0081] An aspect herein provided is a method for treating cancer or at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined herein, [0082] Another aspect is a method for reducing the risks of developing cancer or for reducing the risk of developing at least one cancer in a subject, the cancer being, for example, chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer, the method comprising administering to the subject an effective amount of at least one compound as defined herein.
[0083] Yet a further aspect is a method for inhibiting cancer cell growth, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined herein.
[0084] For example, the cancer cell growth is inhibited by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to an untreated subject.
[0085] Another aspect is a method for inhibiting tumor growth and/or reducing tumor size, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined herein.
[0086] For example the tumor size is measured in weight and/or volume.
[0087] For example, the tumor growth and/or tumor size is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to an untreated subject.
[0088] For example, administration of an effective amount of at least one compound disclosed herein to a subject in need thereof increases time to progression of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
[0089] For example, the compound herein disclosed is for use in reducing risks of developing at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
[0090] For example, the compound is for use in the treatment of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
[0091] For example, the compound is for use as an anticancer agent.
[0092] For example the compound is for use as an anti-inflammatory agent.
[0093] For example the compound is for use as an anti-metastatic agent.
[0094] As described herein, several compounds, namely derivatives 4, 5, 8, 10, 11, and 12, were tested on macrophages and UBC cells for their anti-inflammatory, anti-metastatic and/or anti-cancer properties.
[0095] As shown herein, the compounds presently disclosed display anti-inflammatory properties.
[0096] Referring to Fig. 1 to 10, in vitro studies of human macrophages and UBC cells tested with compounds 4 and 5 were conducted to investigate the anti-inflammatory properties of the compounds on pro-inflammatory cytokines. As shown in Fig. 1, IFNy-induced STAT1 activation and IL6-induced STAT3 activation were decreased in pretreated human macrophages. Similarly, compounds 4 and 5 were found effective in reducing IFNy-induced CD40 and MHC-II expressions, as shown in Fig. 2. Also, referring to Fig. 3, scratch wound healing assays were conducted and compounds 4 and 5 were found effective in inhibiting IFNy-induced STAT1 activation and IL6-induced STAT3 activation in human macrophages.
[0097] An aspect provided is a method for decreasing anti-inflammatory properties of cancer cells, the method comprising contacting the cancer cells with at least one compound as defined herein.
[0098] For example the relative STAT1 activation of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[0099] For example the relative STAT3 activation of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00100] For example the CD40 expression of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00101] For example the MHC-II expression of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00102] Referring now to Fig. 4 and 5, anti-inflammatory activity of compounds 4 and 5 was assessed by measuring nitric oxide (NO) production in murine macrophage-like cells stimulated with inflammatory signals, IFNy/TNFa.
Compounds 4 and 5 were found effective in reducing IFNy/TNFoc induced NO
production.
[00103] For example, NO production in cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00104] Referring to Fig. 6 and 7 it was demonstrated that compounds 4 and 5 have anti-proliferative properties in UBC cells stimulated with IFNy/TNFoc.
[00105] An aspect provided is a method for inducing anti-proliferative properties of cancer cells, the method comprising contacting the cancer cells with at least one compound as defined herein.
[00106] For example, the viability of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00107] For example, the cancer cell growth is inhibited by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to untreated cancer cells.
[00108] Referring now to Fig. 8, compound 4 was shown to inhibit TNFa/NFKB and IL6/STAT3 signaling pathways in murine UBC cells. Compound 4 was also tested in human UBC cells and was shown to inhibit 1L6-induced motility, as shown in Fig. 9. Similarly, referring to Fig. 10, a human breast cancer cell line was treated with compound 4 which demonstrated anti-invasion properties, thus demonstrating that compound 4 is not cell-specific.
[00109] For example, the TNFa/NFKB and/or IL6/STAT3 signaling pathways of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to untreated cells.
[00110] For example, the invasiveness of cells with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00111] In vivo studies were also conducted to evaluate the anticancer, anti-proliferative and anti-metastatic activities of compound 4 in ectopic and orthotopic murine models of UBC.
[00112] Acute toxicity studies in mice, as shown in Fig. 11, demonstrated that treatment with compound 4 had no obvious effect on normal development and viability, as well as in organ weight and hematocrit, suggesting tolerability in the mice. Similarly, referring to Fig. 12, no evidence of toxicity related to compound 4 was found in liver histological analyses in mice treated with various concentrations of compound 4.
[00113] For example, subjects treated with a compound disclosed herein have a similar body weight relative to a comparable untreated subject. "Similar body weight"
as used herein means no greater than a 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% difference in body weight loss.
[00114] For example, subjects treated with a compound disclosed herein have a similar hematocrit relative to a comparable untreated subject. "Similar hematocrit" as used herein means no greater than a 5%, 4%, 3%, 2% or 1% difference in hematocrit level.
[00115] As demonstrated herein, the compounds herein disclosed display anti-proliferative and anti-metastatic activity.
[00116] Referring to Fig. 13 and 14, male mice implanted ectopically with UBC tumors and treated with compound 4 saw a significant decrease in tumor proliferation and in the number of metastases relative to untreated mice. In female mice bearing orthotopically implanted urothelial bladder cancer tumors, as shown in Fig. 15, anti-proliferative properties of compound 4 were also seen. More particularly, the tumor development was stopped after two weeks of treatment. Similarly, mice ectopically implanted with urothelial bladder cancer tumors and treated with compound 4 saw a significant reduction of the tumor size, as illustrated in Fig. 18.
[00117] For example, tumors treated with a compound disclosed herein have a decrease in volume and/or a decrease in tumor growth of at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to untreated tumors.
[00118] Another aspect is a method for decreasing and/or preventing tumor metastases, the method comprising administering to a subject in need thereof an effective amount of at least one compound disclosed herein.
[00119] For example, the number of tumor metastases is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to an untreated subject.
[00120] Referring to Fig. 19, further in vivo murine studies of anti-inflammatory properties of compound 4 were conducted and a significant decrease in NO production and urea synthesis was found in peritoneal macrophages.
[00121] Derivatives of compound 4 were also found to display anti-inflammatory, anticancer, anti-proliferative and anti-metastatic properties.
Additional in vitro and in vivo studies of compound 4 derivatives, compounds 8, 10 and 11 were conducted in macrophages and UBC cells.
[00122] Fig. 21 shows that these compounds were effective in inhibiting NO
production. The compounds were also effective in inhibiting the IFN7-activated STAT1 signaling pathway and the LPS-activated NFK13 signaling pathway in macrophage cells (Fig. 22 and 23).
[00123] For example, the LPS-activated NFic13 signaling pathway of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to untreated cells.
[00124] Referring now to Fig. 25, compounds 4 and 8 were found to have anti-proliferative activity in ectopically implanted UBC tumors in male mice.
[00125] For example, the compound is compound 4.
[00126] For example, the compound is compound 8.
[00127] For example, the compound is compound 10.
[00128] For example, the compound is compound 11.
[00129] For example, the subject is a mammal. For example, the subject is a human.
[00130] For example, the cell is in vitro.
[00131] For example, the cell is in vivo.
[00132] For example, the cell is a cancer cell.
[00133] For example, the cancer is melanoma, uterine cancer, ovarian cancer, prostate cancer or bladder cancer.
[00134] For example, the bladder cancer is superficial UBC or muscle invasive UBC.
[00135] For example the tumor is a melanoma tumor, uterine tumor, ovarian tumor, prostate tumor or bladder tumor.
[00136] For example, the bladder tumor is a superficial UBC tumor or a muscle invasive UBC tumor.
[00137] For example, the methods disclosed herein are effective for presenting the development of superficial UBC into muscle invasive UBC tumor.
[00138] For example, the at least one compound as defined in the present disclosure can be used in the manufacture of a medicament for decreasing and/or preventing pathological humoral and cell-mediated inflammation of at least one disease chosen from inflammatory diseases (Crohn's disease, rheumatoid arthritis, asthma, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, reperfusion injury or transplant rejection); pregnancy complications (preeclampsia or preterm birth); or gynecological pathologies (endometriosis, uterine leiomyoma, polycystic ovary syndrome or recurrent miscarriage).
[00139] In the present disclosure, the following abbreviations are used:
Abbreviation Meaning Ac20 Acetic anhydride AcONa Sodium acetate CH2Cl2 Dichloromethane Boc t-Butyloxycarbonyl Et20 Diethyl ether Et0Ac Ethyl acetate Et3N Triethyl amine Hour MCI Chlorhydric acid i.p. Intraperitoneal m Meta MA Maleic anhydride Me0H Methanol min Minute mmol Millimole MTT 3-(4,5-Dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide NMR Nuclear magnetic resonance o Ortho p Para Phe Phenyl s.c. Subcutaneously TLC Thin layer chromatography TFA Trifluoroacetic acid UBC Urothelial bladder cancer EXAMPLES
[00140] This section also describes the synthesis of several compounds that are presented in this document. These examples are not to be construed as limiting the scope of the present disclosure in any way.
Materials and Methods - Chemistry [00141] Anhydrous reactions were performed under an inert atmosphere, the set-up assembled and cooled under dry nitrogen. Unless otherwise noted, starting material, reactant and solvents were obtained commercially and were used as such or purified and dried by standard means.13 Organic solutions were dried over magnesium sulfate, evaporated on a rotatory evaporator and under reduced pressure. All reactions were monitored by UV fluorescence, or staining with iodine. Commercial TLC
plates were Sigma T 6145 (polyester silica gel 60 A, 0.25mm). Flash column chromatography was performed according to the method of Still and co-workers on Merck grade 60 silica gel, 230-400 mesh.' All solvents used in chromatography had been distilled prior to use.
[00142] The infrared spectra were taken on a Nicolet Impact 420 FT-IR.
Mass spectral assays were obtained using a MS model 6210, Agilent technology instrument.
The high resolution mass spectra (HRMS) were obtained by TOF (time of flight) using ESI (electrospray ionization) using the positive mode (ES1+).
(Plateforme analytique pour molecules organiques de FUniversite du Quebec a Montreal).
[00143] Nuclear magnetic resonance (NMR) spectra were recorded on a Varian 200 MHz NMR apparatus. Samples were dissolved in deuterochloroform (CDC13), deuteroacetone (acetone-d6) or deuterodimethylsulfoxide (DMSO-d6) for data acquisition using tetramethylsilane or chloroform as internal standard (TMS, 8 0.0 ppm for 1H-NMR and CDC13 877.0 ppm for 13C-NMR). Chemical shifts (8) are expressed in parts per million (ppm), the coupling constants (J) are expressed in hertz (Hz). Multiplicities are described by the following abbreviations: s for singlet, d for doublet, dd for doublet of doublets, t for triplet, dt for doublet of triplets, q for quartet, dq for doublet of quartets, m for multiplet, #m for several multiplets, br for a broad signal.
[00144] The following compounds were prepared from a relevant aminobenzoic acid derivative using the procedures summarized in schemes 1, 2, 3 or 4.
Example 1. Preparation of N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoyll-hydrazine carboxylic acid tert-butyl ester (4), its hydrochloric acid salt (5) and its trilluoroacetic acid salt (6) Step A. Synthesis of 4-(3-carboxy-acryloylamino)-benzoic acid (2) [00145] 4-Aminobenzoic acid (1, 5.34 g, 38.93 mmol) was dissolved in dry acetone (12 mL) to which was added methanol (1 mL). Maleic anhydride (1.05 eq.) dissolved in dry acetone was added to the first solution. The reaction mixture was stirred for a period of 2 h allowing sufficient time for the complete precipitation of the diacid 2. The precipitate was filtered and washed twice with acetone (2 x 2 mL) and dried in a desiccator overnight. The crude diacid 2 (9.16 g, 90%) was sufficiently pure to be use without further purification at the next step. IR (v, cm-1): 3500-(CO2H), 1686 cm-1 (C=0); 11-1 NMR (DMSO-d6, (5 ppm): 12.79 (br s, 2 H, 2 x CO2H), 10.58 (s, 1H, NH), 7.89 and 7.71 (2 x d, J=8.6 Hz, 4H, aromatic), 6.48 and 6.30 (2 x d, J=12.2 Hz, 2H, maleimide); 13C NMR (DMSO-d6, (5 ppm): 167.4, 167.3, 164.1, 143.2, 132.1, 130.9 (2), 130.6, 126.0, 119.2 (2); ESI+ HRMS: (M+H)+
calculated for CI iHioN05 = 236.0553; found = 236.0558.
Step B. Synthesis of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid (3) [00146] The diacid 2 (2.01 g, 8.54 mmol) was treated with acetic anhydride (4.0 mL, 36.28 mmol) and anhydrous sodium acetate (350 mg, 4.27 mmol) and the mixture heated at 50 C for 2 h. Afterwards, the solution was evaporated to dryness and stirred with water at 70 C for a period of 2 h. The resulting precipitate was filtered and dried in a desiccator overnight to yield 1.65 g (89%) of maleimide 4. The spectral data of this derivative correspond to those reported in the literature.9,11 IR (v, cm-1): 3475-2600 (CO2H), 1715 (C=0), 1704 (C=0); NMR
(acetone-d6, 6 ppm):
8.14 and 7.57 (2 x d, J=8.6 Hz, 4H, aromatic), 7.08 (s, 2H, maleimide); BC NMR
(acetone-d6, 6 ppm): 169.3 (2), 166.2, 136.2, 134.7 (2), 130.1 (2), 129.3, 125.8 (2);
ESI+ HRMS: (M+H)+ calculated for CliF18N04 = 218.0448; found = 218.0447.
Step C. Synthesis of N44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoy1]-hydrazine carboxylic acid tert-butyl ester (4) [00147] Derivative 4 was synthesized using a modified procedure reported by Willner et al.15 as it is also described by Lau et al. and Hamelin-Morrissette et al.9-11 A cooled suspension (0 C) of molecule 3 (211 mg, 0.97 mmol) in methylene chloride (4.5 mL) was treated with triethylamine (190 ?AL, 1.36 mmol) and isobutyl chloroformate (175 !IL, 1.34 mmol). The mixture was stirrred for I h at 0 C
and at room temperature (22 C) for about 1 h. Afterwards, tert-butyl carbazate (128 mg, 0.97 mmol) dissolved in methylene chloride (0.8 mL) was added dropwise to the mixture and stirred for an additional 12 h at 22 C. The reaction mixture was diluted with ethyl acetate (55 mL) and methylene chloride (20 mL) and washed twice with saturated NaHCO3 (2 x 50 mL), twice with 0.1 N HCI (2 x 50 mL), twice with saturated NaC1 (2 x 50 mL), and finally with H20 (50 mL). The organic phase was dried (MgSO4) and evaporated to give crude derivative 4. The product was purified by flash chromatography, using a mixture of hexanes / acetone (3/2), to yield 173 mg (54%) of 4. The spectral data of this derivative correspond to those reported in the literature.10 IR (v, cm-1): 3360-3240 (NH), 3087 (C=C), 2988 (CH, aliphatic), (C=0), 1706 (C=0); 1H NMR (acetone-d6, 6 ppm): 9.05 (s, 1H, NH), 8.02 and 7.53 (2 x d, J=8.6 Hz, 4H, aromatic), 7.07 (s, 2H, maleimide), 2.84 (br s, 1H, NH), 1.45 (s, 9H, 3 x CH3); 13C NMR (acetone-d6, 6 ppm): 169.3 (2), 166.0, 155.7, 135.1, 134.6 (2), 131.6, 127.9 (2), 125.9 (2), 79.6, 27.5 (3); ES1+ HRMS: (M+Na)+
calculated for Ci6H17N3Na05 = 354.1060; found = 354.1072; (M -2-methylpropene +H)+ calculated for Ci2Hi1N305 = 276.0620; found = 276.0627.
Step D. Synthesis of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid hydrazide hydrochloride (or 4-maleimidbenzoic acid hydrazide hydrochloride) (5) 1001481 The hydrolysis of 4 was performed using a similar procedure reported by Heindel et al. for the cleavage of maleimidoacetic acid (tert-butyloxycarbonyl) hydrazide with hydrochloric acid to form maleimidoacetic acid hydrazide hydrochloride.16 To a solution of 4 (2.41 g, 7.27 mmol) dissolved in dry dioxane (30 mL) was added a solution of hydrochloric acid (60 mL, 1.0 M in diethyl ether, mmol). The mixture was stirred at room temperature for a period of 5 hours.
Afterwards, 150 mL of hexanes were added to complete the precipitation of the hydrochloride salt 5. The crude precipitated was filtered, washed with hexanes and recrystallized twice with a mixture of methanol / isopropyl alcohol / hexanes (8 / 3 /
10) to yield 1.7 g (46%) of the desired material. IR (v, cm-1): 3200-2500 (CO2H), 3269 (NH), 1702 (C=0), 1693 (C=0); 11-1 NMR (DMSO-d6, 6 ppm): 8.06 and 7.52 (2 x d, J=8.8 Hz, 4H, aromatic), 7.21 (s, 2H, maleimide); 13C NMR (DMSO-d6, 6 ppm): 170.0 (2), 165.6, 135.9, 135.4 (2), 129.6, 129.0 (2), 126.8 (2); ESI+
HRMS:
(M+H)+ calculated for CI iHioN303 = 232.0717; found = 232.0717 and ESI+ HRMS:
(M+H)+ calculated for C11FIIICIN303 = 268.0483; found = 268.0483.
Step E. Synthesis of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid hydrazide trifluoroacetic acid salt (6) [00149] A solution of 4 (106 mg, 0.32 mmol) dissolved in trifluoroacetic acid (0.5 mL) was stirred at 0 C for a period of 30 minutes. Afterwards, the excess trifluoroacetic acid was removed under vacum at 22 C to give compound 6 quantitatively. IR (v, cm-1): 3500-2500 (CO2H), 3277 (NH), 1710 (C=0); 1H NMR
(DMSO-d6, 6 ppm): 11.62 (br s, 1H, NHNH3+CF3CO2-), 8.63 (br s, NH3), 8.01 and 7.56 (2 x d, J=8.5 Hz, 4H, aromatic), 7.24 (s, 2H, maleimide); 13C NMR (DMSO-d6, 6 ppm): 169.6 (2), 165.4, 135.5, 135.0 (2), 129.4, 128.4 (2), 126.5 (2).
Example 2. Preparation of N'43-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoyll-hydrazine carboxylic acid tert-butyl ester (4a) Following the procedure of Example 1, steps A ¨ C described above using 3-amino-4-chloro benzoic acid as the starting material instead of 4-amino benzoic acid derivative 4a was prepared efficiently.
Step A. Synthesis of 3-(cis-3-carboxy-acryloylamino)-4-chloro benzoic acid (2a) [00150] Spectral data for 2a: IR (v, cm-1): 3500-2500 (CO2H), 3310 (NH), 1696 (C=0); 1H NMR (DMSO-d6, 6 ppm): 13.08 (s, 2H, 2 x CO2H), 10.13 (s, 1H, NH), 8.37 (s, 1H, aromatic) 7.72 and 7.61 (2 x d, 2H, J = 10.0 Hz, aromatic), 6.59 and 6.34 (2 x d, 2H, 1 = 12.0 Hz, maleimide); 13C MNR (DMSO-d6, 6 ppm): 167.5, 166.7, 164.1, 135.0, 131.6, 131.2 (2), 130.4 (2), 127.2 (2).
Step B. Synthesis of 3-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro benzoic acid (3a) [00151] Spectral data for 3a: IR (v, cm-1): 3300-2500 (CO2H), 3490 (amine), 1674 (C=0). 1H NMR (acetone-d6, 6 ppm): 8.1 (m, 2H, aromatic), 7.76 (d, 1H, J
=
8.0 Hz, aromatic), 7.14 (s, 2H, maleimide) 13C NMR (acetone-d6, 6 ppm): 168.7 (2), 165.0, 143.0, 137.84, 134.9 (2), 132.3, 131.6, 130.6, 130.2.
Step C. Synthesis of N'-[3-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoy1]-hydrazine carboxylic acid tert-butyl ester (4a) [00152] Spectral data for 4a: IR (v, cm-1): 3494 (amine), 3090 (C=C), (aliphatic), 1717 (C=0). 111 NMR (acetone-d6, 6 ppm): 9.71 (s, 1H, NH), 8.05 (dd, I H, J = 8.2 Hz and J = 1.8 Hz, aromatic) 7.95 (d, 1H, J = 1.8 Hz, aromatic), 7.75 (d, 1H, J = 8.6 Hz, aromatic), 7.11 (s, 2H, maleimide), 2.91 (s, 1H, NH), 1.43 (s, 9H, 3 x CH3); 13C NMR (acetone-d6, 6 ppm): 169.5 (2), 166.0, 156.5, 135.0 (2), 134.0 (2), 130.0, 130.7, 129.0 (2), 80.0, 28.1(3).
Example 3. Preparation of N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-2-chloro-benzoy1]-hydrazine carboxylic acid tert-butyl ester (4b) Following the procedure of Example 1, steps A ¨ C described above using 4-amino-2-chloro benzoic acid as the starting material instead of 4-amino benzoic acid derivative 4b was prepared efficiently.
Step A. Synthesis of 4-(cis-3-carboxy-acryloylamino)-2-chloro benzoic acid (2b) [00153] Spectral data for 2b : IR (v, cm-'): 3500-2500 (CO2H), 3262 (NH), 1689 (C=0); 'H NMR (DMSO-d6, 6 ppm): 13.8 (s, 2H, 2 x CO2H), 10.7 (s, 1H, NH), 7.85 (m, 2H, aromatic) 7.55 (dd, 1H, J = 10.0 Hz and J = 2.0 Hz, aromatic), 6.45 and 6.31 (2 x d, 2H, J = 12.0 Hz, maleimide); 13C MNR (DMSO-d6, 6 ppm): 168.0, 166.0, 164.0, 143.0, 136.5, 135.0, 132.0, 131.5, 126.0, 121.5, 119.2.
Step B.
Synthesis of 3-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro benzoic acid (3b) [00154] Spectral data for 3b : IR (v, cm-'): 3300-2500 (CO2H), 3470 (amine), 1723 (C=0). 11-1 NMR (acetone-d6, 6 ppm): 7.90 (d, 1H, J = 8.6 Hz, aromatic), 7,67 (d, 1H, J = 2.2 Hz, aromatic), 7.50 (dd, 1H, J = 8.3 Hz and J = 2.0 Hz, aromatic) 7.11 (s, 2H, maleimide); '3C NMR (acetone-d6, 6 ppm): 168.0 (2), 165.0, 138.0, 136.0 (2), 135.0, 132.0, 128.0, 124.0, 118Ø
Step C.
Synthesis of N43-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoyll-hydrazine carboxylic acid tert-butyl ester (4b) [00155] Spectral data for 4b : IR (v, cm-'): 3473 (amine), 3090 (C=C), 2984 (aliphatic), 1708 (C=0). 'H NMR (acetone-d6, 6 ppm): 9.03 (s, 1H, NH), 7.65(d, 1H, J = 8.0 Hz, aromatic) 7.59 (d, 1H, J = 1.6 Hz, aromatic), 7.45 (dd, 1H, J =
8.2 and J =
1.8 Hz aromatic), 7.08 (s, 2H, maleimide), 2.96 (s, 1H, NH), 1.47 (s. 9H, 3 x CH3);
13C NMR (acetone-d6, 6 ppm): 169.0 (2), 166.0, 156.0, 135.0 (2), 134.6, 133.0, 131.0, 127.9(2), 125.9, 80.0, 27.5 (3).
Example 4. Preparation of N44-(2,5-dioxo-pyrrolidin-1-y1)-benzoyll-hydrazine carboxylic acid tert-butyl ester (12) [00156]
Maleimide 4 (103 mg, 0.31 mmol) was dissolved in methanol (1 mL) to which was added 5% Pd/C (14 mg). Some hydrogen gas was bubbled during 30 seconds into the mixture. The suspension was stirred vigorously under a hydrogen atmosphere for a period of 3 hours. Of note, a longer period of time is required on a larger scale. Afterwards, the suspension was filtered on silica with a mixture of hexanes / acetone (3/2) as the eluent, to yield 87 mg (84%) of 12. IR (v, cm-1): 3400-3100 (NH), 2981 (CH), 1703 (C=0); 111 NMR (acetone-d6, 6 ppm) : 9.54 (br s, 1H, NH), 8.00 and 7.45 (2 x d, J=8.6 Hz, 4H, aromatic), 1.45 (s, 9H, 3 x CH3); 13C
MNR
(acetone-d6, 6 ppm) 176.2 (2), 165.9, 155.7, 136.1, 132.4, 127.8 (2), 126.7 (2), 79.6, 28.2, 27.5; ESI+ HRMS: (M+H)+ calculated for Ci6H20N305 = 334.1397; found =
334.1391 and ESI+ HRMS: (M+H -C4H9)+ calculated for Ci2H:2N305 = 278.0771;
found = 278.0769.
Example 5. Preparation of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid N'-diacetyl-hydrazide (8, R = CH3) 1001571 To a solution of crude 6 (444 mg, 1.28 mmol) dissolved in dichloromethane (10 mL) was added triethylamine (1.07 mL, 780 mg, 7.7 mmol) and acetic anhydride (0.61 mL, 659 mg, 6.4 mmol). The mixtured was stirred at 22 C for about 30 minutes. Afterwards, the organic phase was diluted with ethyl acetate (75 mL) directly into an extraction funnel. The organic phase was washed successively with a 5% sodium bicarbonate aqueous solution (50 mL), with a 10% sodium chloride aoous solution (50 mL) and finnally with water (50 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (111 mg). The product was purified by flash column chromatography using a mixture of hexanes / acetone (7/3) to give 75 mg (18%) of the desired material 8, R =
CH3). Of note, different anhydrides or alkaloyl chlorides can be used to produce analogs of this specific derivative. IR (v, cm-1): 3200 (NH), 1702 (C=0), 1662 (C=0); 'H NMR
(acetone-d6, 6 ppm): 10.15 (br s, 1H, NH), 8.09 and 7.61 (2 x d, J = 8.6 Hz, 4H, aromatic), 7.10 (s, 2H, maleimide), 2.41 (s, 6H, 2 x CH3); 13C NMR (acetone-d6, 6 ppm): 171.1 (2), 169.3 (2), 166.0, 135.8, 134.7 (2), 130.8, 128.2 (2), 126.1 (2), 24.2 (2). ESI+ HRMS: (M+H)+ calculated for C151-114N305 = 316.0928; found =
316.0945 and ESI+ HRMS: (M+H -Ac)+ calculated for Ci3Hi2N304 =275.08252; found =
275.0856.
Example 6. Preparation of N-acetyl-AP-14-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoy11-hydrazinecarboxylic acid tert-butyl ester (10, R = CH3) [00158] To a solution of 4 (100 mg, 0.30 mmol) dissolved in dichloromethane (3 mL) was added triethylamine (252 p.L, 183 mg, 1.81 mmol) and acetic anhydride (71 mt, 76.7 mg, 0.75mmo1). The mixtured was stirred at 22 C for about 30 minutes.
Afterwards, the organic phase was diluted with ethyl acetate (25 mL) directly into an extraction funnel. The organic phase was washed successively with a 5% sodium bicarbonate aqueous solution (10 mL), with a 10% sodium chloride aoous solution (10 mL) and finnally with water (20 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (123 mg). The product was purified by flash column chromatography using a mixture of hexanes /
acetone (4/1) to give 22 mg (20%) of the desired material 10, R = CH3). It is noteworthy, that a longer reaction time (2 hours) lead to higher yield of the desired material. However, some diacetylated product (11) is also present as a side product.
IR (v, cm-1): 3286 (NH), 1753 (C=0), 1711 (C=0), 1652 (C=0); 1H NMR (CDCI3, 6 ppm): 8.28 (br s, 1H, NH), 7.90 and 7.50(2 x d, J = 8.6 Hz, 4H, aromatic), 6.89 (s, 2H, maleimide), 2.61 (s, 3H, CH3), 1.51 (s, 9H, 3 x CH3); 13C NMR (CDCI3, 6 ppm):
170.5, 168.9 (2), 165.2, 151.0, 135.0, 134.4 (2), 130.9, 128.3 (2), 125.7 (2), 84.8, 27.8 (3), 25.5; ESI+ HRMS: (M+Na)+ calculated for C181-119N3Na06 = 396.1166; found =
396.1165 and ESI+ HRMS: (M+H -tert-Boc)+ calculated for C13F112N304 =
274.0822;
found = 274.0824.
Example 7. Preparation of N,N'-diacetyl-N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoy1]-hydrazinecarboxylic acid tert-butyl ester (11, R =
CH3) [00159] To a solution of 4 (100 mg, 0.30 mmol) dissolved in dichloromethane (3 mL) was added triethylamine (252 JAL, 183 mg, 1.81 mmol) and acetyl chloride (54 60 mg, 0.75 mmol). The mixtured was stirred at 22 C for about 2 hours.
Afterwards, the organic phase was diluted with ethyl acetate (25 mL) directly into an extraction funnel. The organic phase was washed successively with a 5% sodium bicarbonate aqueous solution (10 mL), with a 10% sodium chloride aoous solution (10 mL) and finally with water (20 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (118 mg). The product was purified by flash column chromatography using a mixture of hexanes /
acetone (4/1) to give 100 mg (80%) of the desired material 11, R = CH3). IR
(v, cm-1):
3193 (NH), 1701 (C=0), 1660 (C=0); 1H NMR (CDCI3, 6 ppm): 7.68 and 7.50(2 x d, J = 8.6 Hz, 4H, aromatic), 6.89 (s, 2H, maleimide), 2.49 and 2.48 (2 x s, 6H, 2 x CH3), 1.50 (s, 9H, 3 x CH3); 13C NMR (CDCI3, 6 ppm): 170.2, 169.9 (2), 168.8 (2), 150.2, 134.6, 134.4 (2), 132.9, 128.2 (2), 125.0 (2), 85.9, 27.8 (3), 25.4, 24.6;
ESI+ HRMS:
(M+Na)+ calculated for C201-121N3Na07 = 438.1272; found = 438.1281 and ESI+
HRMS: (M+H -Ac and -tert-Boc)+ calculated for C13H12N304 = 274.0822; found =
274.0833.
Example 8. Preparation of N'-{4-13-(2-tert-butoxycarbonylamino-ethylsulfany1)-2,5-dioxo-pyrrolidin-1-y11-benzoyl}-hydrazinecarboxylic acid tert-butyl ester (13) [00160] To a solution of 4 (115 mg, 0.34 mmol) dissolved in methanol (3 mL) was added 2-(Boc-amino) ethanethiol (70 L, 73 mg, 0.41 mmol). The mixture was stirred at 22 C for 2 hours and at 50 C for I hour. The organic phase was diluted with ethyl acetate (30 mL) directly into an extraction funnel and washed successively with a 5% sodium bicarbonate aqueous solution (2 x 10 mL) and with water (2 x 20 mL).
The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (191 mg). The product was purified by flash column chromatography using a mixture of hexanes / acetone (3/2) to give 107 mg (61%) of the desired material 13 [see 0055]. IR (v, cm-1): 3300 (NH), 1707 (C=0), 1680 (C=0); 1H NMR (CDCI3, 6 ppm): 8.80 (br s, IH, NH), 7.86 and 7.34 (2 x d, J =
8.2 Hz, 4H, aromatic), 6.90 (br s, 1H, NH), 5.07 (br s, 1H, NH), 3.98 (1H, m, -CHS-) 2.6-3.6 (several m, 6H, 3 x -CH2-), 1.50 and 1.45 (2 x s, 18H, 2 x 3 x CH3); 13C
NMR
(CDC13, 6 ppm): 175.4, 173.2, 165.8, 155.9 (2), 134.8, 131.7, 128.2 (2), 126.4 (2), 82.1, 79.7, 39.4, 38.9, 36.1, 32.7, 28.4 (3), 28.2 (3); ESI+ FIRMS: (M+Na)+
calculated for C23H321\14Na07S = 531.1884; found = 531.1881.
Example 9. General procedure for the preparation of derivatives of general structure 13 (see scheme 3) [00161] Following the procedure described by Taha et a/.12 compound 5 can be treated with a relevant aldehyde (alkyl aldehydes (linear or branched), benzaldehyde or substituted benzaldehydes) under acidic conditions at reflux in butanol (or other solvent) to give the desired alkylhydrazones or benzoylhydrazones derivatives.
Example 10. General procedure for the preparation of derivatives 14, 15 or 16 (see scheme 4) [00162] Derivative 4 (or any other maleimides described herein) can be reacted with an appropriate diene (butadiene (unsubstituted or substituted), cyclopentadiene, cyclohexadiene cycloheptadiene, furane, thiophene, pyrrole, N-alkylpyrrole) to give the desired cycloadducts (Diels-Alder products) such as for example 14, 15 and 16.
This reaction can be performed by heating the pure reagents (diene and dienophile) either neat or in solution, with or without pressure.
Example 11. Specific procedure for the preparation of hydrazone 13a with R =
4-hydroxy-3-methoxyphenyl (see scheme 3) [00163] The intermediate 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid hydrazide trifluoroacetic acid salt (6) was prepared as described in example 1, step E
using the following quantities: derivative 4 (100 mg, 0.303 mmol), trifluoroacetic acid 250 j.iL, dichloromethane (1 mL). The intermediate 6 was dissolved in dichloromethane (2 mL) and treated with 4-hydroxy-3-methoxybenzaldehyde (vanillin, 46.1 mg, 0.303 mmol) and sodium bicarbonate (25.4 mg, 0.303 mmol).
Dichloromethane (2-3 mL) was used to dissolve the aldehyde stuck to the reaction vessel wall. The reaction was stirred at room temperature for 12 hours.
Afterwards, the reaction mixture was transferred into a separatory funnel containing ethyl acetate (50 mL). The organic phase was washed twice with 3% aqueous solution of sodium bicarbonate (2 x 20 mL) and with water (3 x 15 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude hydrazone 13a, R = 4-hydroxy-3-methoxyphenyl (79 mg, 71%). The product was homogeneous by thin layer chromatography. 1H NMR (DMSO-d6, 6 ppm): 11.71 (br s, 1H, NH), 9.54 (br s, 1H, OH), 8.32 (br s, 1H, -CH=N-), 7.97 and 7.49 (2 x d, J = 8.2 Hz, 4H, aromatic), 7.32 (br s, 1H, aromatic), 7.21 (s, 2H, maleimide), 7.09 (br d, J =
7.8 Hz, 1H, aromatic) 6.83 (d, J = 8.2 Hz, 1H, aromatic), 3.82 (s, 3H, OCH3); ESI+
HRMS:
(M+H)+ calculated for CI9H16N305= 366.1084; found = 366.1076.
[00164] Using iso-vanillin instead of vanillin the hydrazone 13b with R
= 3-hydroxy-4-methoxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 11.71 (br s, 1H, NH), 9.30 (br s, 1H, OH), 8.29 (br s, 1H, -CH=N-), 7.98 (d, J = 8.2 Hz, 2H, aromatic), 7.49 (d, J = 8.6 Hz, 2H, aromatic), 7.27 (d, J = 1.5 Hz, 1H, aromatic), 7.22 (s, 2H, maleimide), 7.04 (dd, J = 1.6 and 8.2 Hz, 1H, aromatic) 6.96 (d, J =
8.2 Hz, 1H, aromatic, 3.80 (s, 3H, OCH3); ESI+ HRMS: (M+H)+ calculated for C191-= 366.1084; found = 366.1058.
[00165] With benzaldehyde the hydrazone 13c, R = phenyl was obtained:
1H NMR (DMSO-d6, 6 ppm): 11.90 (s, 1H, NH), 8.45 (s, 1H, CH=N), 8.00 and 7.47 (2 d, J=8.6 Hz, 4H, aromatic,), 7.73 and 7.45 (2 m, 5H, H aromatique), 7.21 (s, 2H, maleimide); ESI+ FIRMS: (M+H)+ calculated for Ci8HI4N303 = 320.1030; found =
320.1028.
[00166] With 2-hydroxybenzaldehyde the hydrazone 13d, R = 2-hydroxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 12.14 (s, 1E1, NH), 11.23 (s, 1H, OH), 8.64 (s, 1H, CH=N), 8.03 and 7.52 (2d, 4H, H aromatic , J=8.6 Hz), 7.57 (d hidden, 1H, H-6), 7.30 (t, 1H, H-4, J=6.3 Hz), 7.22 (s, 2H, maleimide), 6.93 (d, 1H, H-3, J=7.8 Hz), 6.88 (t hidden, 1H, H-5); ESI+ HRMS: (M+H)+
calculated for Ci8Hi4N304 = 336.0979; found = 336.0973.
[00167] With 3-hydroxybenzaldehyde the hydrazone 13e, R = 3-hydroxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 11.84 (s, 1H, NH), 9.62 (s, 1H, OH), 8.35 (s, 1H, CH=N), 7.99 and 7.50 (2d, 4H, aromatic, J=8.0 Hz), 7.22 (s, 2H, maleimide), 7.23-7.11 (m, 3H, H-4-5-6), 6.82 (d, 1H, H-2, J=6.6 Hz); ESI+
HRMS: (M+H)+ calculated for CI8H141\1304 = 336.0979; found = 336.0978.
[00168] With 4-hydroxybenzaldehyde the hydrazone 13f, R = 4-hydroxyphenyl was obtained: 'H NMR (DMSO-d6, 6 ppm): 11.70 (s, 1H, NH), 9.93 (s, 1H, OH), 8.34 (s, 1H, CH=N), 7.98 and 7.49 (2d, 4H, aromatic , J=8.4 Hz), 7.56 and 6.83 (2d, 4H, H-2-3-5-6, J=8.2 Hz), 7.21 (s, 2H, maleimide); ESI+ HRMS:
(M+H)+ calculated for Ci8Hi4N304 = 336.0979; found = 336.0978.
[00169] With 2,4-dihydroxybenzaldehyde the hydrazone 13g, R = 2,4-dihydroxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 11.95 (s, 1H, NH), 11.41 (s, 1H, OH ortho), 9,97 (s, 1H, OH para), 8.49 (s, I H, CH=N), 8.02 and 7.48(2 d, 4H, aromatic , J=8.4 Hz), 7.33 and 6.37 (2 d, 2H, H-5-6, J=8.2 Hz), 7.21 (s, 2H, maleimide), 6.31 (s, 1H, H-3); ESI+ HRMS: (M+H)+ calculated for C18H14N305 =
352.0928; found = 352.0923.
[00170] With 4-hydroxy-3,5-ditertbutylbenzaldehyde the hydrazone 13h, R
= 3,5-ditertbuty1-4-hydroxybenzaldehyde was obtained: H NMR (DMSO-d6, 6 ppm): 11.68 (s, 1H, NH), 8.37 (s, 1H, CH=N), 7.98 and 7.47 (2 d, 4H, aromatic , J=8.6 Hz), 7.47 (s, 2H, H-2-6), 7.21 (s, 2H, maleimide), 1.40 (s, 18H, C(CH3)3); ESI+
HRMS: (M+H)+ calculated for C26H30N304 = 448.2231; found = 448.2224.
[00171] With 4-methoxybenzaldehyde the hydrazone 13i, R = 4-methoxyphenyl was obtained: 11-1 NMR (DMSO-d6, 6 ppm): 11.78 (s, 1H, NH), 8.39 (s, 1H, CH=N), 7.99 and 7.02 (2 d, 4H, H-2-3-5-6, J=8.6 Hz), 7.67 and 7.49 (2 d, 4H, aromatic , J=8.6 Hz), 7.21 (s, 2H, maleimide), 3.80 (s, 3H, OCH3); ESI+
HRMS:
(M+H)+ calculated for Ci9H16N304 = 350.1135; found = 350.1127.
[00172] With 2-hydroxy-3-methoxybenzaldehyde the hydrazone 13j, R = 2-hydroxy-3-methoxyphenyl was obtained: 11-1 NMR (DMSO-d6, 6 ppm): 12.11 (s, I H, NH), 10.90 (s, 1H, OH), 8.65 (s, 1H, CH=N), 8.01 and 7.53 (2 m, 4H, aromatic), 7.21 (s, 2H, maleimide), 7.01 a 6.86 (m, 3H, H-4-5-6), 3,80 (s, 3H, OCH3);
ESI+
HRMS: (M+H)+ calculated for Ci9H16N305 = 366.1084; found = 366.1075.
[00173] With 3,4-dimethoxybenzaldehyde the hydrazone 13k, R = 3,4-dimethoxyphenyl was obtained: 11-1 NMR (DMSO-d6 and D20, 6 ppm): 11.78 (s, 1H, NH), 8.34 (s, 1H, CH=N), 7.97 and 7.48 (2 d, 4H, aromatic, J=8.6 Hz), 7.40 (s, 1H, H-2), 7.18 and 7.00 (2 d, 2H, H-5-6, J=8.2 Hz), 7.15 (s, 2H, maleimide), 3.79 (2 s, 6H, 2 x OCH3). ESI+ HRMS: (M+H)+ calculated for C20Hi8N305 = 380.1241;
found = 380.1234.
[00174] With 4-allyloxybenzaldehyde the hydrazone 131, R = 4-allyloxyphenyl was obtained: 'H NMR (DMSO-d6, 6 ppm): 11.78 (s, 1H, NH), 8.38 (s, 1H, CH=N), 7.99 and 7.49 (2 d, 4H, aromatic, J=8.6 Hz), 7.66 and 7.03 (2 d, 4H, H-2-3-5-6, J=8.6 Hz), 7.21 (s, 2H, maleimide), 6.04 (m, 1H, H-8), 5.33 (m, 2H, H-9), 4.61 (d, 2H, H-7, J=5.08 Hz); ESI+ HRMS: (M+H)+ calculated for C21Hi8N304 =
376.1292; found = 376.1282.
[00175] With 2-furaldehyde the hydrazone 13m, R = 2-furanyl was obtained: 11-INMR (DMSO-d6, 6 ppm): 11.83 (s, 1H, NH), 8.33 (s, 1H, CH=N), 7.96 and 7.52 (2 d, 4H, aromatic , J=8.2 Hz), 7.84 (s, 1H, H-3), 7.21 (s, 2H, maleimide), 6.93 (d, 1H, H-4, J=3.1 Hz), 6.63 (s, 1H, 1-1-5); ESI+ HRMS: (M+H)+ calculated for Ci6H i2N304 = 310.0822; found = 310.0820.
[00176] With pyridine-2-carbaldehyde the hydrazone 13n, R = 2-pyridyl was obtained: 11-1 NMR (DMSO-d6, 6 ppm): 12.09 (s, 1H, NH), 8.61 (m, 1H, H-3), 8.47 (s, 1H, CH=N), 8.01 and 7.52 (2 d, 4H, aromatic, J=7.10 Hz), 7.89 (m, 2H, 6), 7.43 (m, 1H, H-4), 7.22 (s, 2H, maleimide); ESI+ HRMS: (M+H)+ calculated for CI7F113N403 = 321.0982; found = 321.0977.
[00177] With pyridine-3-carbaldehyde the hydrazone 13o, R = 3-pyridyl was obtained: 12.07 (s, 1H, NH), 8.86 (s, 1H, H-2), 8.60 (d, 1H, H-4, J=3.0 Hz), 8.50 (s, 1H, CH=N), 8.16 (d, 1H, H-6, J=7.1 Hz), 8.01 and 7.51 (2d, 4H, aromatic , J=8.0 Hz), 7.51 (t hidden, 1H, H-5), 7.22 (s, 2H, maleimide); ESI+ HRMS: (M+H)+
calculated for Ci7Hi3N403= 321.0982; found = 321.0979.
[00178] With pyridine-4-carbaldehyde the hydrazone 13p, R = 4-pyridyl was obtained: NMR (DMSO-d6, 6 ppm): 12.29 (s, 1H, NH), 8.72 (d, 2H, H-3-5, J=1.9 Hz), 8.47 (s, 1H, CH=N), 8.00 and 7.53 (2 d, 4H, aromatic, J=6.6 Hz), 7.82 (s, 2H, H-6-2); ESI+ HRMS: (M+H)+ calculated for C17Hi3N403 = 321.0982; found --321.0974.
[00179] With cinnamaldehyde the hydrazone 13q, R = phenylethenyl was obtained: 114 NMR (DMSO-d6, 6 ppm): 11.80 (s, 1H, NH), 8.21 (s, 1H, CH=N), 7.97 and 7.49 (2 d, 4H, aromatic , J=7.8 Hz), 7.60 (d, 2H, H-2-6, J=6.3 Hz), 7.36 (m, 3H, H-3-4-5), 7.18 (s, 2H, maleimide), 7.04 (m, 2H, H-7-8); ESI+ HRMS: (M+H)+
calculated for C20H16N303 = 346.1186; found = 346.1178.
[00180] With 4-chlorobenzaldehyde the hydrazone 13r, R = 4-chlorophenyl was obtained: H NMR (DMSO-d6, 6 ppm): 11.96 (s, 1H, NH), 8.43 (s, 1H, CH=N), 8.00 and 7.51 (2 d, 4H, aromatic, J=8.0 Hz), 7.76 and 7.51 (2 d, 4H, H-2-3-5-6, J=7.8 Hz), 7.22 (s, 1H, maleimide); ESI+ HRMS: (M+H)+ calculated for C181113C1N303 --354.0640; found = 354.0630.
[00181] With 4-fluorobenzaldehyde the hydrazone 13s, R = 4-fluorophenyl was obtained: H NMR (DMSO-d6, 6 ppm): 11.91 (s, 1H, NH), 8.44 (s, 1H, CH=N), 8.00 and 7,50 (2 d, 4H, aromatic, J=6.4 Hz), 7.79 (s, 2H, H-2-6), 7,29 (s, 2H, H-3-5), 7.21 (s, 2H, maleimide); ESI+ HRMS: (M+H)+ calculated for Ci8Hi3EN303 =
338.0935; found = 338.0926.
[00182] With 4-trifluoromethylbenzaldehyde the hydrazone 13t, R = 4-trifluoromethylphenyl was obtained: 'El NMR (DMSO-d6, 6 ppm): 12.09 (s, 1H, NH), 8.51 (s, 1H, CH=N), 8.01 and 7.51 (2 d, 4H, aromatic, J=8.2 Hz), 7.95 and 7.81 (2 d, 4H, H-2-3-5-6, J=7.9 Hz), 7.22 (s, 2H, maleimide); ESI+ HRMS: (M+H)+
calculated for Ci9Hi3F3N303 = 388.0904; found = 388.0897.
[00183] With 4-nitrobenzaldehyde the hydrazone 13u, R = 4-nitrophenyl was obtained: 'H NMR (DMSO-d6, 6 ppm): 11.41 (s, 1H, NH), 7.90 and 7.48(2 d, 4H, aromatic , J=8.2 Hz), 7.67 (d, 1H, CH=N, J=5.1 Hz), 7.20 (s, 2H, maleimide), 2.48 (septet, 1H, H-1), 1.07 (d, 6H, H-2-3, J=6.7 Hz); ESI+ HRMS: (M+H)+
calculated for Ci8Hi3N405= 365.0880; found = 365.0875.
[00184] General structure of hydrazones 13a-13u (see scheme 3) 13a, R = 4-hydroxy-3- 13b, R = 3-hydroxy-4- 13c, R = phenyl methoxyphenyl methoxyphenyl 13d, R = 2-hydroxyphenyl 13e, R = 3-hydroxyphenyl 13f, R = 4-hydroxyphenyl 13g, R = 2,4- 13h, R
= 3,5-ditertbuty1-4- 131, R = 4-methoxyphenyl dihydroxyphenyl hydroxybenzaldehyde 13j, R = 2-hydroxy-3- 13k, R = 3,4- 131, R
= 4-allyloxyphenyl methoxyphenyl dimethoxyphenyl 13m, R = 2-furanyl 13n, R = 2-pyridyl 13o, R = 3-pyridyl 13p, R = 4-pyridyl 13q, R = phenylethenyl 13r, R = 4-chlorophenyl 13s, R = 4-fluorophenyl 13t, R = 4- 13u, R = 4-nitrophenyl trifluoromethylphenyl Materials and Methods - Biology In vitro studies (for derivatives 4, 5, 8, 10, 11, and 12, etc.) [00185] Cell culture ¨ general: Biological assays were performed using the human monocytic cell line THP1, the murine macrophage-like cell lines J774A.1 and RAW 264.7, and the murine UBC cell lines MB49 and MB49-1. The cells were maintained in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and containing 1 mM sodium pyruvate, 10 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and 50 p,g/mL gentamycin (referred as 10% FBS RPMI-1640). The cells were maintained at 37 C in a moisture-saturated atmosphere containing 5% CO2.
THP1 cells, RAW 264.7 cells and J774A.1 cells are the most widely used cell lines to investigate the function and differentiation of monocytes and macrophages in response to various inflammatory mediators.17,18 Undifferentiated THPI cells resemble primary monocytes/macrophages isolated from healthy donors or donors with inflammatory diseases, such as diabetes mellitus and atherosclerosis.I9 After treatment with phorbol esters, THPI cells differentiate into macrophage-like cells which mimic native monocyte-derived macrophages in several respects.2 As we previously described, green fluorescent protein-expressing (GFP)-THP1 cells were cultured for 18 h in 50 nM phorbol 12-myristate 13-acetate to induce monocyte-to-macrophage differentiation.2I-23 The cell lines RAW 264.7 and J774A.1 were kindly provided by Dr Tatiana Scorza (Universite du Quebec a Montreal, Canada). These cell lines are macrophage-like cell models which produce large amount of NO in response to IFNy, TNFet, bacterial infection and bacterial products, such as lipopolysaccharide (LPS),I7 The cell line MB49-I is a highly invasive and tumorigenic UBC cell model that was developed by successive in vivo passages of MB49 primary tumors.24 [00186] Cell signaling studies: THP1-derived human macrophages (750x103 cells/mL) and MB49-I cells (500x103 cells/mL) were pretreated for 30 min with vehicle (DMSO), compounds 4 and 5, at 10, 25 or 50 IAM; and then washed and recovered immediately (t= 0 min) or after 30 min of activation with 50 U/mL
IFNy, 25 ng/mL IL6, or 10 ng/mL TNFa. Cell lysates were prepared and analyzed by immunoblotting as described.2I-23'25 Briefly, protein samples were resolved by SDS-PAGE under reducing conditions and transferred onto a PVDF membrane. Blots were first probed with rabbit polyclonal antibodies against phospho-STAT1 (pSTAT1), pSTAT3, or p-Ix13 (all at 1:2000) overnight at 4 C. Blots were then incubated with HRP-conjugated goat anti-rabbit IgG Ab (1:3000) for 1 h at room temperature.
The same blots were stripped and then probed with anti-STAT1 or anti-STAT3 Abs (both at 1:1000). In both cases, probed molecules were visualized using an enhancement chemiluminescence detection kit (Thermo Fisher Scientific).
[00187] Luciferase assay. To assess the transcriptional activity of NFKI3 in response to TNFa, MB49-I cells cultured in monolayers (7.5x104 cells/well in well plates) were transiently transfected with an expression vector allowing the transcription of the firefly luciferase reporter gene under the control of CMV
promoter and tandem repeats of the NFKB transcriptional response element. The luciferase gene encodes a 61-kDa enzyme that oxidizes D-luciferin in the presence of ATP, oxygen, and MC, yielding a fluorescent product that can be quantified by measuring the released light. Transfection was performed using Opti-MEM
reduced serum media and Lipofectamine 2000 (Thermo Fisher Scientific). Then, MB49-I
cells were pretreated for 30 min with vehicle (DMSO) and compound 4 (at 10 uM or 30 M); and then washed and recovered after 24 h of activation with 10 ng/mL or 50 ng/mL TNFoc. Cell lysates were mixed with Luciferase assay reagent (a mixture of luciferine, coenzyme A, ATP and Mg2+) and the light produced was measured using a luminometer.
[00188] Surface antigen expression analysis. To study membrane receptor expression, THP1-derived human macrophages (750x104 cells/mL) were pretreated for 3 h with DMSO or compounds 4 and 5, and then left untreated (control) or treated for 48 h with 50 U/mL IFNy. The expression level of MHC-II and CD40 was evaluated by flow cytometry as described.21-23 [00189] Motility assays. The in vitro scratch wound healing assay was performed to study the effects of compounds 4 and 5 in 1L6-induced macrophage cell migration, as described.26 Briefly, THP1-derived human macrophages (750x103 cells/mL) were seeded into 24-well tissue culture plate to reach ¨70-80%
confluence as a monolayer. The cell monolayers were scraped in a straight line in one direction to create a "scratch" with a p200 pipet tip. To obtain the same field during the image acquisition, another straight line was scratched perpendicular to the first would line to create a cross in each well. Cell debris were removed and the edges of the scratch were smoothed by washing the cells once with 1 mL of Hank's buffer. Cell monolayers were pretreated for 3 h with vehicle (DMSO) or compounds 4 (10 M) and 5 (25 p.M), and then left untreated (control) or treated for 48 h with 25 ng/mL
IL6. Using the cross as reference points the plate was placed under an inverted fluorescence microscope, and the images of the scratch were acquired at t= 0 h and t=
48 h. The number of motile cells was determined using Java-based image processing program ImageJ (National Institutes of Health) and relative cell motility was expressed as percent (%) of control of motile cells at t= 48 h relative to motile cells within the initial wound (at t= 0 h).
[00190] Microinvasion assays. Invasion was measured by assessment of human UBC T24 cell migration rate through an artificial basement membrane in a modified Boyden chamber (HTS Transwell System). Briefly, the membrane consisted of a polycarbonate filter with 0.4 um pores diameter and was coated on ice with Matrigel (BD Biosciences) diluted 1:2 (v/v) in serum-free culture media. T24 cells (50 x 103 cells) were seeded into the Matrigel coat in the upper well of the chamber, while polarized MI macrophages (50 x 103 cells) were seeded in the lower well. The polycarbonate filter with 0.4 pim pores diameter is too small to left the cells move to the bottom of the lower wells. Thus, non-invading cells into the matrigel coat were removed and cells that migrated down to the polycarbonate filter were stained with Hoescht 33258 dye after a 48-h incubation period, visualized by fluorescence microscopy and counted.
[00191] Cellular analysis of 3D spheroid-based tumor invasion assays.
Cell preparation and spheroid formation were performed following the manufacturer instructions (Corning). Briefly, MDA-MB-231 cells were harvested and diluted to a concentration of 5 x 104 cells/mL in (complete) culture media supplemented with 10%
serum. 100 pilL, of cell suspension was then pipetted to appropriate 96 well spheroid formation plate and placed at 37 C/5% CO2. Spheroid formation was monitored every 24 hours. The typical cell aggregation period was 48 hours. Upon spheroid formation completion, 70 iaL of complete medium was removed from each well, and replaced by 70 tL of serum-free medium. This was repeated on a daily basis to create a serum starvation period of 48 hours. Matrigel matrix (100 [it) was then added to each well. The plate was centrifuged at 300 x g for 5 minutes in a swinging bucket centrifuge. The plate was then transferred to a 37 C/5% CO2 incubator for one hour to initiate gel formation. Following the 1-hour gel formation incubation period, DMSO or compound 4 was added to appropriate wells during 60 minutes. After pretreatment, the media was removed and replaced by complete culture media, and then the media was changed every day for a period of 4 days. Brightfield images at day 0 and day 4 was used to measure invasive protrusion (invadopodia) extending away from the tumoroid and into the extracellular matrix. The role of these protrusions is the breakdown of Matrigel matrix, thus aiding the invasion process.
These protrusions were identified, and their area and perimeter properly quantified using the ImageJ software (National Institutes of Health).
1001921 Evaluation of NO and Urea production by chemical methods. The MB49-I cells and the J774A.1 cells (25x103 cells/well) were grown and pretreated, as indicated, with various anti-inflammatory derivatives, precursors and mono-functional derivatives for a period of 3 h. Afterwards the cells were washed twice with 10% FBS
RPMI-1640 and then activated to produce NO for a period of 24 h with cytokines INFy and TNFcc. NO production was measured using the Griess reagent method as previously described.27 This method involves the detection of nitrite ions (NO2-) formed by the spontaneous oxidation of NO under physiological conditions.
According the manufacture procedure (Life Technologies; # G-7921), equal volumes of sulfanilic acid and N-(1-naphthyl)ethylenediamine are mixed together to form the Griess reagent. In the presence of NO2-, sulfanilic acid is converted to a diazonium salt, which in turn is coupled to N-(1-naphthyl)ethylenediamine to produce a pink coloration that is measured with a spectrophotometer (Biotek, synergy HT) at 548 nm.
In the same manner, urea synthesis through arginase-1 activity was measured using commercially available kit.
[00193] Evaluation of cell proliferation by the MTT assay. To evaluate the anti-proliferative activity, cell viability/proliferation MTT assays were performed as previously described.21-23,25,28 Briefly, MB49-I cells (5x103 cells/well) were plated in 96-well plates in 100 [it 10% FBS RPMI-1640 and cultured for 24 h at 37 C and 5%
CO2. Cells were pretreated for a period of 3 h with vehicle (DMSO) or derivatives 1 and 1A at 0, 10, 25, 37.5, and 50 p,M, and then incubated for 24 h in the absence or the presence of INFy and TNFa. At the end of the culture period, 10 1.1L of 5 mg/mL
methylthiazolyldiphenyl-tetrazolium bromide (MTT) solution was added to each well.
After a 3-h incubation period with MTT reagent, 100 1.11L of MTT
solubilization buffer (10% SDS in 10 mM HC1) was added and plates were placed overnight in the cell incubator before absorbance measure. The optical density was read at 580 nm using the Microplate Reader Manager (from Bio-Rad Laboratories).
[00194] Statistical analyses. For all biological assays, data were presented as mean 1 SD from three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferonni post-test using Prism software, version 3.03 (GraphPad, San Diego, CA). p values of < 0.05 were considered to indicate statistical significance.
In vivo studies (for derivatives 4 and 8) [00195] Ectopic UBC model. Male C57BL/6J mice (6-8 weeks old), each weighing 15-18 g, were used for the experiments (supplied by Charles River).
The mice were housed with free access to food and water on a 12:12 h light:dark cycle with the room temperature maintained at 21 C. MB49 cells, MB49-1 cells, and iNOS-deficient MB49-I cells (5 x 104 in 100 j.L PBS) were injected subcutaneously (s.c.) into the right flank of the mice. Growth rates of the s.c. tumors were monitored. The size of tumors was determined every 3 days for 24-28 days using a digital caliper and by measuring luciferin luminescence at days 15 and 25 using the IVIS imaging system. A blinded observer measured tumor length and width. The volume of the tumor was calculated from the formula: Length x width2 x 0.52, where length and width were tumor diameters measured with calipers in mutually perpendicular directions. At a tumor size of approximately 10 mm3 the mice were divided into different groups. A control group received PBS as treatment. As indicated, other groups were treated at different doses (90, 150 or 300 1.1M) with an intraperitoneal (i.p.) injection of compounds 4 or 8 every 3-4 days for 18-20 days.24,27 [00196] Orthotopic UBC model. Female C57BL/6J mice (6-8 weeks old), each weighing 15-18 g, were anesthetized and a 24-gauge Teflon catheter was introduced into the bladder lumen through the urethra. To prepare the bladder for tumor implantation, a point lesion was induced in the bladder wall by electrocauterization.
Then, 1 x 105 of MB49-I cells in 100 uI of PBS were instilled into the bladder. When indicated, control mice were electrocauterized and PBS was instilled into the bladder.
Syringes containing the cell suspension were maintained into the catheter for 20 min to allow cell attachment to the bladder wal1.24,27 [00197] Statistical analyses. Mann¨Whitney test was used to compare tumor growth, using Prism software, version 3.03 (GraphPad, San Diego, CA). p values of <
0.05 were considered to indicate statistical significance.
The results from the in vitro and in vivo experiments are presented in figures 1 to 25.
REFERENCES
1. LaFond, R. In Cancer: The outlaw cell, 3rd Ed., ACS publication, Washington, DC, 384 pages (2012) 2. Alderton GK. The tumor microenvironment drives metastasis, Nat. Rev.
Cancer 16, 199 (2016) 3. Steeg PS. Targeting metastasis, Nat. Rev. Cancer 16, 201-218 (2016) 4. Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, Richter C, Zips D, Bortfeld T. Radiation oncology in the era of precision medicine, Nat. Rev. Cancer 16, 234-249 (2016) 5. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment, Nat. Rev. Cancer 12, 237-251 (2012) 6. Scott AM, Wolchok JD, Old U. Antibody therapy of cancer. Nat. Rev.
Cancer 12, 278-287 (2012) 7. Phillips AP, Mentha JW. US Patent 3,046,301 (October 29, 1959); Deglin JH, Vallerand AH. In Guide des medicaments, ERPI, pp. 424-427 (1995) 8. Remers, WA. Antineoplastic agents, In Wilson and Gisvold's Textbook of organic Medicinal and pharmaceutical chemistry, 9th Ed., Delgado JN, Remers, WA. J.B. Eds, Lippincott, New York, Chapter 8, 321-322 (1989) 9. Lau A, Berube G, Ford CHJ. Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents, Bioorg. Med Chem., 3, 1299-1304 (1995) 10. Lau A, Berube G, Ford CHJ, Gallant M. Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro, Bioorg.
Med. Chem., 3, 1305-1312 (1995) 11. Hamelin-Morrissette J, Cloutier S, Girouard J, Belgorosky D, Eijan A-M, Legault J, Reyes-Moreno C, and Berube G. Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells, Eur. J. Med. Chem., 96, 259-269 (2015) 12. Taha M, Ismail NH Lalani S, Fatmi MQ, Atia-tul-Wahab, Siddiqui S, Khan KM, Imran S, Choudhary MI. Synthesis of novel inhibitors of a-glucosidase based on the benzothiazole skeleton containing benzohydrazide moiety and their molecular docking studies, Eur. J. Med Chem., 92, 387-400 (2015) 13. Perrin DD, Armarego CF. In Purification of Laboratory Chemicals, 3' Ed., Pergamon Press, Oxford, New York (1988) 14. Still WC, Kahn M, Mitra A. Rapid chromatographic technique for preparative separations with moderate resolution, J. Org. Chem., 43, 2923-2925 (1978) 15. Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA. (6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicin, Bioconjug. Chem., 4, 521-527 (1993) 16. Heindel ND, Zhao HR, Egolf RA, Chang CH, Schray KJ, Emrich JG, McLaughlin JP, Woo DV, A novel heterobifunctional linker for formyl to thiol coupling, Bioconjug. Chem., 2, 427-430 (1991) 17. Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation, Antimicrobial agents and chemotherapy, 58 2059-2066 (2014) 18. Auwerx J, The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation, Experientia, 47, 22-31 (1991) 19. Qin Z, The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature, Atherosclerosis, 221,2-11 (2012) 20. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages, PloS one, 5, 0008668 (2010) 21. Dufresne M, Dumas G, Asselin E, Carrier C, Pouliot M, Reyes-Moreno C, Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells, Mob. Immunol., 48 1556-1567 (2011) 22. Dumas G, Dufresne M, Asselin E, Girouard J, Carrier C, Reyes-Moreno C.
CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasion, Cancer Immunol. Immunother., 62, 273-283,(2013) 23. Dallagi A, Girouard J, Hamelin-Morrissette J, Dadzie R, Laurent L, Vaillancourt C, Lafond J, Carrier C, Reyes-Moreno C. The activating effect of IFN-gamma on monocytes/macrophages is regulated by the LIF-trophoblast-IL-10 axis via Statl inhibition and Stat3 activation, Cell. Mob. Immunol., 12, 326-341 (2015).
24. Fabris VT, Lodillinsky C, Pampena MB, Belgorosky D, Lanari C, Eijan AM.
Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-1, Cancer Genet., 205, 168-176 (2012).
25. Leduc, Bourassa V, Asselin E, Leclerc P, Lafond, Reyes-Moreno C. Leukemia Inhibitory Factor Regulates Differentiation of Trophoblast-Like BeWo Cells Through the Activation of JAK/STAT and MAPK3/1 MAP Kinase-Signaling Pathways, Biol. Reprod, 86, 54, 1-10 (2012) 26. Menon MB, Ronkina N, Schwermann J, Kotlyarov A, Gaestel M.
Fluorescence-based quantitative scratch wound healing assay demonstrating the role of MAPKAPK-2/3 in fibroblast migration, Cell. Motil. Cytoskeleton, 66, 1041-1047 (2009) 27. Belgorosky D, Langle Y, Prack Mc Cormick B, Colombo L, Sandes E, Eijan A.M. Inhibition of nitric oxide is a good therapeutic target for bladder tumors that express iNOS, Nitric Oxide, 36, 11-18 (2014) 28. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JD. Evaluation of a tetrazolium-based semiautmated colorimetric assay : Assessment of radiosensitivity. Cancer Res., 47, 943-946 (1987) 1001981 The present disclosure has been described with regard to specific examples. The description was intended to help the understanding of the present disclosure, rather than to limit its scope. It will be apparent to one skilled in the art that various modifications may be made to the present disclosure without departing from the scope of the present disclosure as described herein, and such modifications are intended to be covered by the present document.
HN __ N
HN¨N
HO OCH, HN __ N
N
FIN N
o/
j(1 0 FIN¨N
100711 For example, RI I can be chosen from 2,4-dihydroxyphenyl 3,5-ditertbuty1-4- 4-methoxyphenyl hydroxybenzaldehyde 2-hydroxy-3-methoxyphenyl 3,4-dimethoxyphenyl 4-allyloxyphenyl 2-furanyl 2-pyridyl 3-pyridyl 4-pyridyl phenylethenyl 4-chlorophenyl 4-fluorophenyl 4-trifluoromethylphenyl and .. 4-nitrophenyl.
[0072] Schemes 1 to 4 represent examples of synthetic routes used for the preparation of the compounds of the present disclosure. The reaction conditions of each step are presented directly in the schemes.
[0073] Using para-amino benzoic acid (1) as the starting material derivative 4 was made in a three-step reaction sequence (Scheme 1).9-11 Para-amino benzoic acid (1 or PABA) was first reacted with maleic anhydride (MA) in dry acetone to give the diacid (2) with 90% yield. Cyclisation to form the maleimide was accomplished with acetic anhydride and sodium acetate to give compound 3 with 89% yield after hydrolysis of the mixed anhydride intermediate with water. Finally, activation of acid 3 with iso-butyl chloroformate in the presence of pyridine was done followed by treatment with tert-butyl carbazate gave the desired anti-inflammatory derivative 4 with 54% yield. Deprotection of 4 with hydrochloric acid in ether gave the hydrochloride salt 5 with 46% yield after recrystallization. Example 1 shows the preparation of compounds 4 and 5. This reaction sequence can be used to produce other derivatives starting from unsubstituted or substituted ortho-, meta- and para-benzoic acid starting materials. Hence, this approach lead to the synthesis of N'13-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoy11-hydrazine carboxylic acid tent-butyl ester (4a) and N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-2-chloro-benzoyl]-hydrazine carboxylic acid tert-butyl ester (4b) shown in examples 2 and 3, respectively.
1-1,1\1 =
a HN
1 2 (90%) 3 (88%) <14 () N 0 IN
NHNH¨ ( NHNII)*IICI
0 0 ___________________ 0 4 (54%) 5 (46%) Reagents and conditions: a) Maleic anhydride (MA), dry acetone, methanol, 22 C, 1 h; b) I) Ac,O.
AcONa, 50 C, 2 h; 2) H20, 70 C, 2 h; c) 1) iso-butyl chloroformate, Et3N, CH2Cl2, 0 C, I h and 22 C, 1 h; 2) tert-butyl carbazate, CH2Cl2, 22 C, 12 h; d) HCI, dioxane, 22 C, 5 h.
Scheme 1 100741 Further transformations of derivative 4 can lead to novel compounds with anti-inflammatory, anti-metastatic, anti-proliferative and anticancer activities (Scheme 2). However, catalytic hydrogenation of 4 led to compound 12 which lost its anti-inflammatory activity (see example 4). Otherwise, compound 4 is transformed into its trifluoroacetate salt 6 upon treatment with trifluoroacetic acid in dichloromethane. The crude material 6 can be reacted either with acetyl chloride or acetic anhydride (or any relevant anhydride or acid chloride) to give derivative 8. Of note, derivatives 7 and 9 were likely produced but not isolated in example 5.
Alternatively, compound 4 can be acylated with a relevant anhydride or acid chloride to yield compound 10 and 11. Interestingly, using acetyl chloride, compound 4 was transformed efficienly into the diacetylated derivative 11 (R = CH3) and, with acetic anhydride the main product of the reaction was the monoacetylated derivative 10 (R =
CH3). Derivative 10 can be deprotected to give 7 and derivative 11 can lead to derivative 9. It is possible to produce efficienly compound 7 and 9 via a two-step sequence from 4.
- o o 11 NHNHBoc NHNHBoc a [ N '11 b HN¨N
NHNH2*CF3CO2H 0 +
b N *
N XR
NHNHBoc li = e*
NHNIT¨R
0 0 =c' 8 (R = CH3) 0 e + N * Boc 0 NHNBoc N¨N. a 0 0 N li .1c, (from 11 to yield 9) NNH 1\ 0 10 (R = CH3) 11 (R = CH3) 9 OR
Reagents and conditions: a) TFA, CH2C12, 22 C, 0.5 h; b) Relevant anhydride or acid chloride, Et0Ac, 22 C, 30 mm to 2 h; c) H2, Pd/C, CH3OH, 22 C, 3 h.
Scheme 2 [0075] Scheme 3 presents the methodology leading to 13 the alkylhydrazones or arylhydrazones derivatives following the procedure described by Taha et al.12 Accordingly, compound 5 can be treated with a relevant aldehyde (alkyl aldehydes (linear or branched), benzaldehyde or substituted benzaldehydes or other arylaldehydes) under acidic conditions at reflux in butanol (or other solvent) to give the desired derivatives of general structure 13.
N li a .---1( NHNH2 --,..------ HN¨N=\
R = alkyl or aromatic (unsubstituted or substituted) Reagents and conditions: a) RCHO, H+, Butanol, reflux, 1 to 5 h.
Scheme 3 [0076] On Scheme 4, derivative 4 (or any other maleimides described herein) can be reacted with an appropriate diene (butadiene (unsubstituted or substituted), cyclopentadiene, cyclohexadiene cycloheptadiene, furane, thiophene, pyrrole, N-alkylpyrrole) to give the desired cycloadducts (Diets-Alder products) such as 14, 15 and 16. This reaction can be performed by heating the pure reagents (diene and dienophile) either neat or in solution, with or without pressure as it is described in example 10.
H
N
HN¨Q
a or or 41) N
NI-I-Q
4 H X=O,S,NHorNR
N
n = I, 2 or 3 Relevant diene = butadiene (unsubstituted or substituted), cyclopentadiene, cyclohexadiene, furane, thiophene, pyrrole, N-alkyl pyrrole.
Reagents and conditions: a) Relevant diene, toluene, A, 3 h.
Scheme 4 [0077] As it can be appreciated by the skilled artisan, the above synthetic schemes are not intended to be a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized.
Further methods can also potentially be used to prepare the compounds of the present disclosure.
[0078] The compounds of the present disclosure may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
[0079] The compounds of the present disclosure may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomer, diastereomeric mixtures and individual diastereoisomers.
All such isomeric forms of these compounds are expressly included in the present disclosure.
Each stereogenic carbon may be of the R or S configuration.
[0080] It has been found that the small aminobenzoic acid derivatives herein disclosed display anti-inflammatory, anti-metastatic, anti-proliferative and/or anti-cancer properties as well as favorable toxicity profiles, and may be used for example in treating malignancies, for example muscle-invasive and superficial UBC
tumors, for example in humans.
[0081] An aspect herein provided is a method for treating cancer or at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined herein, [0082] Another aspect is a method for reducing the risks of developing cancer or for reducing the risk of developing at least one cancer in a subject, the cancer being, for example, chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer, the method comprising administering to the subject an effective amount of at least one compound as defined herein.
[0083] Yet a further aspect is a method for inhibiting cancer cell growth, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined herein.
[0084] For example, the cancer cell growth is inhibited by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to an untreated subject.
[0085] Another aspect is a method for inhibiting tumor growth and/or reducing tumor size, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined herein.
[0086] For example the tumor size is measured in weight and/or volume.
[0087] For example, the tumor growth and/or tumor size is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to an untreated subject.
[0088] For example, administration of an effective amount of at least one compound disclosed herein to a subject in need thereof increases time to progression of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
[0089] For example, the compound herein disclosed is for use in reducing risks of developing at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
[0090] For example, the compound is for use in the treatment of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
[0091] For example, the compound is for use as an anticancer agent.
[0092] For example the compound is for use as an anti-inflammatory agent.
[0093] For example the compound is for use as an anti-metastatic agent.
[0094] As described herein, several compounds, namely derivatives 4, 5, 8, 10, 11, and 12, were tested on macrophages and UBC cells for their anti-inflammatory, anti-metastatic and/or anti-cancer properties.
[0095] As shown herein, the compounds presently disclosed display anti-inflammatory properties.
[0096] Referring to Fig. 1 to 10, in vitro studies of human macrophages and UBC cells tested with compounds 4 and 5 were conducted to investigate the anti-inflammatory properties of the compounds on pro-inflammatory cytokines. As shown in Fig. 1, IFNy-induced STAT1 activation and IL6-induced STAT3 activation were decreased in pretreated human macrophages. Similarly, compounds 4 and 5 were found effective in reducing IFNy-induced CD40 and MHC-II expressions, as shown in Fig. 2. Also, referring to Fig. 3, scratch wound healing assays were conducted and compounds 4 and 5 were found effective in inhibiting IFNy-induced STAT1 activation and IL6-induced STAT3 activation in human macrophages.
[0097] An aspect provided is a method for decreasing anti-inflammatory properties of cancer cells, the method comprising contacting the cancer cells with at least one compound as defined herein.
[0098] For example the relative STAT1 activation of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[0099] For example the relative STAT3 activation of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00100] For example the CD40 expression of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00101] For example the MHC-II expression of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00102] Referring now to Fig. 4 and 5, anti-inflammatory activity of compounds 4 and 5 was assessed by measuring nitric oxide (NO) production in murine macrophage-like cells stimulated with inflammatory signals, IFNy/TNFa.
Compounds 4 and 5 were found effective in reducing IFNy/TNFoc induced NO
production.
[00103] For example, NO production in cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00104] Referring to Fig. 6 and 7 it was demonstrated that compounds 4 and 5 have anti-proliferative properties in UBC cells stimulated with IFNy/TNFoc.
[00105] An aspect provided is a method for inducing anti-proliferative properties of cancer cells, the method comprising contacting the cancer cells with at least one compound as defined herein.
[00106] For example, the viability of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00107] For example, the cancer cell growth is inhibited by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to untreated cancer cells.
[00108] Referring now to Fig. 8, compound 4 was shown to inhibit TNFa/NFKB and IL6/STAT3 signaling pathways in murine UBC cells. Compound 4 was also tested in human UBC cells and was shown to inhibit 1L6-induced motility, as shown in Fig. 9. Similarly, referring to Fig. 10, a human breast cancer cell line was treated with compound 4 which demonstrated anti-invasion properties, thus demonstrating that compound 4 is not cell-specific.
[00109] For example, the TNFa/NFKB and/or IL6/STAT3 signaling pathways of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to untreated cells.
[00110] For example, the invasiveness of cells with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
[00111] In vivo studies were also conducted to evaluate the anticancer, anti-proliferative and anti-metastatic activities of compound 4 in ectopic and orthotopic murine models of UBC.
[00112] Acute toxicity studies in mice, as shown in Fig. 11, demonstrated that treatment with compound 4 had no obvious effect on normal development and viability, as well as in organ weight and hematocrit, suggesting tolerability in the mice. Similarly, referring to Fig. 12, no evidence of toxicity related to compound 4 was found in liver histological analyses in mice treated with various concentrations of compound 4.
[00113] For example, subjects treated with a compound disclosed herein have a similar body weight relative to a comparable untreated subject. "Similar body weight"
as used herein means no greater than a 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% difference in body weight loss.
[00114] For example, subjects treated with a compound disclosed herein have a similar hematocrit relative to a comparable untreated subject. "Similar hematocrit" as used herein means no greater than a 5%, 4%, 3%, 2% or 1% difference in hematocrit level.
[00115] As demonstrated herein, the compounds herein disclosed display anti-proliferative and anti-metastatic activity.
[00116] Referring to Fig. 13 and 14, male mice implanted ectopically with UBC tumors and treated with compound 4 saw a significant decrease in tumor proliferation and in the number of metastases relative to untreated mice. In female mice bearing orthotopically implanted urothelial bladder cancer tumors, as shown in Fig. 15, anti-proliferative properties of compound 4 were also seen. More particularly, the tumor development was stopped after two weeks of treatment. Similarly, mice ectopically implanted with urothelial bladder cancer tumors and treated with compound 4 saw a significant reduction of the tumor size, as illustrated in Fig. 18.
[00117] For example, tumors treated with a compound disclosed herein have a decrease in volume and/or a decrease in tumor growth of at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to untreated tumors.
[00118] Another aspect is a method for decreasing and/or preventing tumor metastases, the method comprising administering to a subject in need thereof an effective amount of at least one compound disclosed herein.
[00119] For example, the number of tumor metastases is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to an untreated subject.
[00120] Referring to Fig. 19, further in vivo murine studies of anti-inflammatory properties of compound 4 were conducted and a significant decrease in NO production and urea synthesis was found in peritoneal macrophages.
[00121] Derivatives of compound 4 were also found to display anti-inflammatory, anticancer, anti-proliferative and anti-metastatic properties.
Additional in vitro and in vivo studies of compound 4 derivatives, compounds 8, 10 and 11 were conducted in macrophages and UBC cells.
[00122] Fig. 21 shows that these compounds were effective in inhibiting NO
production. The compounds were also effective in inhibiting the IFN7-activated STAT1 signaling pathway and the LPS-activated NFK13 signaling pathway in macrophage cells (Fig. 22 and 23).
[00123] For example, the LPS-activated NFic13 signaling pathway of cells treated with a compound herein disclosed is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to untreated cells.
[00124] Referring now to Fig. 25, compounds 4 and 8 were found to have anti-proliferative activity in ectopically implanted UBC tumors in male mice.
[00125] For example, the compound is compound 4.
[00126] For example, the compound is compound 8.
[00127] For example, the compound is compound 10.
[00128] For example, the compound is compound 11.
[00129] For example, the subject is a mammal. For example, the subject is a human.
[00130] For example, the cell is in vitro.
[00131] For example, the cell is in vivo.
[00132] For example, the cell is a cancer cell.
[00133] For example, the cancer is melanoma, uterine cancer, ovarian cancer, prostate cancer or bladder cancer.
[00134] For example, the bladder cancer is superficial UBC or muscle invasive UBC.
[00135] For example the tumor is a melanoma tumor, uterine tumor, ovarian tumor, prostate tumor or bladder tumor.
[00136] For example, the bladder tumor is a superficial UBC tumor or a muscle invasive UBC tumor.
[00137] For example, the methods disclosed herein are effective for presenting the development of superficial UBC into muscle invasive UBC tumor.
[00138] For example, the at least one compound as defined in the present disclosure can be used in the manufacture of a medicament for decreasing and/or preventing pathological humoral and cell-mediated inflammation of at least one disease chosen from inflammatory diseases (Crohn's disease, rheumatoid arthritis, asthma, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, reperfusion injury or transplant rejection); pregnancy complications (preeclampsia or preterm birth); or gynecological pathologies (endometriosis, uterine leiomyoma, polycystic ovary syndrome or recurrent miscarriage).
[00139] In the present disclosure, the following abbreviations are used:
Abbreviation Meaning Ac20 Acetic anhydride AcONa Sodium acetate CH2Cl2 Dichloromethane Boc t-Butyloxycarbonyl Et20 Diethyl ether Et0Ac Ethyl acetate Et3N Triethyl amine Hour MCI Chlorhydric acid i.p. Intraperitoneal m Meta MA Maleic anhydride Me0H Methanol min Minute mmol Millimole MTT 3-(4,5-Dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide NMR Nuclear magnetic resonance o Ortho p Para Phe Phenyl s.c. Subcutaneously TLC Thin layer chromatography TFA Trifluoroacetic acid UBC Urothelial bladder cancer EXAMPLES
[00140] This section also describes the synthesis of several compounds that are presented in this document. These examples are not to be construed as limiting the scope of the present disclosure in any way.
Materials and Methods - Chemistry [00141] Anhydrous reactions were performed under an inert atmosphere, the set-up assembled and cooled under dry nitrogen. Unless otherwise noted, starting material, reactant and solvents were obtained commercially and were used as such or purified and dried by standard means.13 Organic solutions were dried over magnesium sulfate, evaporated on a rotatory evaporator and under reduced pressure. All reactions were monitored by UV fluorescence, or staining with iodine. Commercial TLC
plates were Sigma T 6145 (polyester silica gel 60 A, 0.25mm). Flash column chromatography was performed according to the method of Still and co-workers on Merck grade 60 silica gel, 230-400 mesh.' All solvents used in chromatography had been distilled prior to use.
[00142] The infrared spectra were taken on a Nicolet Impact 420 FT-IR.
Mass spectral assays were obtained using a MS model 6210, Agilent technology instrument.
The high resolution mass spectra (HRMS) were obtained by TOF (time of flight) using ESI (electrospray ionization) using the positive mode (ES1+).
(Plateforme analytique pour molecules organiques de FUniversite du Quebec a Montreal).
[00143] Nuclear magnetic resonance (NMR) spectra were recorded on a Varian 200 MHz NMR apparatus. Samples were dissolved in deuterochloroform (CDC13), deuteroacetone (acetone-d6) or deuterodimethylsulfoxide (DMSO-d6) for data acquisition using tetramethylsilane or chloroform as internal standard (TMS, 8 0.0 ppm for 1H-NMR and CDC13 877.0 ppm for 13C-NMR). Chemical shifts (8) are expressed in parts per million (ppm), the coupling constants (J) are expressed in hertz (Hz). Multiplicities are described by the following abbreviations: s for singlet, d for doublet, dd for doublet of doublets, t for triplet, dt for doublet of triplets, q for quartet, dq for doublet of quartets, m for multiplet, #m for several multiplets, br for a broad signal.
[00144] The following compounds were prepared from a relevant aminobenzoic acid derivative using the procedures summarized in schemes 1, 2, 3 or 4.
Example 1. Preparation of N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoyll-hydrazine carboxylic acid tert-butyl ester (4), its hydrochloric acid salt (5) and its trilluoroacetic acid salt (6) Step A. Synthesis of 4-(3-carboxy-acryloylamino)-benzoic acid (2) [00145] 4-Aminobenzoic acid (1, 5.34 g, 38.93 mmol) was dissolved in dry acetone (12 mL) to which was added methanol (1 mL). Maleic anhydride (1.05 eq.) dissolved in dry acetone was added to the first solution. The reaction mixture was stirred for a period of 2 h allowing sufficient time for the complete precipitation of the diacid 2. The precipitate was filtered and washed twice with acetone (2 x 2 mL) and dried in a desiccator overnight. The crude diacid 2 (9.16 g, 90%) was sufficiently pure to be use without further purification at the next step. IR (v, cm-1): 3500-(CO2H), 1686 cm-1 (C=0); 11-1 NMR (DMSO-d6, (5 ppm): 12.79 (br s, 2 H, 2 x CO2H), 10.58 (s, 1H, NH), 7.89 and 7.71 (2 x d, J=8.6 Hz, 4H, aromatic), 6.48 and 6.30 (2 x d, J=12.2 Hz, 2H, maleimide); 13C NMR (DMSO-d6, (5 ppm): 167.4, 167.3, 164.1, 143.2, 132.1, 130.9 (2), 130.6, 126.0, 119.2 (2); ESI+ HRMS: (M+H)+
calculated for CI iHioN05 = 236.0553; found = 236.0558.
Step B. Synthesis of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid (3) [00146] The diacid 2 (2.01 g, 8.54 mmol) was treated with acetic anhydride (4.0 mL, 36.28 mmol) and anhydrous sodium acetate (350 mg, 4.27 mmol) and the mixture heated at 50 C for 2 h. Afterwards, the solution was evaporated to dryness and stirred with water at 70 C for a period of 2 h. The resulting precipitate was filtered and dried in a desiccator overnight to yield 1.65 g (89%) of maleimide 4. The spectral data of this derivative correspond to those reported in the literature.9,11 IR (v, cm-1): 3475-2600 (CO2H), 1715 (C=0), 1704 (C=0); NMR
(acetone-d6, 6 ppm):
8.14 and 7.57 (2 x d, J=8.6 Hz, 4H, aromatic), 7.08 (s, 2H, maleimide); BC NMR
(acetone-d6, 6 ppm): 169.3 (2), 166.2, 136.2, 134.7 (2), 130.1 (2), 129.3, 125.8 (2);
ESI+ HRMS: (M+H)+ calculated for CliF18N04 = 218.0448; found = 218.0447.
Step C. Synthesis of N44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoy1]-hydrazine carboxylic acid tert-butyl ester (4) [00147] Derivative 4 was synthesized using a modified procedure reported by Willner et al.15 as it is also described by Lau et al. and Hamelin-Morrissette et al.9-11 A cooled suspension (0 C) of molecule 3 (211 mg, 0.97 mmol) in methylene chloride (4.5 mL) was treated with triethylamine (190 ?AL, 1.36 mmol) and isobutyl chloroformate (175 !IL, 1.34 mmol). The mixture was stirrred for I h at 0 C
and at room temperature (22 C) for about 1 h. Afterwards, tert-butyl carbazate (128 mg, 0.97 mmol) dissolved in methylene chloride (0.8 mL) was added dropwise to the mixture and stirred for an additional 12 h at 22 C. The reaction mixture was diluted with ethyl acetate (55 mL) and methylene chloride (20 mL) and washed twice with saturated NaHCO3 (2 x 50 mL), twice with 0.1 N HCI (2 x 50 mL), twice with saturated NaC1 (2 x 50 mL), and finally with H20 (50 mL). The organic phase was dried (MgSO4) and evaporated to give crude derivative 4. The product was purified by flash chromatography, using a mixture of hexanes / acetone (3/2), to yield 173 mg (54%) of 4. The spectral data of this derivative correspond to those reported in the literature.10 IR (v, cm-1): 3360-3240 (NH), 3087 (C=C), 2988 (CH, aliphatic), (C=0), 1706 (C=0); 1H NMR (acetone-d6, 6 ppm): 9.05 (s, 1H, NH), 8.02 and 7.53 (2 x d, J=8.6 Hz, 4H, aromatic), 7.07 (s, 2H, maleimide), 2.84 (br s, 1H, NH), 1.45 (s, 9H, 3 x CH3); 13C NMR (acetone-d6, 6 ppm): 169.3 (2), 166.0, 155.7, 135.1, 134.6 (2), 131.6, 127.9 (2), 125.9 (2), 79.6, 27.5 (3); ES1+ HRMS: (M+Na)+
calculated for Ci6H17N3Na05 = 354.1060; found = 354.1072; (M -2-methylpropene +H)+ calculated for Ci2Hi1N305 = 276.0620; found = 276.0627.
Step D. Synthesis of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid hydrazide hydrochloride (or 4-maleimidbenzoic acid hydrazide hydrochloride) (5) 1001481 The hydrolysis of 4 was performed using a similar procedure reported by Heindel et al. for the cleavage of maleimidoacetic acid (tert-butyloxycarbonyl) hydrazide with hydrochloric acid to form maleimidoacetic acid hydrazide hydrochloride.16 To a solution of 4 (2.41 g, 7.27 mmol) dissolved in dry dioxane (30 mL) was added a solution of hydrochloric acid (60 mL, 1.0 M in diethyl ether, mmol). The mixture was stirred at room temperature for a period of 5 hours.
Afterwards, 150 mL of hexanes were added to complete the precipitation of the hydrochloride salt 5. The crude precipitated was filtered, washed with hexanes and recrystallized twice with a mixture of methanol / isopropyl alcohol / hexanes (8 / 3 /
10) to yield 1.7 g (46%) of the desired material. IR (v, cm-1): 3200-2500 (CO2H), 3269 (NH), 1702 (C=0), 1693 (C=0); 11-1 NMR (DMSO-d6, 6 ppm): 8.06 and 7.52 (2 x d, J=8.8 Hz, 4H, aromatic), 7.21 (s, 2H, maleimide); 13C NMR (DMSO-d6, 6 ppm): 170.0 (2), 165.6, 135.9, 135.4 (2), 129.6, 129.0 (2), 126.8 (2); ESI+
HRMS:
(M+H)+ calculated for CI iHioN303 = 232.0717; found = 232.0717 and ESI+ HRMS:
(M+H)+ calculated for C11FIIICIN303 = 268.0483; found = 268.0483.
Step E. Synthesis of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid hydrazide trifluoroacetic acid salt (6) [00149] A solution of 4 (106 mg, 0.32 mmol) dissolved in trifluoroacetic acid (0.5 mL) was stirred at 0 C for a period of 30 minutes. Afterwards, the excess trifluoroacetic acid was removed under vacum at 22 C to give compound 6 quantitatively. IR (v, cm-1): 3500-2500 (CO2H), 3277 (NH), 1710 (C=0); 1H NMR
(DMSO-d6, 6 ppm): 11.62 (br s, 1H, NHNH3+CF3CO2-), 8.63 (br s, NH3), 8.01 and 7.56 (2 x d, J=8.5 Hz, 4H, aromatic), 7.24 (s, 2H, maleimide); 13C NMR (DMSO-d6, 6 ppm): 169.6 (2), 165.4, 135.5, 135.0 (2), 129.4, 128.4 (2), 126.5 (2).
Example 2. Preparation of N'43-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoyll-hydrazine carboxylic acid tert-butyl ester (4a) Following the procedure of Example 1, steps A ¨ C described above using 3-amino-4-chloro benzoic acid as the starting material instead of 4-amino benzoic acid derivative 4a was prepared efficiently.
Step A. Synthesis of 3-(cis-3-carboxy-acryloylamino)-4-chloro benzoic acid (2a) [00150] Spectral data for 2a: IR (v, cm-1): 3500-2500 (CO2H), 3310 (NH), 1696 (C=0); 1H NMR (DMSO-d6, 6 ppm): 13.08 (s, 2H, 2 x CO2H), 10.13 (s, 1H, NH), 8.37 (s, 1H, aromatic) 7.72 and 7.61 (2 x d, 2H, J = 10.0 Hz, aromatic), 6.59 and 6.34 (2 x d, 2H, 1 = 12.0 Hz, maleimide); 13C MNR (DMSO-d6, 6 ppm): 167.5, 166.7, 164.1, 135.0, 131.6, 131.2 (2), 130.4 (2), 127.2 (2).
Step B. Synthesis of 3-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro benzoic acid (3a) [00151] Spectral data for 3a: IR (v, cm-1): 3300-2500 (CO2H), 3490 (amine), 1674 (C=0). 1H NMR (acetone-d6, 6 ppm): 8.1 (m, 2H, aromatic), 7.76 (d, 1H, J
=
8.0 Hz, aromatic), 7.14 (s, 2H, maleimide) 13C NMR (acetone-d6, 6 ppm): 168.7 (2), 165.0, 143.0, 137.84, 134.9 (2), 132.3, 131.6, 130.6, 130.2.
Step C. Synthesis of N'-[3-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoy1]-hydrazine carboxylic acid tert-butyl ester (4a) [00152] Spectral data for 4a: IR (v, cm-1): 3494 (amine), 3090 (C=C), (aliphatic), 1717 (C=0). 111 NMR (acetone-d6, 6 ppm): 9.71 (s, 1H, NH), 8.05 (dd, I H, J = 8.2 Hz and J = 1.8 Hz, aromatic) 7.95 (d, 1H, J = 1.8 Hz, aromatic), 7.75 (d, 1H, J = 8.6 Hz, aromatic), 7.11 (s, 2H, maleimide), 2.91 (s, 1H, NH), 1.43 (s, 9H, 3 x CH3); 13C NMR (acetone-d6, 6 ppm): 169.5 (2), 166.0, 156.5, 135.0 (2), 134.0 (2), 130.0, 130.7, 129.0 (2), 80.0, 28.1(3).
Example 3. Preparation of N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-2-chloro-benzoy1]-hydrazine carboxylic acid tert-butyl ester (4b) Following the procedure of Example 1, steps A ¨ C described above using 4-amino-2-chloro benzoic acid as the starting material instead of 4-amino benzoic acid derivative 4b was prepared efficiently.
Step A. Synthesis of 4-(cis-3-carboxy-acryloylamino)-2-chloro benzoic acid (2b) [00153] Spectral data for 2b : IR (v, cm-'): 3500-2500 (CO2H), 3262 (NH), 1689 (C=0); 'H NMR (DMSO-d6, 6 ppm): 13.8 (s, 2H, 2 x CO2H), 10.7 (s, 1H, NH), 7.85 (m, 2H, aromatic) 7.55 (dd, 1H, J = 10.0 Hz and J = 2.0 Hz, aromatic), 6.45 and 6.31 (2 x d, 2H, J = 12.0 Hz, maleimide); 13C MNR (DMSO-d6, 6 ppm): 168.0, 166.0, 164.0, 143.0, 136.5, 135.0, 132.0, 131.5, 126.0, 121.5, 119.2.
Step B.
Synthesis of 3-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro benzoic acid (3b) [00154] Spectral data for 3b : IR (v, cm-'): 3300-2500 (CO2H), 3470 (amine), 1723 (C=0). 11-1 NMR (acetone-d6, 6 ppm): 7.90 (d, 1H, J = 8.6 Hz, aromatic), 7,67 (d, 1H, J = 2.2 Hz, aromatic), 7.50 (dd, 1H, J = 8.3 Hz and J = 2.0 Hz, aromatic) 7.11 (s, 2H, maleimide); '3C NMR (acetone-d6, 6 ppm): 168.0 (2), 165.0, 138.0, 136.0 (2), 135.0, 132.0, 128.0, 124.0, 118Ø
Step C.
Synthesis of N43-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-4-chloro-benzoyll-hydrazine carboxylic acid tert-butyl ester (4b) [00155] Spectral data for 4b : IR (v, cm-'): 3473 (amine), 3090 (C=C), 2984 (aliphatic), 1708 (C=0). 'H NMR (acetone-d6, 6 ppm): 9.03 (s, 1H, NH), 7.65(d, 1H, J = 8.0 Hz, aromatic) 7.59 (d, 1H, J = 1.6 Hz, aromatic), 7.45 (dd, 1H, J =
8.2 and J =
1.8 Hz aromatic), 7.08 (s, 2H, maleimide), 2.96 (s, 1H, NH), 1.47 (s. 9H, 3 x CH3);
13C NMR (acetone-d6, 6 ppm): 169.0 (2), 166.0, 156.0, 135.0 (2), 134.6, 133.0, 131.0, 127.9(2), 125.9, 80.0, 27.5 (3).
Example 4. Preparation of N44-(2,5-dioxo-pyrrolidin-1-y1)-benzoyll-hydrazine carboxylic acid tert-butyl ester (12) [00156]
Maleimide 4 (103 mg, 0.31 mmol) was dissolved in methanol (1 mL) to which was added 5% Pd/C (14 mg). Some hydrogen gas was bubbled during 30 seconds into the mixture. The suspension was stirred vigorously under a hydrogen atmosphere for a period of 3 hours. Of note, a longer period of time is required on a larger scale. Afterwards, the suspension was filtered on silica with a mixture of hexanes / acetone (3/2) as the eluent, to yield 87 mg (84%) of 12. IR (v, cm-1): 3400-3100 (NH), 2981 (CH), 1703 (C=0); 111 NMR (acetone-d6, 6 ppm) : 9.54 (br s, 1H, NH), 8.00 and 7.45 (2 x d, J=8.6 Hz, 4H, aromatic), 1.45 (s, 9H, 3 x CH3); 13C
MNR
(acetone-d6, 6 ppm) 176.2 (2), 165.9, 155.7, 136.1, 132.4, 127.8 (2), 126.7 (2), 79.6, 28.2, 27.5; ESI+ HRMS: (M+H)+ calculated for Ci6H20N305 = 334.1397; found =
334.1391 and ESI+ HRMS: (M+H -C4H9)+ calculated for Ci2H:2N305 = 278.0771;
found = 278.0769.
Example 5. Preparation of 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid N'-diacetyl-hydrazide (8, R = CH3) 1001571 To a solution of crude 6 (444 mg, 1.28 mmol) dissolved in dichloromethane (10 mL) was added triethylamine (1.07 mL, 780 mg, 7.7 mmol) and acetic anhydride (0.61 mL, 659 mg, 6.4 mmol). The mixtured was stirred at 22 C for about 30 minutes. Afterwards, the organic phase was diluted with ethyl acetate (75 mL) directly into an extraction funnel. The organic phase was washed successively with a 5% sodium bicarbonate aqueous solution (50 mL), with a 10% sodium chloride aoous solution (50 mL) and finnally with water (50 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (111 mg). The product was purified by flash column chromatography using a mixture of hexanes / acetone (7/3) to give 75 mg (18%) of the desired material 8, R =
CH3). Of note, different anhydrides or alkaloyl chlorides can be used to produce analogs of this specific derivative. IR (v, cm-1): 3200 (NH), 1702 (C=0), 1662 (C=0); 'H NMR
(acetone-d6, 6 ppm): 10.15 (br s, 1H, NH), 8.09 and 7.61 (2 x d, J = 8.6 Hz, 4H, aromatic), 7.10 (s, 2H, maleimide), 2.41 (s, 6H, 2 x CH3); 13C NMR (acetone-d6, 6 ppm): 171.1 (2), 169.3 (2), 166.0, 135.8, 134.7 (2), 130.8, 128.2 (2), 126.1 (2), 24.2 (2). ESI+ HRMS: (M+H)+ calculated for C151-114N305 = 316.0928; found =
316.0945 and ESI+ HRMS: (M+H -Ac)+ calculated for Ci3Hi2N304 =275.08252; found =
275.0856.
Example 6. Preparation of N-acetyl-AP-14-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoy11-hydrazinecarboxylic acid tert-butyl ester (10, R = CH3) [00158] To a solution of 4 (100 mg, 0.30 mmol) dissolved in dichloromethane (3 mL) was added triethylamine (252 p.L, 183 mg, 1.81 mmol) and acetic anhydride (71 mt, 76.7 mg, 0.75mmo1). The mixtured was stirred at 22 C for about 30 minutes.
Afterwards, the organic phase was diluted with ethyl acetate (25 mL) directly into an extraction funnel. The organic phase was washed successively with a 5% sodium bicarbonate aqueous solution (10 mL), with a 10% sodium chloride aoous solution (10 mL) and finnally with water (20 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (123 mg). The product was purified by flash column chromatography using a mixture of hexanes /
acetone (4/1) to give 22 mg (20%) of the desired material 10, R = CH3). It is noteworthy, that a longer reaction time (2 hours) lead to higher yield of the desired material. However, some diacetylated product (11) is also present as a side product.
IR (v, cm-1): 3286 (NH), 1753 (C=0), 1711 (C=0), 1652 (C=0); 1H NMR (CDCI3, 6 ppm): 8.28 (br s, 1H, NH), 7.90 and 7.50(2 x d, J = 8.6 Hz, 4H, aromatic), 6.89 (s, 2H, maleimide), 2.61 (s, 3H, CH3), 1.51 (s, 9H, 3 x CH3); 13C NMR (CDCI3, 6 ppm):
170.5, 168.9 (2), 165.2, 151.0, 135.0, 134.4 (2), 130.9, 128.3 (2), 125.7 (2), 84.8, 27.8 (3), 25.5; ESI+ HRMS: (M+Na)+ calculated for C181-119N3Na06 = 396.1166; found =
396.1165 and ESI+ HRMS: (M+H -tert-Boc)+ calculated for C13F112N304 =
274.0822;
found = 274.0824.
Example 7. Preparation of N,N'-diacetyl-N'44-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoy1]-hydrazinecarboxylic acid tert-butyl ester (11, R =
CH3) [00159] To a solution of 4 (100 mg, 0.30 mmol) dissolved in dichloromethane (3 mL) was added triethylamine (252 JAL, 183 mg, 1.81 mmol) and acetyl chloride (54 60 mg, 0.75 mmol). The mixtured was stirred at 22 C for about 2 hours.
Afterwards, the organic phase was diluted with ethyl acetate (25 mL) directly into an extraction funnel. The organic phase was washed successively with a 5% sodium bicarbonate aqueous solution (10 mL), with a 10% sodium chloride aoous solution (10 mL) and finally with water (20 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (118 mg). The product was purified by flash column chromatography using a mixture of hexanes /
acetone (4/1) to give 100 mg (80%) of the desired material 11, R = CH3). IR
(v, cm-1):
3193 (NH), 1701 (C=0), 1660 (C=0); 1H NMR (CDCI3, 6 ppm): 7.68 and 7.50(2 x d, J = 8.6 Hz, 4H, aromatic), 6.89 (s, 2H, maleimide), 2.49 and 2.48 (2 x s, 6H, 2 x CH3), 1.50 (s, 9H, 3 x CH3); 13C NMR (CDCI3, 6 ppm): 170.2, 169.9 (2), 168.8 (2), 150.2, 134.6, 134.4 (2), 132.9, 128.2 (2), 125.0 (2), 85.9, 27.8 (3), 25.4, 24.6;
ESI+ HRMS:
(M+Na)+ calculated for C201-121N3Na07 = 438.1272; found = 438.1281 and ESI+
HRMS: (M+H -Ac and -tert-Boc)+ calculated for C13H12N304 = 274.0822; found =
274.0833.
Example 8. Preparation of N'-{4-13-(2-tert-butoxycarbonylamino-ethylsulfany1)-2,5-dioxo-pyrrolidin-1-y11-benzoyl}-hydrazinecarboxylic acid tert-butyl ester (13) [00160] To a solution of 4 (115 mg, 0.34 mmol) dissolved in methanol (3 mL) was added 2-(Boc-amino) ethanethiol (70 L, 73 mg, 0.41 mmol). The mixture was stirred at 22 C for 2 hours and at 50 C for I hour. The organic phase was diluted with ethyl acetate (30 mL) directly into an extraction funnel and washed successively with a 5% sodium bicarbonate aqueous solution (2 x 10 mL) and with water (2 x 20 mL).
The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude material (191 mg). The product was purified by flash column chromatography using a mixture of hexanes / acetone (3/2) to give 107 mg (61%) of the desired material 13 [see 0055]. IR (v, cm-1): 3300 (NH), 1707 (C=0), 1680 (C=0); 1H NMR (CDCI3, 6 ppm): 8.80 (br s, IH, NH), 7.86 and 7.34 (2 x d, J =
8.2 Hz, 4H, aromatic), 6.90 (br s, 1H, NH), 5.07 (br s, 1H, NH), 3.98 (1H, m, -CHS-) 2.6-3.6 (several m, 6H, 3 x -CH2-), 1.50 and 1.45 (2 x s, 18H, 2 x 3 x CH3); 13C
NMR
(CDC13, 6 ppm): 175.4, 173.2, 165.8, 155.9 (2), 134.8, 131.7, 128.2 (2), 126.4 (2), 82.1, 79.7, 39.4, 38.9, 36.1, 32.7, 28.4 (3), 28.2 (3); ESI+ FIRMS: (M+Na)+
calculated for C23H321\14Na07S = 531.1884; found = 531.1881.
Example 9. General procedure for the preparation of derivatives of general structure 13 (see scheme 3) [00161] Following the procedure described by Taha et a/.12 compound 5 can be treated with a relevant aldehyde (alkyl aldehydes (linear or branched), benzaldehyde or substituted benzaldehydes) under acidic conditions at reflux in butanol (or other solvent) to give the desired alkylhydrazones or benzoylhydrazones derivatives.
Example 10. General procedure for the preparation of derivatives 14, 15 or 16 (see scheme 4) [00162] Derivative 4 (or any other maleimides described herein) can be reacted with an appropriate diene (butadiene (unsubstituted or substituted), cyclopentadiene, cyclohexadiene cycloheptadiene, furane, thiophene, pyrrole, N-alkylpyrrole) to give the desired cycloadducts (Diels-Alder products) such as for example 14, 15 and 16.
This reaction can be performed by heating the pure reagents (diene and dienophile) either neat or in solution, with or without pressure.
Example 11. Specific procedure for the preparation of hydrazone 13a with R =
4-hydroxy-3-methoxyphenyl (see scheme 3) [00163] The intermediate 4-(2,5-dioxo-2,5-dihydro-pyrrol-1-y1)-benzoic acid hydrazide trifluoroacetic acid salt (6) was prepared as described in example 1, step E
using the following quantities: derivative 4 (100 mg, 0.303 mmol), trifluoroacetic acid 250 j.iL, dichloromethane (1 mL). The intermediate 6 was dissolved in dichloromethane (2 mL) and treated with 4-hydroxy-3-methoxybenzaldehyde (vanillin, 46.1 mg, 0.303 mmol) and sodium bicarbonate (25.4 mg, 0.303 mmol).
Dichloromethane (2-3 mL) was used to dissolve the aldehyde stuck to the reaction vessel wall. The reaction was stirred at room temperature for 12 hours.
Afterwards, the reaction mixture was transferred into a separatory funnel containing ethyl acetate (50 mL). The organic phase was washed twice with 3% aqueous solution of sodium bicarbonate (2 x 20 mL) and with water (3 x 15 mL). The organic phase was dried with anhydrous magnesium sulfate, filtered and evaporated to the crude hydrazone 13a, R = 4-hydroxy-3-methoxyphenyl (79 mg, 71%). The product was homogeneous by thin layer chromatography. 1H NMR (DMSO-d6, 6 ppm): 11.71 (br s, 1H, NH), 9.54 (br s, 1H, OH), 8.32 (br s, 1H, -CH=N-), 7.97 and 7.49 (2 x d, J = 8.2 Hz, 4H, aromatic), 7.32 (br s, 1H, aromatic), 7.21 (s, 2H, maleimide), 7.09 (br d, J =
7.8 Hz, 1H, aromatic) 6.83 (d, J = 8.2 Hz, 1H, aromatic), 3.82 (s, 3H, OCH3); ESI+
HRMS:
(M+H)+ calculated for CI9H16N305= 366.1084; found = 366.1076.
[00164] Using iso-vanillin instead of vanillin the hydrazone 13b with R
= 3-hydroxy-4-methoxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 11.71 (br s, 1H, NH), 9.30 (br s, 1H, OH), 8.29 (br s, 1H, -CH=N-), 7.98 (d, J = 8.2 Hz, 2H, aromatic), 7.49 (d, J = 8.6 Hz, 2H, aromatic), 7.27 (d, J = 1.5 Hz, 1H, aromatic), 7.22 (s, 2H, maleimide), 7.04 (dd, J = 1.6 and 8.2 Hz, 1H, aromatic) 6.96 (d, J =
8.2 Hz, 1H, aromatic, 3.80 (s, 3H, OCH3); ESI+ HRMS: (M+H)+ calculated for C191-= 366.1084; found = 366.1058.
[00165] With benzaldehyde the hydrazone 13c, R = phenyl was obtained:
1H NMR (DMSO-d6, 6 ppm): 11.90 (s, 1H, NH), 8.45 (s, 1H, CH=N), 8.00 and 7.47 (2 d, J=8.6 Hz, 4H, aromatic,), 7.73 and 7.45 (2 m, 5H, H aromatique), 7.21 (s, 2H, maleimide); ESI+ FIRMS: (M+H)+ calculated for Ci8HI4N303 = 320.1030; found =
320.1028.
[00166] With 2-hydroxybenzaldehyde the hydrazone 13d, R = 2-hydroxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 12.14 (s, 1E1, NH), 11.23 (s, 1H, OH), 8.64 (s, 1H, CH=N), 8.03 and 7.52 (2d, 4H, H aromatic , J=8.6 Hz), 7.57 (d hidden, 1H, H-6), 7.30 (t, 1H, H-4, J=6.3 Hz), 7.22 (s, 2H, maleimide), 6.93 (d, 1H, H-3, J=7.8 Hz), 6.88 (t hidden, 1H, H-5); ESI+ HRMS: (M+H)+
calculated for Ci8Hi4N304 = 336.0979; found = 336.0973.
[00167] With 3-hydroxybenzaldehyde the hydrazone 13e, R = 3-hydroxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 11.84 (s, 1H, NH), 9.62 (s, 1H, OH), 8.35 (s, 1H, CH=N), 7.99 and 7.50 (2d, 4H, aromatic, J=8.0 Hz), 7.22 (s, 2H, maleimide), 7.23-7.11 (m, 3H, H-4-5-6), 6.82 (d, 1H, H-2, J=6.6 Hz); ESI+
HRMS: (M+H)+ calculated for CI8H141\1304 = 336.0979; found = 336.0978.
[00168] With 4-hydroxybenzaldehyde the hydrazone 13f, R = 4-hydroxyphenyl was obtained: 'H NMR (DMSO-d6, 6 ppm): 11.70 (s, 1H, NH), 9.93 (s, 1H, OH), 8.34 (s, 1H, CH=N), 7.98 and 7.49 (2d, 4H, aromatic , J=8.4 Hz), 7.56 and 6.83 (2d, 4H, H-2-3-5-6, J=8.2 Hz), 7.21 (s, 2H, maleimide); ESI+ HRMS:
(M+H)+ calculated for Ci8Hi4N304 = 336.0979; found = 336.0978.
[00169] With 2,4-dihydroxybenzaldehyde the hydrazone 13g, R = 2,4-dihydroxyphenyl was obtained: 1H NMR (DMSO-d6, 6 ppm): 11.95 (s, 1H, NH), 11.41 (s, 1H, OH ortho), 9,97 (s, 1H, OH para), 8.49 (s, I H, CH=N), 8.02 and 7.48(2 d, 4H, aromatic , J=8.4 Hz), 7.33 and 6.37 (2 d, 2H, H-5-6, J=8.2 Hz), 7.21 (s, 2H, maleimide), 6.31 (s, 1H, H-3); ESI+ HRMS: (M+H)+ calculated for C18H14N305 =
352.0928; found = 352.0923.
[00170] With 4-hydroxy-3,5-ditertbutylbenzaldehyde the hydrazone 13h, R
= 3,5-ditertbuty1-4-hydroxybenzaldehyde was obtained: H NMR (DMSO-d6, 6 ppm): 11.68 (s, 1H, NH), 8.37 (s, 1H, CH=N), 7.98 and 7.47 (2 d, 4H, aromatic , J=8.6 Hz), 7.47 (s, 2H, H-2-6), 7.21 (s, 2H, maleimide), 1.40 (s, 18H, C(CH3)3); ESI+
HRMS: (M+H)+ calculated for C26H30N304 = 448.2231; found = 448.2224.
[00171] With 4-methoxybenzaldehyde the hydrazone 13i, R = 4-methoxyphenyl was obtained: 11-1 NMR (DMSO-d6, 6 ppm): 11.78 (s, 1H, NH), 8.39 (s, 1H, CH=N), 7.99 and 7.02 (2 d, 4H, H-2-3-5-6, J=8.6 Hz), 7.67 and 7.49 (2 d, 4H, aromatic , J=8.6 Hz), 7.21 (s, 2H, maleimide), 3.80 (s, 3H, OCH3); ESI+
HRMS:
(M+H)+ calculated for Ci9H16N304 = 350.1135; found = 350.1127.
[00172] With 2-hydroxy-3-methoxybenzaldehyde the hydrazone 13j, R = 2-hydroxy-3-methoxyphenyl was obtained: 11-1 NMR (DMSO-d6, 6 ppm): 12.11 (s, I H, NH), 10.90 (s, 1H, OH), 8.65 (s, 1H, CH=N), 8.01 and 7.53 (2 m, 4H, aromatic), 7.21 (s, 2H, maleimide), 7.01 a 6.86 (m, 3H, H-4-5-6), 3,80 (s, 3H, OCH3);
ESI+
HRMS: (M+H)+ calculated for Ci9H16N305 = 366.1084; found = 366.1075.
[00173] With 3,4-dimethoxybenzaldehyde the hydrazone 13k, R = 3,4-dimethoxyphenyl was obtained: 11-1 NMR (DMSO-d6 and D20, 6 ppm): 11.78 (s, 1H, NH), 8.34 (s, 1H, CH=N), 7.97 and 7.48 (2 d, 4H, aromatic, J=8.6 Hz), 7.40 (s, 1H, H-2), 7.18 and 7.00 (2 d, 2H, H-5-6, J=8.2 Hz), 7.15 (s, 2H, maleimide), 3.79 (2 s, 6H, 2 x OCH3). ESI+ HRMS: (M+H)+ calculated for C20Hi8N305 = 380.1241;
found = 380.1234.
[00174] With 4-allyloxybenzaldehyde the hydrazone 131, R = 4-allyloxyphenyl was obtained: 'H NMR (DMSO-d6, 6 ppm): 11.78 (s, 1H, NH), 8.38 (s, 1H, CH=N), 7.99 and 7.49 (2 d, 4H, aromatic, J=8.6 Hz), 7.66 and 7.03 (2 d, 4H, H-2-3-5-6, J=8.6 Hz), 7.21 (s, 2H, maleimide), 6.04 (m, 1H, H-8), 5.33 (m, 2H, H-9), 4.61 (d, 2H, H-7, J=5.08 Hz); ESI+ HRMS: (M+H)+ calculated for C21Hi8N304 =
376.1292; found = 376.1282.
[00175] With 2-furaldehyde the hydrazone 13m, R = 2-furanyl was obtained: 11-INMR (DMSO-d6, 6 ppm): 11.83 (s, 1H, NH), 8.33 (s, 1H, CH=N), 7.96 and 7.52 (2 d, 4H, aromatic , J=8.2 Hz), 7.84 (s, 1H, H-3), 7.21 (s, 2H, maleimide), 6.93 (d, 1H, H-4, J=3.1 Hz), 6.63 (s, 1H, 1-1-5); ESI+ HRMS: (M+H)+ calculated for Ci6H i2N304 = 310.0822; found = 310.0820.
[00176] With pyridine-2-carbaldehyde the hydrazone 13n, R = 2-pyridyl was obtained: 11-1 NMR (DMSO-d6, 6 ppm): 12.09 (s, 1H, NH), 8.61 (m, 1H, H-3), 8.47 (s, 1H, CH=N), 8.01 and 7.52 (2 d, 4H, aromatic, J=7.10 Hz), 7.89 (m, 2H, 6), 7.43 (m, 1H, H-4), 7.22 (s, 2H, maleimide); ESI+ HRMS: (M+H)+ calculated for CI7F113N403 = 321.0982; found = 321.0977.
[00177] With pyridine-3-carbaldehyde the hydrazone 13o, R = 3-pyridyl was obtained: 12.07 (s, 1H, NH), 8.86 (s, 1H, H-2), 8.60 (d, 1H, H-4, J=3.0 Hz), 8.50 (s, 1H, CH=N), 8.16 (d, 1H, H-6, J=7.1 Hz), 8.01 and 7.51 (2d, 4H, aromatic , J=8.0 Hz), 7.51 (t hidden, 1H, H-5), 7.22 (s, 2H, maleimide); ESI+ HRMS: (M+H)+
calculated for Ci7Hi3N403= 321.0982; found = 321.0979.
[00178] With pyridine-4-carbaldehyde the hydrazone 13p, R = 4-pyridyl was obtained: NMR (DMSO-d6, 6 ppm): 12.29 (s, 1H, NH), 8.72 (d, 2H, H-3-5, J=1.9 Hz), 8.47 (s, 1H, CH=N), 8.00 and 7.53 (2 d, 4H, aromatic, J=6.6 Hz), 7.82 (s, 2H, H-6-2); ESI+ HRMS: (M+H)+ calculated for C17Hi3N403 = 321.0982; found --321.0974.
[00179] With cinnamaldehyde the hydrazone 13q, R = phenylethenyl was obtained: 114 NMR (DMSO-d6, 6 ppm): 11.80 (s, 1H, NH), 8.21 (s, 1H, CH=N), 7.97 and 7.49 (2 d, 4H, aromatic , J=7.8 Hz), 7.60 (d, 2H, H-2-6, J=6.3 Hz), 7.36 (m, 3H, H-3-4-5), 7.18 (s, 2H, maleimide), 7.04 (m, 2H, H-7-8); ESI+ HRMS: (M+H)+
calculated for C20H16N303 = 346.1186; found = 346.1178.
[00180] With 4-chlorobenzaldehyde the hydrazone 13r, R = 4-chlorophenyl was obtained: H NMR (DMSO-d6, 6 ppm): 11.96 (s, 1H, NH), 8.43 (s, 1H, CH=N), 8.00 and 7.51 (2 d, 4H, aromatic, J=8.0 Hz), 7.76 and 7.51 (2 d, 4H, H-2-3-5-6, J=7.8 Hz), 7.22 (s, 1H, maleimide); ESI+ HRMS: (M+H)+ calculated for C181113C1N303 --354.0640; found = 354.0630.
[00181] With 4-fluorobenzaldehyde the hydrazone 13s, R = 4-fluorophenyl was obtained: H NMR (DMSO-d6, 6 ppm): 11.91 (s, 1H, NH), 8.44 (s, 1H, CH=N), 8.00 and 7,50 (2 d, 4H, aromatic, J=6.4 Hz), 7.79 (s, 2H, H-2-6), 7,29 (s, 2H, H-3-5), 7.21 (s, 2H, maleimide); ESI+ HRMS: (M+H)+ calculated for Ci8Hi3EN303 =
338.0935; found = 338.0926.
[00182] With 4-trifluoromethylbenzaldehyde the hydrazone 13t, R = 4-trifluoromethylphenyl was obtained: 'El NMR (DMSO-d6, 6 ppm): 12.09 (s, 1H, NH), 8.51 (s, 1H, CH=N), 8.01 and 7.51 (2 d, 4H, aromatic, J=8.2 Hz), 7.95 and 7.81 (2 d, 4H, H-2-3-5-6, J=7.9 Hz), 7.22 (s, 2H, maleimide); ESI+ HRMS: (M+H)+
calculated for Ci9Hi3F3N303 = 388.0904; found = 388.0897.
[00183] With 4-nitrobenzaldehyde the hydrazone 13u, R = 4-nitrophenyl was obtained: 'H NMR (DMSO-d6, 6 ppm): 11.41 (s, 1H, NH), 7.90 and 7.48(2 d, 4H, aromatic , J=8.2 Hz), 7.67 (d, 1H, CH=N, J=5.1 Hz), 7.20 (s, 2H, maleimide), 2.48 (septet, 1H, H-1), 1.07 (d, 6H, H-2-3, J=6.7 Hz); ESI+ HRMS: (M+H)+
calculated for Ci8Hi3N405= 365.0880; found = 365.0875.
[00184] General structure of hydrazones 13a-13u (see scheme 3) 13a, R = 4-hydroxy-3- 13b, R = 3-hydroxy-4- 13c, R = phenyl methoxyphenyl methoxyphenyl 13d, R = 2-hydroxyphenyl 13e, R = 3-hydroxyphenyl 13f, R = 4-hydroxyphenyl 13g, R = 2,4- 13h, R
= 3,5-ditertbuty1-4- 131, R = 4-methoxyphenyl dihydroxyphenyl hydroxybenzaldehyde 13j, R = 2-hydroxy-3- 13k, R = 3,4- 131, R
= 4-allyloxyphenyl methoxyphenyl dimethoxyphenyl 13m, R = 2-furanyl 13n, R = 2-pyridyl 13o, R = 3-pyridyl 13p, R = 4-pyridyl 13q, R = phenylethenyl 13r, R = 4-chlorophenyl 13s, R = 4-fluorophenyl 13t, R = 4- 13u, R = 4-nitrophenyl trifluoromethylphenyl Materials and Methods - Biology In vitro studies (for derivatives 4, 5, 8, 10, 11, and 12, etc.) [00185] Cell culture ¨ general: Biological assays were performed using the human monocytic cell line THP1, the murine macrophage-like cell lines J774A.1 and RAW 264.7, and the murine UBC cell lines MB49 and MB49-1. The cells were maintained in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and containing 1 mM sodium pyruvate, 10 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and 50 p,g/mL gentamycin (referred as 10% FBS RPMI-1640). The cells were maintained at 37 C in a moisture-saturated atmosphere containing 5% CO2.
THP1 cells, RAW 264.7 cells and J774A.1 cells are the most widely used cell lines to investigate the function and differentiation of monocytes and macrophages in response to various inflammatory mediators.17,18 Undifferentiated THPI cells resemble primary monocytes/macrophages isolated from healthy donors or donors with inflammatory diseases, such as diabetes mellitus and atherosclerosis.I9 After treatment with phorbol esters, THPI cells differentiate into macrophage-like cells which mimic native monocyte-derived macrophages in several respects.2 As we previously described, green fluorescent protein-expressing (GFP)-THP1 cells were cultured for 18 h in 50 nM phorbol 12-myristate 13-acetate to induce monocyte-to-macrophage differentiation.2I-23 The cell lines RAW 264.7 and J774A.1 were kindly provided by Dr Tatiana Scorza (Universite du Quebec a Montreal, Canada). These cell lines are macrophage-like cell models which produce large amount of NO in response to IFNy, TNFet, bacterial infection and bacterial products, such as lipopolysaccharide (LPS),I7 The cell line MB49-I is a highly invasive and tumorigenic UBC cell model that was developed by successive in vivo passages of MB49 primary tumors.24 [00186] Cell signaling studies: THP1-derived human macrophages (750x103 cells/mL) and MB49-I cells (500x103 cells/mL) were pretreated for 30 min with vehicle (DMSO), compounds 4 and 5, at 10, 25 or 50 IAM; and then washed and recovered immediately (t= 0 min) or after 30 min of activation with 50 U/mL
IFNy, 25 ng/mL IL6, or 10 ng/mL TNFa. Cell lysates were prepared and analyzed by immunoblotting as described.2I-23'25 Briefly, protein samples were resolved by SDS-PAGE under reducing conditions and transferred onto a PVDF membrane. Blots were first probed with rabbit polyclonal antibodies against phospho-STAT1 (pSTAT1), pSTAT3, or p-Ix13 (all at 1:2000) overnight at 4 C. Blots were then incubated with HRP-conjugated goat anti-rabbit IgG Ab (1:3000) for 1 h at room temperature.
The same blots were stripped and then probed with anti-STAT1 or anti-STAT3 Abs (both at 1:1000). In both cases, probed molecules were visualized using an enhancement chemiluminescence detection kit (Thermo Fisher Scientific).
[00187] Luciferase assay. To assess the transcriptional activity of NFKI3 in response to TNFa, MB49-I cells cultured in monolayers (7.5x104 cells/well in well plates) were transiently transfected with an expression vector allowing the transcription of the firefly luciferase reporter gene under the control of CMV
promoter and tandem repeats of the NFKB transcriptional response element. The luciferase gene encodes a 61-kDa enzyme that oxidizes D-luciferin in the presence of ATP, oxygen, and MC, yielding a fluorescent product that can be quantified by measuring the released light. Transfection was performed using Opti-MEM
reduced serum media and Lipofectamine 2000 (Thermo Fisher Scientific). Then, MB49-I
cells were pretreated for 30 min with vehicle (DMSO) and compound 4 (at 10 uM or 30 M); and then washed and recovered after 24 h of activation with 10 ng/mL or 50 ng/mL TNFoc. Cell lysates were mixed with Luciferase assay reagent (a mixture of luciferine, coenzyme A, ATP and Mg2+) and the light produced was measured using a luminometer.
[00188] Surface antigen expression analysis. To study membrane receptor expression, THP1-derived human macrophages (750x104 cells/mL) were pretreated for 3 h with DMSO or compounds 4 and 5, and then left untreated (control) or treated for 48 h with 50 U/mL IFNy. The expression level of MHC-II and CD40 was evaluated by flow cytometry as described.21-23 [00189] Motility assays. The in vitro scratch wound healing assay was performed to study the effects of compounds 4 and 5 in 1L6-induced macrophage cell migration, as described.26 Briefly, THP1-derived human macrophages (750x103 cells/mL) were seeded into 24-well tissue culture plate to reach ¨70-80%
confluence as a monolayer. The cell monolayers were scraped in a straight line in one direction to create a "scratch" with a p200 pipet tip. To obtain the same field during the image acquisition, another straight line was scratched perpendicular to the first would line to create a cross in each well. Cell debris were removed and the edges of the scratch were smoothed by washing the cells once with 1 mL of Hank's buffer. Cell monolayers were pretreated for 3 h with vehicle (DMSO) or compounds 4 (10 M) and 5 (25 p.M), and then left untreated (control) or treated for 48 h with 25 ng/mL
IL6. Using the cross as reference points the plate was placed under an inverted fluorescence microscope, and the images of the scratch were acquired at t= 0 h and t=
48 h. The number of motile cells was determined using Java-based image processing program ImageJ (National Institutes of Health) and relative cell motility was expressed as percent (%) of control of motile cells at t= 48 h relative to motile cells within the initial wound (at t= 0 h).
[00190] Microinvasion assays. Invasion was measured by assessment of human UBC T24 cell migration rate through an artificial basement membrane in a modified Boyden chamber (HTS Transwell System). Briefly, the membrane consisted of a polycarbonate filter with 0.4 um pores diameter and was coated on ice with Matrigel (BD Biosciences) diluted 1:2 (v/v) in serum-free culture media. T24 cells (50 x 103 cells) were seeded into the Matrigel coat in the upper well of the chamber, while polarized MI macrophages (50 x 103 cells) were seeded in the lower well. The polycarbonate filter with 0.4 pim pores diameter is too small to left the cells move to the bottom of the lower wells. Thus, non-invading cells into the matrigel coat were removed and cells that migrated down to the polycarbonate filter were stained with Hoescht 33258 dye after a 48-h incubation period, visualized by fluorescence microscopy and counted.
[00191] Cellular analysis of 3D spheroid-based tumor invasion assays.
Cell preparation and spheroid formation were performed following the manufacturer instructions (Corning). Briefly, MDA-MB-231 cells were harvested and diluted to a concentration of 5 x 104 cells/mL in (complete) culture media supplemented with 10%
serum. 100 pilL, of cell suspension was then pipetted to appropriate 96 well spheroid formation plate and placed at 37 C/5% CO2. Spheroid formation was monitored every 24 hours. The typical cell aggregation period was 48 hours. Upon spheroid formation completion, 70 iaL of complete medium was removed from each well, and replaced by 70 tL of serum-free medium. This was repeated on a daily basis to create a serum starvation period of 48 hours. Matrigel matrix (100 [it) was then added to each well. The plate was centrifuged at 300 x g for 5 minutes in a swinging bucket centrifuge. The plate was then transferred to a 37 C/5% CO2 incubator for one hour to initiate gel formation. Following the 1-hour gel formation incubation period, DMSO or compound 4 was added to appropriate wells during 60 minutes. After pretreatment, the media was removed and replaced by complete culture media, and then the media was changed every day for a period of 4 days. Brightfield images at day 0 and day 4 was used to measure invasive protrusion (invadopodia) extending away from the tumoroid and into the extracellular matrix. The role of these protrusions is the breakdown of Matrigel matrix, thus aiding the invasion process.
These protrusions were identified, and their area and perimeter properly quantified using the ImageJ software (National Institutes of Health).
1001921 Evaluation of NO and Urea production by chemical methods. The MB49-I cells and the J774A.1 cells (25x103 cells/well) were grown and pretreated, as indicated, with various anti-inflammatory derivatives, precursors and mono-functional derivatives for a period of 3 h. Afterwards the cells were washed twice with 10% FBS
RPMI-1640 and then activated to produce NO for a period of 24 h with cytokines INFy and TNFcc. NO production was measured using the Griess reagent method as previously described.27 This method involves the detection of nitrite ions (NO2-) formed by the spontaneous oxidation of NO under physiological conditions.
According the manufacture procedure (Life Technologies; # G-7921), equal volumes of sulfanilic acid and N-(1-naphthyl)ethylenediamine are mixed together to form the Griess reagent. In the presence of NO2-, sulfanilic acid is converted to a diazonium salt, which in turn is coupled to N-(1-naphthyl)ethylenediamine to produce a pink coloration that is measured with a spectrophotometer (Biotek, synergy HT) at 548 nm.
In the same manner, urea synthesis through arginase-1 activity was measured using commercially available kit.
[00193] Evaluation of cell proliferation by the MTT assay. To evaluate the anti-proliferative activity, cell viability/proliferation MTT assays were performed as previously described.21-23,25,28 Briefly, MB49-I cells (5x103 cells/well) were plated in 96-well plates in 100 [it 10% FBS RPMI-1640 and cultured for 24 h at 37 C and 5%
CO2. Cells were pretreated for a period of 3 h with vehicle (DMSO) or derivatives 1 and 1A at 0, 10, 25, 37.5, and 50 p,M, and then incubated for 24 h in the absence or the presence of INFy and TNFa. At the end of the culture period, 10 1.1L of 5 mg/mL
methylthiazolyldiphenyl-tetrazolium bromide (MTT) solution was added to each well.
After a 3-h incubation period with MTT reagent, 100 1.11L of MTT
solubilization buffer (10% SDS in 10 mM HC1) was added and plates were placed overnight in the cell incubator before absorbance measure. The optical density was read at 580 nm using the Microplate Reader Manager (from Bio-Rad Laboratories).
[00194] Statistical analyses. For all biological assays, data were presented as mean 1 SD from three independent experiments. Data were analyzed by one-way ANOVA followed by Bonferonni post-test using Prism software, version 3.03 (GraphPad, San Diego, CA). p values of < 0.05 were considered to indicate statistical significance.
In vivo studies (for derivatives 4 and 8) [00195] Ectopic UBC model. Male C57BL/6J mice (6-8 weeks old), each weighing 15-18 g, were used for the experiments (supplied by Charles River).
The mice were housed with free access to food and water on a 12:12 h light:dark cycle with the room temperature maintained at 21 C. MB49 cells, MB49-1 cells, and iNOS-deficient MB49-I cells (5 x 104 in 100 j.L PBS) were injected subcutaneously (s.c.) into the right flank of the mice. Growth rates of the s.c. tumors were monitored. The size of tumors was determined every 3 days for 24-28 days using a digital caliper and by measuring luciferin luminescence at days 15 and 25 using the IVIS imaging system. A blinded observer measured tumor length and width. The volume of the tumor was calculated from the formula: Length x width2 x 0.52, where length and width were tumor diameters measured with calipers in mutually perpendicular directions. At a tumor size of approximately 10 mm3 the mice were divided into different groups. A control group received PBS as treatment. As indicated, other groups were treated at different doses (90, 150 or 300 1.1M) with an intraperitoneal (i.p.) injection of compounds 4 or 8 every 3-4 days for 18-20 days.24,27 [00196] Orthotopic UBC model. Female C57BL/6J mice (6-8 weeks old), each weighing 15-18 g, were anesthetized and a 24-gauge Teflon catheter was introduced into the bladder lumen through the urethra. To prepare the bladder for tumor implantation, a point lesion was induced in the bladder wall by electrocauterization.
Then, 1 x 105 of MB49-I cells in 100 uI of PBS were instilled into the bladder. When indicated, control mice were electrocauterized and PBS was instilled into the bladder.
Syringes containing the cell suspension were maintained into the catheter for 20 min to allow cell attachment to the bladder wal1.24,27 [00197] Statistical analyses. Mann¨Whitney test was used to compare tumor growth, using Prism software, version 3.03 (GraphPad, San Diego, CA). p values of <
0.05 were considered to indicate statistical significance.
The results from the in vitro and in vivo experiments are presented in figures 1 to 25.
REFERENCES
1. LaFond, R. In Cancer: The outlaw cell, 3rd Ed., ACS publication, Washington, DC, 384 pages (2012) 2. Alderton GK. The tumor microenvironment drives metastasis, Nat. Rev.
Cancer 16, 199 (2016) 3. Steeg PS. Targeting metastasis, Nat. Rev. Cancer 16, 201-218 (2016) 4. Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, Richter C, Zips D, Bortfeld T. Radiation oncology in the era of precision medicine, Nat. Rev. Cancer 16, 234-249 (2016) 5. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment, Nat. Rev. Cancer 12, 237-251 (2012) 6. Scott AM, Wolchok JD, Old U. Antibody therapy of cancer. Nat. Rev.
Cancer 12, 278-287 (2012) 7. Phillips AP, Mentha JW. US Patent 3,046,301 (October 29, 1959); Deglin JH, Vallerand AH. In Guide des medicaments, ERPI, pp. 424-427 (1995) 8. Remers, WA. Antineoplastic agents, In Wilson and Gisvold's Textbook of organic Medicinal and pharmaceutical chemistry, 9th Ed., Delgado JN, Remers, WA. J.B. Eds, Lippincott, New York, Chapter 8, 321-322 (1989) 9. Lau A, Berube G, Ford CHJ. Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents, Bioorg. Med Chem., 3, 1299-1304 (1995) 10. Lau A, Berube G, Ford CHJ, Gallant M. Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro, Bioorg.
Med. Chem., 3, 1305-1312 (1995) 11. Hamelin-Morrissette J, Cloutier S, Girouard J, Belgorosky D, Eijan A-M, Legault J, Reyes-Moreno C, and Berube G. Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells, Eur. J. Med. Chem., 96, 259-269 (2015) 12. Taha M, Ismail NH Lalani S, Fatmi MQ, Atia-tul-Wahab, Siddiqui S, Khan KM, Imran S, Choudhary MI. Synthesis of novel inhibitors of a-glucosidase based on the benzothiazole skeleton containing benzohydrazide moiety and their molecular docking studies, Eur. J. Med Chem., 92, 387-400 (2015) 13. Perrin DD, Armarego CF. In Purification of Laboratory Chemicals, 3' Ed., Pergamon Press, Oxford, New York (1988) 14. Still WC, Kahn M, Mitra A. Rapid chromatographic technique for preparative separations with moderate resolution, J. Org. Chem., 43, 2923-2925 (1978) 15. Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA. (6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicin, Bioconjug. Chem., 4, 521-527 (1993) 16. Heindel ND, Zhao HR, Egolf RA, Chang CH, Schray KJ, Emrich JG, McLaughlin JP, Woo DV, A novel heterobifunctional linker for formyl to thiol coupling, Bioconjug. Chem., 2, 427-430 (1991) 17. Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation, Antimicrobial agents and chemotherapy, 58 2059-2066 (2014) 18. Auwerx J, The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation, Experientia, 47, 22-31 (1991) 19. Qin Z, The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature, Atherosclerosis, 221,2-11 (2012) 20. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages, PloS one, 5, 0008668 (2010) 21. Dufresne M, Dumas G, Asselin E, Carrier C, Pouliot M, Reyes-Moreno C, Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells, Mob. Immunol., 48 1556-1567 (2011) 22. Dumas G, Dufresne M, Asselin E, Girouard J, Carrier C, Reyes-Moreno C.
CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasion, Cancer Immunol. Immunother., 62, 273-283,(2013) 23. Dallagi A, Girouard J, Hamelin-Morrissette J, Dadzie R, Laurent L, Vaillancourt C, Lafond J, Carrier C, Reyes-Moreno C. The activating effect of IFN-gamma on monocytes/macrophages is regulated by the LIF-trophoblast-IL-10 axis via Statl inhibition and Stat3 activation, Cell. Mob. Immunol., 12, 326-341 (2015).
24. Fabris VT, Lodillinsky C, Pampena MB, Belgorosky D, Lanari C, Eijan AM.
Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-1, Cancer Genet., 205, 168-176 (2012).
25. Leduc, Bourassa V, Asselin E, Leclerc P, Lafond, Reyes-Moreno C. Leukemia Inhibitory Factor Regulates Differentiation of Trophoblast-Like BeWo Cells Through the Activation of JAK/STAT and MAPK3/1 MAP Kinase-Signaling Pathways, Biol. Reprod, 86, 54, 1-10 (2012) 26. Menon MB, Ronkina N, Schwermann J, Kotlyarov A, Gaestel M.
Fluorescence-based quantitative scratch wound healing assay demonstrating the role of MAPKAPK-2/3 in fibroblast migration, Cell. Motil. Cytoskeleton, 66, 1041-1047 (2009) 27. Belgorosky D, Langle Y, Prack Mc Cormick B, Colombo L, Sandes E, Eijan A.M. Inhibition of nitric oxide is a good therapeutic target for bladder tumors that express iNOS, Nitric Oxide, 36, 11-18 (2014) 28. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JD. Evaluation of a tetrazolium-based semiautmated colorimetric assay : Assessment of radiosensitivity. Cancer Res., 47, 943-946 (1987) 1001981 The present disclosure has been described with regard to specific examples. The description was intended to help the understanding of the present disclosure, rather than to limit its scope. It will be apparent to one skilled in the art that various modifications may be made to the present disclosure without departing from the scope of the present disclosure as described herein, and such modifications are intended to be covered by the present document.
Claims (52)
1. A compound of formula (IF) R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R11 is a substituted or unsubstituted member chosen from phenyl, phenylethenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
wherein R11, when substituted, are substituted with at least one substituent chosen from -OR12, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, -CH2OH, nitrophenyl, phenylethenyl, -CF3, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
R12 is H, acetyl, propiolyl, Cl-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
R11 is a substituted or unsubstituted member chosen from phenyl, phenylethenyl, furanyl, thiophenyl, pyridinyl, naphthyl, quinolyl and isoquinolyl;
wherein R11, when substituted, are substituted with at least one substituent chosen from -OR12, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, -CH2OH, nitrophenyl, phenylethenyl, -CF3, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
R12 is H, acetyl, propiolyl, Cl-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
2. The compound of claim 1, wherein R11 is a substituted or unsubstituted member chosen from phenyl, furanyl and thiophenyl.
3. A compound of formula (IG) R2 is H, or a substituted or unsubstituted member chosen from acetyl, propiolyl, butyryl, isobutyryl and benzoyl;
R12 is H, acetyl, propiolyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
R13, R14 and R15 are each independently chosen from H, -OR12, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
R12 is H, acetyl, propiolyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl or C3-C8 cycloalkenyl;
R13, R14 and R15 are each independently chosen from H, -OR12, -F, -Cl, -Br, -I, acetyl, propiolyl, butyryl, isobutyryl, benzoyl, -NO2, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkenyl, methoxycarbonyl- and alkyloxycarbonyl-;
or an enantiomer, diastereoisomer, racemic mixture, pharmaceutically acceptable salt, solvate or prodrug thereof.
4. The compound of claim 3, wherein at least one of R13, R14 and R15 is different from H.
5. The compound of claim 3, wherein at least one of R13, R14 and R15 is -OH.
6. The compound of claim 3, wherein at least one of R13, R14 and R15 is -OCH3.
7. The compound of claim 3, wherein at least one of R13, R14 and R15 is C2-C8 alkyl.
8. The compound of claim 3, wherein at least one of R13, R14 and R15 is -OR12 in which R12 is C2-C8 alkenyl.
9. The compound of claim 3, wherein said compound is chosen from
10. The compound of claim 3, wherein said compound is chosen from
11. The compound of claim 1, wherein R11 2,4-dihydroxyphenyl 3,5-ditertbutyl-4- 4-methoxyphenyl hydroxybenzaldehyde 2-hydroxy-3-methoxyphenyl 3,4-dimethoxyphenyl 4-allyloxyphenyl 2-furanyl 2-pyridyl 3-pyridyl 4-pyridyl phenylethenyl 4-chlorophenyl 4-fluorophenyl 4-trifluoromethylphenyl and 4-nitrophenyl.
12. A compound of formula (IH) wherein R16 is chosen from 2,4-dihydroxyphenyl 3,5-ditertbutyl-4- 4-methoxyphenyl hydroxybenzaldehyde 2-hydroxy-3-methoxyphenyl 3,4-dimethoxyphenyl 4-allyloxyphenyl 2-furanyl 2-pyridyl 3-pyridyl 4-pyridyl phenylethenyl 4-chlorophenyl 4-fluorophenyl 4-trifluoromethylphenyl and 4-nitrophenyl.
13. The compound of any one of claims 1 to 12, for use in medicine.
14. The compound of any one of claims 1 to 12, for use in reducing risks of developing at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
15. The compound of any one of claims 1 to 12, for use in the treatment of at least one cancer chosen from breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
16. The compound of any one of claims 1 to 12, for use as an anticancer agent.
17. The compound of any one of claims 1 to 12, for use as an anti-inflammatory agent.
18. The compound of any one of claims 1 to 12, for use as an anti-metastatic agent.
19. The compound of any one of claims 1 to 10, for use as an anti-proliferative agent.
20. Use of at least one compound as defined in any one of claims 1 to 12, for for treating at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
21. Use of at least one compound as defined in any one of claims 1 to 12, for reducing the risks of developing at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
22. Use of at least one compound as defined in any one of claims 1 to 12, for inhibiting cancer cell growth of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
23. Use of at least one compound as defined in any one of claims 1 to 12, for inhibiting cancer tumor growth and/or cancer tumor size of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
24. Use of at least one compound as defined in any one of claims 1 to 12, for for decreasing and/or preventing cancer tumor metastases of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer.
25. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for treating at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
26. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for reducing the risks of developing of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
27. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for inhibiting cancer cell growth of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
28. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for inhibiting cancer tumor growth and/or cancer tumor size of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
29. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for decreasing and/or preventing cancer tumor metastases of at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer prostate cancer and bladder cancer.
30. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for inhibiting cancer tumor growth and/or cancer tumor size of at least one cancer chosen from melanoma, breast cancer, lung cancer, colon cancer, uterine/endometrial cancer, ovarian cancer, prostate cancer, and bladder cancer.
31. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for decreasing and/or preventing cancer tumor metastases of at least one cancer chosen from melanoma, breast cancer, lung cancer, colon cancer, uterine/endometrial cancer, ovarian cancer, prostate cancer, and bladder cancer.
32. Use of at least one compound as defined in any one of claims 1 to 12 in the manufacture of a medicament for decreasing and/or preventing pathological humoral and cell-mediated inflammation of at least one disease chosen from inflammatory diseases (Crohn's disease, rheumatoid arthritis, asthma, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, reperfusion injury or transplant rejection); pregnancy complications (preeclampsia or preterm birth); or gynecological pathologies (endometriosis, uterine leiomyoma, polycystic ovary syndrome or recurrent miscarriage).
33. Use of at least one compound as defined in any one of claims 1 to 12 for use as an anticancer agent.
34. Use of at least one compound as defined in any one of claims 1 to 12 for use as an anti-inflammatory agent.
35. Use of at least one compound as defined in any one of claims 1 to 12 for use as an anti-metastatic agent.
36. Use of at least one compound as defined in any one of claims 1 to 12 for use as an anti-proliferative agent.
37. A method for treating cancer or at least one cancer chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer, said method comprising administering to a subject in need thereof an effective amount of at least one compound as defined in any one of claims 1 to 12.
38. A method for reducing the risks of developing cancer or for reducing the risk of developing at least one cancer in a subject, the cancer being, for example, chosen from melanoma, breast cancer, uterine cancer, ovarian cancer, prostate cancer and bladder cancer, said method comprising administering to the subject an effective amount of at least one compound as defined in any one of claims 1 to 12.
39. A method for inhibiting cancer cell growth, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined in any one of claims 1 to 12.
40. The method of claim 39, wherein said cancer cell growth is inhibited by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to an untreated subject.
41. A method for inhibiting cancer cell growth, the method comprising contacting cancer cells with an effective amount of at least one compound as defined in any one of claims 1 to 12.
42. The method of claim 41, wherein a relative STAT1 activation of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cancer cells.
43. The method of claim 41 or 42, wherein a relative STAT3 activation of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cancer cells.
44. The method of any one of claims 41 to 43 , wherein a CD40 expression of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cancer cells.
45. The method of any one of claims 41 to 44, wherein a MHC-II
expression of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cancer cells.
expression of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cancer cells.
46. The method of any one of claims 41 to 45, wherein a production of NO
of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cancer cells.
of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cancer cells.
47. The method of any one of claims 41 to 46, wherein TNF.alpha./NF.kappa.B
and/or IL6/STAT3 signaling pathways of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
and/or IL6/STAT3 signaling pathways of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80% relative to untreated cells.
48. The method of any one of claims 41 to 47, wherein an LPS-activated NF.kappa.B signaling pathway of said cells is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70% or about 80%
relative to untreated cells.
relative to untreated cells.
49. A method for inhibiting cancer tumor growth and/or cancer tumor size, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined in any one of claims 1 to 12.
50. The method of claim 49, wherein the tumor growth and/or tumor size is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to an untreated subject.
51. A method for decreasing and/or preventing cancer tumor metastases, the method comprising administering to a subject in need thereof an effective amount of at least one compound as defined in any one of claims 1 to 12.
52. The method of claim 51, wherein a number of tumor metastases is decreased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80% or about 90% relative to an untreated subject.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3021417A CA3021417A1 (en) | 2018-10-18 | 2018-10-18 | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
PCT/CA2019/051473 WO2020077459A1 (en) | 2018-10-18 | 2019-10-17 | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3021417A CA3021417A1 (en) | 2018-10-18 | 2018-10-18 | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3021417A1 true CA3021417A1 (en) | 2020-04-18 |
Family
ID=70278495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3021417A Abandoned CA3021417A1 (en) | 2018-10-18 | 2018-10-18 | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3021417A1 (en) |
WO (1) | WO2020077459A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022071777A1 (en) * | 2020-09-29 | 2022-04-07 | 연세대학교 산학협력단 | Composition and method for prevention or treatment of respiratory disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2926928A1 (en) * | 2016-04-11 | 2017-10-11 | 3R Valo, S.E.C. | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
CA3020348A1 (en) * | 2016-04-11 | 2017-10-19 | 3R Valo, S.E.C. | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
-
2018
- 2018-10-18 CA CA3021417A patent/CA3021417A1/en not_active Abandoned
-
2019
- 2019-10-17 WO PCT/CA2019/051473 patent/WO2020077459A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2020077459A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210002222A1 (en) | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents | |
JP6023250B2 (en) | Diglycid ether derivative therapeutic agent and method of use thereof | |
Zhu et al. | Design, synthesis, and evaluation of chalcone analogues incorporate α, β-Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis | |
JP6113751B2 (en) | Synthesis of polyhydroxybenzopyran ketone compounds and their antitumor effects | |
KR102343865B1 (en) | Compound inhibiting YAP-TEAD interaction and pharmaceutical composition for treating or preventing cancer comprising the same as an active ingredient | |
WO2023125928A1 (en) | Menin inhibitor and use thereof | |
WO2023142518A1 (en) | Hydroxynaphthalenone-phenylboronic acid compound, preparation method, and use | |
Hamelin-Morrissette et al. | Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells | |
CA2926928A1 (en) | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents | |
CA3021417A1 (en) | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents | |
US11370766B2 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
US20220274972A1 (en) | Class of triaromatic compounds targeting bifunctional phosphorylation site of stat3 and applications thereof | |
CN117580849A (en) | Steroid compound, pharmaceutical composition and application thereof | |
CN111170980B (en) | Calycosin derivative and synthesis method and application thereof | |
CN103906751A (en) | [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer | |
WO2024140754A1 (en) | Naphthylamide compound, and preparation method therefor and use thereof | |
RU2527526C2 (en) | Indolyl-substituted pyrazino-quinolines and using them for treating cancer | |
KR101576235B1 (en) | Novel disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for inhibiting the metastasis of cancer containing the same as an active ingredient | |
JP6082488B1 (en) | Preparation of ester of PAK1 blocker acidified by carboxyl group and application to treatment of cancer and other PAK1-dependent diseases | |
Lin et al. | Identification of a new class of activators of the Hippo pathway with antitumor activity in vitro and in vivo | |
ES2648538B1 (en) | BENZO-HETEROCICLOS OF SIX MEMBERS WITH OXYGEN AND NITROGEN ATOMS WITH ANTITUMORAL ACTIVITY | |
CA3153282A1 (en) | Treatment or prevention of leukaemia | |
ES2718000A1 (en) | BENZOPIRANS PRENILATED AGGREGATES OF PPAR (Machine-translation by Google Translate, not legally binding) | |
TW201733976A (en) | Compositions and methods for treating liver cancer | |
JP2019501137A (en) | 4-oxo-4,5-dihydrothiazole derivatives, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20240418 |